{"meta":{"query_hash":"0a6c9d7b2298","filters":{"venue":"JCO Precision Oncology"},"cohort_total":105,"direct_labels_cover":0,"predictions_cover":105,"exported":105,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/0a6c9d7b2298","api":"https://metacan.xera.ac/api/v1/cohort?venue=JCO+Precision+Oncology"},"results":[{"id":"W2598368982","doi":"10.1200/po.17.00127","title":"Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Enzalutamide; Taxane; Prostate cancer; Medicine; Docetaxel; Oncology; Internal medicine; Androgen receptor; Cabazitaxel; Androgen deprivation therapy; Cancer; Breast cancer","score_opus":0.16266761043451983,"score_gpt":0.4792556454121008,"score_spread":0.316588034977581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598368982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935314,0.001437293,0.0003556988,0.00045264227,0.000031316584,0.00007092205,0.0006787579,0.00002651771,0.003415461],"genre_scores_gemma":[0.9988714,0.00022197052,0.0004014877,0.00016817231,0.00002499849,0.00001083348,0.00021524259,0.0000032209377,0.000082770486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980342,0.0006795102,0.00023810526,0.0002729107,0.00054284633,0.00023242681],"domain_scores_gemma":[0.993718,0.0015543717,0.0024440538,0.00016735846,0.0013546556,0.00076142064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014012781,0.00023795587,0.00029928403,0.0009954424,0.0003950291,0.00074838556,0.000567861,0.00046477249,0.0014332708],"category_scores_gemma":[0.0072892946,0.00012318415,0.0002451352,0.00093187124,0.00036168055,0.00036254065,0.00039737407,0.0004871011,0.00027072194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061586725,0.000023719109,0.9960335,0.000022505788,0.0000085980155,0.00012640416,0.00007073489,0.000057796813,0.00021481638,0.000013206596,0.0003373788,0.0030298112],"study_design_scores_gemma":[0.0000144971655,0.00024500323,0.9945574,0.00006904138,0.00003336013,0.0015493779,0.0007070437,0.001238188,0.00048644663,0.00004633345,0.0010396865,0.000013540179],"about_ca_topic_score_codex":0.020252803,"about_ca_topic_score_gemma":0.03196844,"teacher_disagreement_score":0.020252803,"about_ca_system_score_codex":0.0010190906,"about_ca_system_score_gemma":0.0009972246,"threshold_uncertainty_score":0.040269792},"labels":[],"label_agreement":null},{"id":"W2652345243","doi":"10.1200/po.16.00031","title":"Homologous Recombination Deficiency in Breast Cancer: A Clinical Review","year":2017,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Homologous recombination; Breast cancer; Homologous chromosome; BRCA2 Protein; Medicine; DNA repair; Germline mutation; Germline; Cancer; Clinical significance; Bioinformatics; Mutation; Genetics; Biology; Internal medicine; DNA; Gene","score_opus":0.3056827032087479,"score_gpt":0.5919253871315462,"score_spread":0.2862426839227983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2652345243","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041784228,0.9990773,0.000043163174,0.00020213964,0.000116339696,0.0000044830813,0.000014345477,0.0000035797573,0.00049678196],"genre_scores_gemma":[0.0002402298,0.99930906,0.00008118809,0.00012210391,0.00008171467,0.000003845647,0.000017960981,7.64356e-7,0.00014316624],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99976844,0.00004131429,0.00004580469,0.000037134898,0.0000907903,0.000016571015],"domain_scores_gemma":[0.9993556,0.00035287705,0.00008897194,0.000014011977,0.00014869505,0.00003986421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007349577,0.00075969443,0.0013483937,0.0028429015,0.0002954257,0.0010107736,0.0010589845,0.0009776349,0.0042589223],"category_scores_gemma":[0.0013263443,0.00029986037,0.0006449921,0.002815385,0.0003877664,0.0011462201,0.0006904527,0.001517989,0.0019575842],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005524432,0.000050960716,0.00017933639,0.02845794,0.00010058834,0.00016402465,0.000054520104,0.00025362973,0.00043865014,0.0020789683,0.040326595,0.9278395],"study_design_scores_gemma":[0.00001992324,0.00008964838,0.0007717153,0.01631206,0.00019839294,0.00157717,0.00006646998,0.00007437459,0.00018282062,0.001659026,0.9790268,0.000021555228],"about_ca_topic_score_codex":0.0011100702,"about_ca_topic_score_gemma":0.002452391,"teacher_disagreement_score":0.0042589223,"about_ca_system_score_codex":0.00052847713,"about_ca_system_score_gemma":0.001196644,"threshold_uncertainty_score":0.014247537},"labels":[],"label_agreement":null},{"id":"W2728001194","doi":"10.1200/po.17.00027","title":"Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype","year":2017,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Urinary and Genital Oncology Studies","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Smiths Detection (Canada)","funders":"National Cancer Institute","keywords":"MSH6; Microsatellite instability; Adenocarcinoma; MSH2; MLH1; Immune checkpoint; Cancer research; Medicine; Colorectal cancer; Oncology; DNA mismatch repair; Internal medicine; Biology; Cancer; Immunotherapy; Genetics; Gene","score_opus":0.06723622734382263,"score_gpt":0.3636070110342152,"score_spread":0.2963707836903926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2728001194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553055,0.0011543976,0.00223712,0.00006152406,0.0000056891795,0.000028088203,0.00040780497,0.000035360565,0.00053949206],"genre_scores_gemma":[0.996318,0.00045774228,0.0022649644,0.00004487973,0.0000060289126,0.000015117678,0.00054048933,0.000008555275,0.0003442238],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998568,0.000015671727,0.000015016176,0.000042315198,0.00004303152,0.000027165148],"domain_scores_gemma":[0.99978644,0.000039252383,0.000070951326,0.000029864317,0.000031676824,0.000041856372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010677999,0.00020744254,0.0002658204,0.00056498154,0.00021982235,0.00028567857,0.000121746736,0.00020925008,0.0006098197],"category_scores_gemma":[0.00028003924,0.0000965595,0.00020933327,0.00031994152,0.0001934982,0.000120874196,0.00021002302,0.00021526117,0.00014174872],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002495623,0.000021403608,0.05002227,0.00009330941,0.000043576205,0.0021119567,0.00008610655,0.00021558265,0.93795323,0.00010682114,0.00006878368,0.009027349],"study_design_scores_gemma":[0.000022379367,0.0007306939,0.71148366,0.000027156468,0.00013609816,0.03029484,0.00052470015,0.002588948,0.24689472,0.00027719073,0.006998741,0.000020904215],"about_ca_topic_score_codex":0.00052202004,"about_ca_topic_score_gemma":0.0014405991,"teacher_disagreement_score":0.0006098197,"about_ca_system_score_codex":0.00015292778,"about_ca_system_score_gemma":0.00012204628,"threshold_uncertainty_score":0.0020400286},"labels":[],"label_agreement":null},{"id":"W2765106815","doi":"10.1200/po.17.00132","title":"Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance","year":2017,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Balance (ability); Real world evidence; Randomized controlled trial; Precision oncology; Medicine; Oncology; Internal medicine; Precision medicine; Pathology; Physical medicine and rehabilitation","score_opus":0.11517459532314453,"score_gpt":0.39121708773981617,"score_spread":0.27604249241667167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765106815","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034179094,0.5022352,0.009902515,0.46181345,0.01689052,0.00028135098,0.0010913995,0.00010288619,0.0042647375],"genre_scores_gemma":[0.15385962,0.25306457,0.0293738,0.49173254,0.066359505,0.0010916753,0.0016437394,0.00049248384,0.0023820754],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.7752193,0.15662348,0.034159645,0.01176178,0.019099262,0.0031364355],"domain_scores_gemma":[0.16782199,0.7473514,0.030208467,0.027240423,0.022799961,0.0045777303],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.3410081,0.0030853387,0.01719288,0.0058468417,0.0026777058,0.021028696,0.009339221,0.025333153,0.026418848],"category_scores_gemma":[0.63473433,0.0025698838,0.0095563345,0.008152134,0.018055927,0.03761965,0.008255654,0.023622433,0.004717097],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022544261,0.0009985116,0.023120126,0.08620306,0.058897845,0.0007883005,0.0014059157,0.0049881367,0.0011189947,0.26366183,0.16594158,0.37033144],"study_design_scores_gemma":[0.013289305,0.001019906,0.009536058,0.08308611,0.019193888,0.00043478195,0.0017727681,0.0029579767,0.0006795549,0.71381336,0.15369542,0.0005209905],"about_ca_topic_score_codex":0.007175306,"about_ca_topic_score_gemma":0.008178304,"teacher_disagreement_score":0.65899193,"about_ca_system_score_codex":0.008770992,"about_ca_system_score_gemma":0.010932789,"threshold_uncertainty_score":0.8126544},"labels":[],"label_agreement":null},{"id":"W2767438024","doi":"10.1200/po.17.00154","title":"Targeted Error-Suppressed Detection of Circulating Paternal DNA to Establish a Diagnosis of Gestational Trophoblastic Neoplasm","year":2017,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Gestational Trophoblastic Disease Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Neoplasm; Obstetrics; DNA; Medicine; Biology; Genetics; Pathology","score_opus":0.032786361760688644,"score_gpt":0.339348977761677,"score_spread":0.30656261600098833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767438024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669904,0.003539595,0.023236433,0.000469733,0.00014457719,0.00011395733,0.00060510193,0.00017895924,0.004721254],"genre_scores_gemma":[0.9903562,0.00045804167,0.007991543,0.00026014537,0.000024105066,0.000025627869,0.00019864106,0.0000233783,0.000662406],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99769235,0.0008211649,0.0001161175,0.00048269035,0.00071485783,0.00017281882],"domain_scores_gemma":[0.99532664,0.0021514331,0.0007240156,0.00075091893,0.0008750653,0.0001719478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003136228,0.00042901008,0.00037660345,0.0009893096,0.00033151841,0.0010354922,0.0005701567,0.0009895458,0.0009600825],"category_scores_gemma":[0.0111236125,0.0004493962,0.0002771359,0.00054974033,0.0007209806,0.00040363835,0.00043299227,0.0007973721,0.0003073906],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003937857,0.00040676305,0.6401422,0.00047300907,0.00059223315,0.0012875175,0.0014859624,0.0031670132,0.26392636,0.0035978854,0.0012439758,0.07973928],"study_design_scores_gemma":[0.0003351507,0.004102808,0.28138572,0.0003412672,0.0012743144,0.0101351,0.0007243368,0.026640732,0.65789866,0.003714912,0.013372402,0.00007465083],"about_ca_topic_score_codex":0.0015307829,"about_ca_topic_score_gemma":0.0020816044,"teacher_disagreement_score":0.003136228,"about_ca_system_score_codex":0.00058762333,"about_ca_system_score_gemma":0.0007271071,"threshold_uncertainty_score":0.016586185},"labels":[],"label_agreement":null},{"id":"W2782876837","doi":"10.1200/po.17.00098","title":"Reflex Testing for Germline<i>BRCA1</i>,<i>BRCA2</i>,<i>PALB2</i>, and<i>ATM</i>Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries","year":2018,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PALB2; Germline mutation; Medicine; Founder effect; Breast cancer; Internal medicine; Pancreatic cancer; Oncology; Cancer; Mutation; Genetics; Gene; Biology; Genotype; Haplotype","score_opus":0.10428491355846134,"score_gpt":0.45428596827818557,"score_spread":0.3500010547197242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782876837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982664,0.0002834849,0.00007688313,0.00005382285,0.0000020345665,0.000015301493,0.0006432117,0.000011754528,0.00064708013],"genre_scores_gemma":[0.998944,0.00017149563,0.00017478254,0.000031942167,0.0000023063394,0.000004498886,0.00059366354,0.0000021431392,0.00007523852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859256,0.00018363316,0.0001171604,0.0002841154,0.0005443554,0.00027814624],"domain_scores_gemma":[0.9958786,0.0006564212,0.0013253044,0.0003768473,0.0012590012,0.00050384476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014218931,0.00031901253,0.00026632092,0.0012977622,0.00080876076,0.0006269323,0.0010213193,0.00026751673,0.0008437511],"category_scores_gemma":[0.006083586,0.00022389872,0.0002956951,0.0018684452,0.0007068285,0.00021988964,0.00069877395,0.00030688522,0.00012039519],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032159012,0.000006361072,0.99752766,0.000008797085,0.000014581163,0.000051617564,0.000089817935,0.00005995462,0.00021193677,0.00001139381,0.00008998752,0.0018958028],"study_design_scores_gemma":[0.000008375255,0.00004164957,0.9983909,0.000012984051,0.000033228516,0.00039107926,0.00027755063,0.00023946083,0.0002734864,0.000011432636,0.00031446738,0.000005486443],"about_ca_topic_score_codex":0.77349234,"about_ca_topic_score_gemma":0.807755,"teacher_disagreement_score":0.22650766,"about_ca_system_score_codex":0.004707745,"about_ca_system_score_gemma":0.0055601005,"threshold_uncertainty_score":0.45568317},"labels":[],"label_agreement":null},{"id":"W2788554175","doi":"10.1200/po.17.00122","title":"Oncologists’ Use of Genomic Sequencing Data to Inform Clinical Management","year":2018,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"National Center for Advancing Translational Sciences; National Human Genome Research Institute","keywords":"Medicine; Medical record; Documentation; Clinical Oncology; DNA sequencing; MEDLINE; Family medicine; Cancer; Internal medicine","score_opus":0.20396029520431297,"score_gpt":0.4327402469800385,"score_spread":0.22877995177572552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788554175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822939,0.0021364142,0.0014167123,0.008209015,0.000059596852,0.000060528033,0.00033532744,0.00003523008,0.005453293],"genre_scores_gemma":[0.9958442,0.0008009519,0.0015492995,0.0013792173,0.000051280236,0.000039472896,0.00010954764,0.0000048909988,0.00022116763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98977834,0.0071856943,0.0008955978,0.00045906083,0.0013279938,0.0003533199],"domain_scores_gemma":[0.94002646,0.029280776,0.023767397,0.0018316038,0.0032222718,0.0018715106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008068981,0.00009789223,0.000119907345,0.00079287146,0.00068829866,0.00090661016,0.00032663843,0.00057357695,0.0011761407],"category_scores_gemma":[0.052260946,0.00014428326,0.00012079618,0.00055779424,0.00050773023,0.00069530134,0.0009554397,0.00056503597,0.00023058169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013902625,0.00007748654,0.9396229,0.0001503539,0.000037777103,0.00029232464,0.0064522782,0.00022965093,0.0015188507,0.00016723195,0.0029173908,0.048394766],"study_design_scores_gemma":[0.00005010329,0.0006507464,0.9348012,0.0008113846,0.00010454308,0.0030897458,0.025236988,0.0022116888,0.0040475866,0.0005331085,0.0284048,0.000058033595],"about_ca_topic_score_codex":0.0026285069,"about_ca_topic_score_gemma":0.0052288417,"teacher_disagreement_score":0.008068981,"about_ca_system_score_codex":0.0008910151,"about_ca_system_score_gemma":0.0019221553,"threshold_uncertainty_score":0.04267335},"labels":[],"label_agreement":null},{"id":"W2796418582","doi":"10.1200/po.17.00125","title":"Fundamental Concepts in the Application of Plasma Genotyping (Liquid Biopsy) to <i>EGFR</i> Mutation Detection in Non–Small-Cell Lung Cancer","year":2018,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Genotyping; T790M; KRAS; Liquid biopsy; Lung cancer; Epidermal growth factor receptor; Biomarker; Medicine; Oncology; Cancer; Biology; Cancer research; Internal medicine; Genotype; Gene; Genetics","score_opus":0.03265072183519806,"score_gpt":0.4358843568916937,"score_spread":0.4032336350564956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796418582","genre_codex":"methods","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011315991,0.06683688,0.8541922,0.02985031,0.0038871593,0.0005813554,0.00032766737,0.00038508815,0.032623325],"genre_scores_gemma":[0.29759282,0.081247896,0.573813,0.019814849,0.007923192,0.0037387197,0.00046311022,0.0003023747,0.015103943],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939459,0.0025980219,0.0003484012,0.0011890534,0.0016469327,0.00027167404],"domain_scores_gemma":[0.99435186,0.0033264342,0.00048412976,0.0006947008,0.0009411841,0.00020174535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0101118805,0.000999998,0.0010495321,0.0019244858,0.0012374276,0.004693135,0.003252629,0.0048008547,0.0019591406],"category_scores_gemma":[0.013525519,0.0013395541,0.0014756458,0.0011292541,0.011316416,0.004410907,0.0030430544,0.005478565,0.0016422363],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020464088,0.00026138348,0.0039748778,0.0015769032,0.000084156825,0.0012411168,0.0013069529,0.0067327493,0.03867266,0.8052588,0.008740238,0.1319456],"study_design_scores_gemma":[0.00010485996,0.00095255306,0.0052771876,0.001666954,0.00008573108,0.007004565,0.000703037,0.031553417,0.033994578,0.7063612,0.21189201,0.0004039463],"about_ca_topic_score_codex":0.0023586135,"about_ca_topic_score_gemma":0.0009803828,"teacher_disagreement_score":0.0101118805,"about_ca_system_score_codex":0.00287675,"about_ca_system_score_gemma":0.0025908994,"threshold_uncertainty_score":0.053477407},"labels":[],"label_agreement":null},{"id":"W2801588305","doi":"10.1200/po.17.00198","title":"Comparative RNA-Sequencing Analysis Benefits a Pediatric Patient With Relapsed Cancer","year":2018,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Alex's Lemonade Stand Foundation for Childhood Cancer; Canadian Institutes of Health Research; National Cancer Institute; BC Cancer Foundation; St. Baldrick's Foundation; Canada Research Chairs","keywords":"Pediatric cancer; Gene; RNA; DNA sequencing; Computational biology; Biology; Cancer; Genome; Cancer genome sequencing; Genetics; Medicine; Genomics; Bioinformatics","score_opus":0.02454373684747535,"score_gpt":0.31008613930356066,"score_spread":0.2855424024560853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801588305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876152,0.00086240243,0.0060180533,0.0013763924,0.000056129877,0.00004419146,0.00054971175,0.00015296102,0.0033250572],"genre_scores_gemma":[0.9914301,0.0007677505,0.0061485884,0.0003824133,0.000059442154,0.00001792188,0.000281888,0.00007666701,0.0008352316],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99972934,0.000028273029,0.000021498321,0.00009829446,0.00006354284,0.000059059614],"domain_scores_gemma":[0.9994966,0.00019524952,0.0000977132,0.000027205102,0.000064456806,0.000118768425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021668924,0.0004887757,0.0004777204,0.0008097667,0.00073889527,0.00062925974,0.0003644952,0.0013358016,0.0009746723],"category_scores_gemma":[0.0010360803,0.00021579443,0.00035818096,0.0004399327,0.00063254853,0.0003298463,0.00039662604,0.0009839985,0.00040532276],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019333286,0.00006123453,0.0517487,0.00006849935,0.000021708336,0.89308244,0.0010458939,0.00084218616,0.03769776,0.0010512545,0.0010860864,0.013101032],"study_design_scores_gemma":[0.0000086018545,0.00026928136,0.031140193,0.000028143753,0.000038967115,0.94095045,0.0006117519,0.0022351511,0.020368272,0.000437976,0.003889346,0.000021947848],"about_ca_topic_score_codex":0.0017843609,"about_ca_topic_score_gemma":0.002499336,"teacher_disagreement_score":0.0017843609,"about_ca_system_score_codex":0.0007461833,"about_ca_system_score_gemma":0.00040307135,"threshold_uncertainty_score":0.005414009},"labels":[],"label_agreement":null},{"id":"W2888423222","doi":"10.1200/po.17.00311","title":"Economic Evaluations of Next-Generation Precision Oncology: A Critical Review","year":2018,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control","funders":"","keywords":"MEDLINE; Medicine; Precision medicine; Precision oncology; Economic evaluation; Medical physics; Scope (computer science); Computer science; Oncology; Pathology","score_opus":0.14373500341559128,"score_gpt":0.46145102725154385,"score_spread":0.31771602383595254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888423222","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030515747,0.99530196,0.00037788256,0.0028658186,0.00032100588,0.00018909496,0.0000991568,0.0000056975696,0.00053420477],"genre_scores_gemma":[0.014307413,0.9794698,0.001978816,0.0025990985,0.00066967163,0.0007262038,0.00011984564,0.000014766752,0.000114444345],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9421034,0.035520952,0.0117408335,0.0012990036,0.00839862,0.0009372903],"domain_scores_gemma":[0.5410032,0.4169178,0.01899096,0.0023019223,0.019772228,0.0010139181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0793914,0.0026272747,0.009856295,0.012739615,0.0009866068,0.0067371386,0.004011105,0.0053245886,0.00702754],"category_scores_gemma":[0.29031253,0.0017483275,0.010076836,0.01010656,0.002185253,0.005669559,0.0020565083,0.005579542,0.0005888669],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018169564,0.00013077396,0.001035309,0.6499163,0.016140692,0.00029335226,0.000259778,0.002736723,0.00013898358,0.008823069,0.016158978,0.30254912],"study_design_scores_gemma":[0.0005336676,0.00044630867,0.0019686553,0.9051856,0.023647055,0.00046550957,0.00026435524,0.0009947293,0.00026671233,0.008267896,0.057867717,0.00009195075],"about_ca_topic_score_codex":0.0059411903,"about_ca_topic_score_gemma":0.008069809,"teacher_disagreement_score":0.0793914,"about_ca_system_score_codex":0.01888896,"about_ca_system_score_gemma":0.018624542,"threshold_uncertainty_score":0.41986686},"labels":[],"label_agreement":null},{"id":"W2900293586","doi":"10.1200/po.18.00195","title":"Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology","year":2018,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cetuximab; Panitumumab; V600E; Colorectal cancer; Cancer research; Medicine; Mutation; Mutant; Epidermal growth factor receptor; Kinase; Targeted therapy; Biology; Oncology; Cancer; Internal medicine; Genetics; Gene","score_opus":0.06216558966071428,"score_gpt":0.4363235543107215,"score_spread":0.3741579646500072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900293586","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004697431,0.9954873,0.00056616566,0.0020407164,0.00033995413,0.000005574819,0.000026771357,0.000023073555,0.0010406466],"genre_scores_gemma":[0.0029594554,0.9937162,0.0010041738,0.0010087686,0.0006161743,0.000014480235,0.000056116638,0.0000056229806,0.00061907736],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978536,0.00005310649,0.000023764853,0.00003631225,0.00007482805,0.000026639522],"domain_scores_gemma":[0.99957186,0.00020389141,0.000060555896,0.000013335593,0.000108966415,0.00004149687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085118425,0.0005643231,0.0012352667,0.0014592195,0.00021815574,0.0010309799,0.00071675505,0.0009556813,0.0026931765],"category_scores_gemma":[0.00067491503,0.00016487196,0.0007846779,0.00094575016,0.00048865925,0.0017167723,0.0005188754,0.0024455355,0.0010508507],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017332072,0.00013016627,0.00042980417,0.008546976,0.00013195962,0.0005261872,0.00010280574,0.0009048307,0.007998708,0.007861988,0.038262133,0.93493116],"study_design_scores_gemma":[0.000057991452,0.0005512554,0.0018947537,0.0031688327,0.00019828508,0.0034651123,0.00013206189,0.000523768,0.0012743224,0.006987291,0.9817005,0.0000458187],"about_ca_topic_score_codex":0.0006100583,"about_ca_topic_score_gemma":0.0019809967,"teacher_disagreement_score":0.0026931765,"about_ca_system_score_codex":0.00083251006,"about_ca_system_score_gemma":0.00076468976,"threshold_uncertainty_score":0.0090096},"labels":[],"label_agreement":null},{"id":"W2936145201","doi":"10.1200/po.18.00327","title":"Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"DNA repair; Mutation; Prostate cancer; Cancer research; Wnt signaling pathway; Cancer; Gene; Biology; Medicine; Adenocarcinoma; DNA sequencing; Germline mutation; Genetics","score_opus":0.016093856726091864,"score_gpt":0.2903022285146727,"score_spread":0.2742083717885808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936145201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986613,0.00042924544,0.00038205835,0.000018771983,0.0000017644561,0.0000068801105,0.00013217775,0.000016200758,0.00035156708],"genre_scores_gemma":[0.999172,0.00013952435,0.00042643383,0.000015544276,0.0000053449817,0.0000044976687,0.00016514487,0.000004075351,0.000067449175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995059,0.00006922977,0.000058250906,0.00014609125,0.0001690946,0.000051459563],"domain_scores_gemma":[0.99918586,0.00022606894,0.00026594457,0.000083385145,0.0001312622,0.00010746126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034391403,0.00018863856,0.00022832245,0.0017746709,0.00036949504,0.00052442186,0.00028249505,0.00027522977,0.0015104997],"category_scores_gemma":[0.0011472775,0.00015968307,0.0001331304,0.0009954202,0.00032397284,0.00020726165,0.00033246257,0.00019896656,0.00022810811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081440776,0.000024087029,0.95786893,0.000051191677,0.00004723911,0.0014880829,0.00016136658,0.00012493868,0.031080564,0.000040414965,0.00009643379,0.008935277],"study_design_scores_gemma":[0.0000058032556,0.000121589735,0.9722163,0.000012214894,0.000044020002,0.017138917,0.00034596675,0.00037317487,0.008822446,0.000052654505,0.0008615769,0.000005325478],"about_ca_topic_score_codex":0.00079585006,"about_ca_topic_score_gemma":0.0018424733,"teacher_disagreement_score":0.0017746709,"about_ca_system_score_codex":0.00020549029,"about_ca_system_score_gemma":0.00020911224,"threshold_uncertainty_score":0.005053103},"labels":[],"label_agreement":null},{"id":"W2944384594","doi":"10.1200/po.18.00373","title":"Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy–Resistant Early Breast Cancers","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"PTEN; Oncology; Breast cancer; Internal medicine; Hazard ratio; Medicine; Cancer research; Palbociclib; Tamoxifen; PI3K/AKT/mTOR pathway; Metastatic breast cancer; Cancer; Biology; Bioinformatics; Signal transduction; Genetics","score_opus":0.008638226300876335,"score_gpt":0.27731147722765076,"score_spread":0.2686732509267744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944384594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99773765,0.0006051517,0.0008057509,0.00016006689,0.000008180537,0.000012484277,0.00021856694,0.000009849682,0.00044237802],"genre_scores_gemma":[0.99920326,0.00008384831,0.00037201593,0.000047893755,0.000016752303,0.000008475392,0.00018336928,0.0000034638974,0.000080934755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915254,0.00029747395,0.00008155932,0.00018931256,0.00016364633,0.00011545491],"domain_scores_gemma":[0.99803525,0.0008509125,0.00066606427,0.00016883308,0.00012648705,0.0001525479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014217936,0.00025911996,0.0004398893,0.000859156,0.0002846984,0.000664796,0.0004159735,0.00038587945,0.0012910991],"category_scores_gemma":[0.00453975,0.000085157575,0.00036687814,0.00061122025,0.00032205615,0.0004434724,0.0005096603,0.00033295454,0.00019429409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007164226,0.00003371266,0.97747326,0.00001850581,0.000093797855,0.00012981192,0.000060735354,0.00029158362,0.0030505992,0.000104358645,0.00017480785,0.017852485],"study_design_scores_gemma":[0.000036742833,0.0002658666,0.9938531,0.000011092926,0.00010259959,0.0006745276,0.00013045025,0.00259897,0.0011561612,0.00064261176,0.00052027655,0.000007677392],"about_ca_topic_score_codex":0.0004987003,"about_ca_topic_score_gemma":0.0010984177,"teacher_disagreement_score":0.0014217936,"about_ca_system_score_codex":0.00022852782,"about_ca_system_score_gemma":0.00025196202,"threshold_uncertainty_score":0.007519245},"labels":[],"label_agreement":null},{"id":"W2944851422","doi":"10.1200/po.18.00356","title":"Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"KRAS; Medicine; Oncology; ROS1; Internal medicine; Personalized medicine; Genetic testing; Medicaid; Bevacizumab; Bioinformatics; Cancer; Adenocarcinoma; Chemotherapy; Biology; Health care","score_opus":0.14300265678417756,"score_gpt":0.42021702317582477,"score_spread":0.2772143663916472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944851422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8775183,0.002603788,0.097013175,0.0068,0.0001932932,0.0012202953,0.0016718286,0.00013490232,0.0128444005],"genre_scores_gemma":[0.986978,0.00061293977,0.009984839,0.00032198595,0.000044394776,0.00023006384,0.000269434,0.000011492873,0.0015469556],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99430096,0.004384263,0.00011011492,0.0003634896,0.00026383973,0.0005773324],"domain_scores_gemma":[0.9766971,0.020578368,0.0011742766,0.00018607826,0.00045350334,0.0009106556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008551859,0.0019752572,0.0022639008,0.0017940891,0.0008133007,0.0028061755,0.0016976859,0.001784253,0.004330883],"category_scores_gemma":[0.017638398,0.0011750646,0.0023055298,0.0010768669,0.00107578,0.001726718,0.0016133784,0.0022865532,0.00017427126],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006565665,0.00016136201,0.003929216,0.000051848143,0.00016874877,0.00010500176,0.000020450456,0.98860323,0.00008753051,0.002814979,0.00029546567,0.0031055533],"study_design_scores_gemma":[0.0001527583,0.00024781714,0.0006631371,0.000017714536,0.00009627189,0.000038991955,0.000046213307,0.99650985,0.00004931476,0.0019832568,0.0001814534,0.000013244148],"about_ca_topic_score_codex":0.028032273,"about_ca_topic_score_gemma":0.011925204,"teacher_disagreement_score":0.028032273,"about_ca_system_score_codex":0.006038099,"about_ca_system_score_gemma":0.0052577765,"threshold_uncertainty_score":0.05573821},"labels":[],"label_agreement":null},{"id":"W2952198271","doi":"10.1200/po.18.00325","title":"Therapeutic Implication of Genomic Landscape of Adult Metastatic Sarcoma","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Kelowna General Hospital; University of British Columbia","funders":"Common Fund; National Institutes of Health; National Cancer Institute; BC Cancer Foundation; Genome British Columbia; American Society of Clinical Oncology","keywords":"Sarcoma; Biology; Copy-number variation; Cancer research; Transcriptome; Cancer; Carcinogenesis; Trabectedin; Genome; Gene; Medicine; Genetics; Pathology; Soft tissue sarcoma; Gene expression","score_opus":0.027120588246155212,"score_gpt":0.33847762245615637,"score_spread":0.31135703421000116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952198271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99558926,0.0014021257,0.0015913375,0.000072042654,0.0000050756566,0.000013875524,0.00050712883,0.00003461246,0.0007845251],"genre_scores_gemma":[0.998326,0.00035878652,0.0006624518,0.000044973272,0.000005933469,0.000009004824,0.00040303863,0.000006408052,0.00018343206],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99988794,0.000021816564,0.0000048065785,0.000037125596,0.000032663764,0.000015722635],"domain_scores_gemma":[0.99988437,0.000023570243,0.00005292735,0.000007948355,0.000014800028,0.000016423968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001465412,0.00016572846,0.00022871136,0.00029002005,0.000093920826,0.0002754482,0.00009629817,0.00018511823,0.0009690232],"category_scores_gemma":[0.00038088046,0.00008819057,0.00013000863,0.00027406585,0.00016090274,0.00014632227,0.00018258374,0.00017129089,0.00016463161],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097597897,0.00010188134,0.23545146,0.0002713017,0.00013019804,0.0013407468,0.00015694251,0.0023907244,0.69684356,0.0004548889,0.0006128487,0.06126947],"study_design_scores_gemma":[0.00004258557,0.0010786549,0.8906427,0.000039663766,0.00020348317,0.0076263784,0.00036997537,0.0078165,0.085842595,0.0011095208,0.005211746,0.000016167389],"about_ca_topic_score_codex":0.0002507171,"about_ca_topic_score_gemma":0.00042168563,"teacher_disagreement_score":0.0009690232,"about_ca_system_score_codex":0.000162225,"about_ca_system_score_gemma":0.00012304584,"threshold_uncertainty_score":0.0032417178},"labels":[],"label_agreement":null},{"id":"W2953100444","doi":"10.1200/po.19.00014","title":"Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"China Scholarship Council; Tulane University","keywords":"Prostate cancer; Concordance; Somatic cell; COLD-PCR; Germline mutation; Germline; Biology; Digital polymerase chain reaction; Allele; Cancer research; DNA sequencing; Mutation; Gene; Cancer; Genetics; Oncology; Medicine; Point mutation; Polymerase chain reaction","score_opus":0.031891046241851226,"score_gpt":0.35677489044950844,"score_spread":0.3248838442076572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953100444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928844,0.0023498263,0.002693209,0.00011735642,0.000043307038,0.000061079474,0.000324306,0.000127945,0.001398555],"genre_scores_gemma":[0.996811,0.00016719218,0.0025203996,0.00005157561,0.000016849004,0.000013008248,0.00026037768,0.0000074250497,0.00015227057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976544,0.0006822515,0.00017804098,0.00057130656,0.00081467134,0.00009942567],"domain_scores_gemma":[0.99607337,0.0016197155,0.00091090624,0.00017601777,0.00083956,0.0003804599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002224429,0.00036615488,0.00037703844,0.0009940701,0.00019089122,0.0005781689,0.0005122525,0.00044018816,0.001120086],"category_scores_gemma":[0.0069392496,0.00016087927,0.00021010535,0.0005572171,0.0004794768,0.00030697446,0.0003046891,0.00032784612,0.00026481767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003047539,0.00011803289,0.8895371,0.00022326091,0.000093368944,0.0009468543,0.0002719318,0.0010687633,0.05894828,0.00024924992,0.0005052129,0.044990454],"study_design_scores_gemma":[0.00016515628,0.01136023,0.79817694,0.00009873045,0.00033636173,0.019816883,0.00041572936,0.019994324,0.14120854,0.00043949095,0.007924478,0.00006316073],"about_ca_topic_score_codex":0.0012788622,"about_ca_topic_score_gemma":0.0011751244,"teacher_disagreement_score":0.002224429,"about_ca_system_score_codex":0.00055902393,"about_ca_system_score_gemma":0.00040924372,"threshold_uncertainty_score":0.0117640495},"labels":[],"label_agreement":null},{"id":"W2953511998","doi":"10.1200/po.18.00266","title":"Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Vemurafenib; Internal medicine; Cohort; Lung cancer; Clinical endpoint; Oncology; Adverse effect; Progression-free survival; Cancer; Surgery; Clinical trial; Overall survival; Metastatic melanoma","score_opus":0.01430066329293688,"score_gpt":0.27751511090114606,"score_spread":0.26321444760820917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953511998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99852186,0.00040491723,0.00014511081,0.00004556979,0.000024770547,0.00031298562,0.00032428402,0.000010516515,0.00021013903],"genre_scores_gemma":[0.99745315,0.00026283893,0.0002837612,0.00015553118,0.00008922601,0.00034092073,0.0011266598,0.0000068353943,0.00028109227],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990085,0.00043111062,0.00007475265,0.0001996825,0.00011928273,0.00016664602],"domain_scores_gemma":[0.9985141,0.00023008292,0.0003221113,0.00019536124,0.00011707905,0.00062118954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025381844,0.0015581917,0.0029148033,0.00033058738,0.00046585407,0.0011854814,0.0006749228,0.0008793737,0.0010801423],"category_scores_gemma":[0.001629779,0.0005619148,0.0016363381,0.00029075594,0.0008290364,0.0011586645,0.0005323995,0.001932544,0.000335213],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75470203,0.024644371,0.12441629,0.00037742255,0.0024570718,0.0007595526,0.0003986525,0.0020574438,0.03923932,0.00018905617,0.001973713,0.048785098],"study_design_scores_gemma":[0.34277898,0.39015463,0.24801539,0.000054707147,0.0021035182,0.0013108664,0.0002930133,0.0039161006,0.007865633,0.00042967335,0.00291423,0.00016319007],"about_ca_topic_score_codex":0.00044087222,"about_ca_topic_score_gemma":0.00092743576,"teacher_disagreement_score":0.0029148033,"about_ca_system_score_codex":0.00061574584,"about_ca_system_score_gemma":0.0008525419,"threshold_uncertainty_score":0.013423383},"labels":[],"label_agreement":null},{"id":"W2974725190","doi":"10.1200/po.19.00119","title":"Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; European Hematology Association","keywords":"Decitabine; Medicine; Cohort; Confidence interval; Myelodysplastic syndromes; Internal medicine; Oncology; Azacitidine; Hypomethylating agent; Bioinformatics; Gene; Genetics; Biology; DNA methylation","score_opus":0.052698284647689414,"score_gpt":0.3537519948482408,"score_spread":0.3010537102005514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974725190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9663458,0.0014167933,0.029881684,0.0006202006,0.000020887692,0.000091005495,0.00081570377,0.000121705656,0.00068630336],"genre_scores_gemma":[0.9892659,0.00014776469,0.0096367095,0.00010380039,0.0000242399,0.00003023199,0.000677158,0.0000033732733,0.000110763765],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9987565,0.0005934194,0.00011885571,0.00023952888,0.00022291846,0.00006885456],"domain_scores_gemma":[0.9971209,0.0015552801,0.00087936834,0.000115215764,0.00020384528,0.00012537505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022141563,0.0007334862,0.000746237,0.0022716972,0.00022838818,0.0007627709,0.00048115643,0.00054741354,0.00044589097],"category_scores_gemma":[0.0050207144,0.00019362666,0.00073008507,0.00097231223,0.0003752078,0.00033519638,0.0004869163,0.0005974535,0.000116947216],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005544306,0.0002469914,0.90036887,0.000070967915,0.0005703155,0.0002458338,0.00005511911,0.047214508,0.0024761898,0.0004025592,0.0004244422,0.04736984],"study_design_scores_gemma":[0.00015796615,0.0012282189,0.31568182,0.000057696787,0.0004286445,0.0008199652,0.00010107896,0.6726155,0.0034943847,0.0039379955,0.0014350379,0.000041722393],"about_ca_topic_score_codex":0.001650684,"about_ca_topic_score_gemma":0.0020003307,"teacher_disagreement_score":0.0022716972,"about_ca_system_score_codex":0.00043160084,"about_ca_system_score_gemma":0.000629076,"threshold_uncertainty_score":0.01170975},"labels":[],"label_agreement":null},{"id":"W2976445677","doi":"10.1200/po.19.00123","title":"Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Astellas Pharma; Prostate Cancer Canada; Emil Aaltosen Säätiö; Prostate Cancer Foundation; Jane ja Aatos Erkon Säätiö; DOD Prostate Cancer Research Program; Medical Research Council; Movember Foundation","keywords":"Prostate cancer; Androgen receptor; Oncology; Castration; Internal medicine; Medicine; Prostate; Biology; Cancer; Cancer research; Hormone","score_opus":0.02958628538235672,"score_gpt":0.3815232097330643,"score_spread":0.35193692435070756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976445677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97649014,0.011424036,0.0050321347,0.0000747431,0.00010633707,0.00035374085,0.0055902847,0.00010938026,0.0008191581],"genre_scores_gemma":[0.9954822,0.0006175765,0.0010874203,0.0000680342,0.00006914903,0.00020592981,0.002181003,0.000024799838,0.0002637693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931003,0.002804077,0.00069607113,0.0022634543,0.0008512666,0.00028475042],"domain_scores_gemma":[0.9924551,0.0024791528,0.002130259,0.0020140018,0.0006727452,0.00024871723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011410623,0.0011309668,0.0026247294,0.0021005333,0.00035660143,0.0011528432,0.00077635807,0.00092835876,0.0015331599],"category_scores_gemma":[0.01074926,0.0006153818,0.0061264443,0.0016339903,0.0003447127,0.000783752,0.00095198175,0.00058555696,0.00023388948],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031232819,0.00021837659,0.8133792,0.0013732306,0.12918247,0.0002957089,0.00025763045,0.002174544,0.0036127486,0.00020638738,0.0015788493,0.016487971],"study_design_scores_gemma":[0.0012248141,0.004896082,0.9170889,0.000120435965,0.067373544,0.0008157624,0.00023865819,0.00481086,0.0008329179,0.00042166852,0.0020830526,0.00009316605],"about_ca_topic_score_codex":0.0018231614,"about_ca_topic_score_gemma":0.0017556254,"teacher_disagreement_score":0.011410623,"about_ca_system_score_codex":0.0004386615,"about_ca_system_score_gemma":0.00040344114,"threshold_uncertainty_score":0.06034589},"labels":[],"label_agreement":null},{"id":"W2980850490","doi":"10.1200/po.19.00221","title":"Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Cancer Institute; Sanofi; Servier; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Fibroblast growth factor receptor 1; Tolerability; Medicine; Fibroblast growth factor receptor; Cancer; Breast cancer; Oncology; Internal medicine; Cancer research; Pharmacology; Receptor; Adverse effect; Fibroblast growth factor","score_opus":0.007405147188545542,"score_gpt":0.2759090181197813,"score_spread":0.26850387093123573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980850490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955499,0.0022573262,0.00036423368,0.00017318061,0.0000341633,0.00029335407,0.00014906851,0.00005456671,0.0011242081],"genre_scores_gemma":[0.9981585,0.0005029057,0.0006267101,0.00007611772,0.000030084091,0.00011939421,0.00017642291,0.0000052416144,0.00030453652],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995055,0.00015275442,0.000056393204,0.00010632761,0.00007919385,0.00009978672],"domain_scores_gemma":[0.9997613,0.00003423013,0.000056049485,0.000025810918,0.000017696953,0.00010497049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009657351,0.00084659713,0.0017205168,0.0004349343,0.00026764147,0.0006368194,0.0004865484,0.00038036305,0.0010969092],"category_scores_gemma":[0.0005818448,0.0002820362,0.00080977945,0.00050648913,0.0003832558,0.00052573264,0.0004017069,0.0012006063,0.00028391613],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32854614,0.016859852,0.042374156,0.0011036387,0.0028981909,0.0011647923,0.0005716823,0.010946506,0.15006013,0.00048972055,0.002806759,0.44217855],"study_design_scores_gemma":[0.18860793,0.6189846,0.09272242,0.00010580596,0.0027266855,0.0043441094,0.00027827497,0.010216845,0.0700037,0.0006460702,0.011240956,0.00012259014],"about_ca_topic_score_codex":0.0006649294,"about_ca_topic_score_gemma":0.0029241533,"teacher_disagreement_score":0.0017205168,"about_ca_system_score_codex":0.0008603291,"about_ca_system_score_gemma":0.00073928543,"threshold_uncertainty_score":0.006242156},"labels":[],"label_agreement":null},{"id":"W2985820722","doi":"10.1200/po.19.00235","title":"Parents’, Health Care Professionals’, and Scientists’ Experiences of a Precision Medicine Pilot Trial for Patients With High-Risk Childhood Cancer: A Qualitative Study","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Precision medicine; Qualitative research; Psychosocial; Health care; Alternative medicine; Pilot trial; Transparency (behavior); Primary care","score_opus":0.03929112324080108,"score_gpt":0.43794867917744806,"score_spread":0.398657555936647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985820722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98002964,0.0020745266,0.003101441,0.009689601,0.00023185872,0.0003050799,0.00033641126,0.000037752383,0.0041936473],"genre_scores_gemma":[0.99205136,0.0012594931,0.0012451728,0.0033724643,0.000056933673,0.00042654914,0.0001015761,0.00003790333,0.0014485896],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9806718,0.015662214,0.0004524245,0.00082025,0.0007380346,0.0016552118],"domain_scores_gemma":[0.9548084,0.0357092,0.0023814908,0.0007645207,0.0024807055,0.0038555746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016267927,0.000795438,0.0010329797,0.0010823162,0.012260189,0.0040569827,0.0020161672,0.002962064,0.003859325],"category_scores_gemma":[0.03614531,0.0009435028,0.000634435,0.000974566,0.009574382,0.005976615,0.006826958,0.005837074,0.0004727735],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034957964,0.000035380865,0.0018683298,0.00012726591,0.00000512751,0.0009764704,0.9935481,0.000022309581,0.00018878048,0.0004508697,0.00082462956,0.0019177776],"study_design_scores_gemma":[0.0000042839156,0.000041369738,0.00056367135,0.00012908313,0.0000034702532,0.00027355397,0.99379987,0.000038627342,0.000111857764,0.0001388392,0.0048850686,0.0000101715295],"about_ca_topic_score_codex":0.009227505,"about_ca_topic_score_gemma":0.01083315,"teacher_disagreement_score":0.016267927,"about_ca_system_score_codex":0.006439164,"about_ca_system_score_gemma":0.0061299,"threshold_uncertainty_score":0.08603406},"labels":[],"label_agreement":null},{"id":"W3024577926","doi":"10.1200/po.19.00335","title":"Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Mount Sinai Hospital; McGill University Health Centre; Lakeridge Health; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"T790M; Osimertinib; Concordance; Medicine; Epidermal growth factor receptor; Liquid biopsy; Internal medicine; Biopsy; Oncology; Cancer; Gefitinib","score_opus":0.10926900412114984,"score_gpt":0.47808154929876795,"score_spread":0.3688125451776181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024577926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94675934,0.00054831564,0.013103017,0.0021992675,0.00037987382,0.025877569,0.003795108,0.0006945315,0.0066430187],"genre_scores_gemma":[0.9519091,0.00011597746,0.021942573,0.0019189969,0.00019126285,0.017259132,0.005531675,0.00014046048,0.0009908397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9455733,0.040941425,0.0022870454,0.0039037194,0.0054241265,0.001870476],"domain_scores_gemma":[0.928871,0.0121646635,0.013444287,0.014524421,0.024504686,0.006491004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.080272935,0.0015841593,0.0007590139,0.00056611275,0.0015374135,0.002110223,0.0029942535,0.0021269033,0.0031241712],"category_scores_gemma":[0.06541714,0.000752623,0.0011307036,0.00096766703,0.001592196,0.0017964639,0.0022192239,0.0021664535,0.0019155744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11201906,0.041965038,0.68055785,0.0006281289,0.0015781447,0.0004006789,0.0031513944,0.004755592,0.018677715,0.0019275721,0.03374997,0.10058884],"study_design_scores_gemma":[0.06317582,0.16147959,0.69487643,0.00042529855,0.0009960348,0.0010318427,0.0014609246,0.018967776,0.016264396,0.0010042666,0.04011854,0.00019916601],"about_ca_topic_score_codex":0.008949772,"about_ca_topic_score_gemma":0.0070351143,"teacher_disagreement_score":0.080272935,"about_ca_system_score_codex":0.0046566348,"about_ca_system_score_gemma":0.012504835,"threshold_uncertainty_score":0.42452896},"labels":[],"label_agreement":null},{"id":"W3028415293","doi":"10.1200/po.19.00298","title":"Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Alberta; SickKids Foundation; University of Toronto; Stollery Children's Hospital; Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; CDKN2A; Glioma; Internal medicine; Oncology; Discontinuation; Concomitant; V600E; Chemotherapy; Cancer research; Mutation; Cancer; Gene","score_opus":0.024815737788784174,"score_gpt":0.2994300955933155,"score_spread":0.27461435780453136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028415293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990752,0.00033606068,0.00007979888,0.00003703596,0.0000023464238,0.0000069735397,0.00018104822,0.0000040821283,0.0002775412],"genre_scores_gemma":[0.99919456,0.00020610586,0.00007038851,0.000020908728,0.000008094667,0.000007750267,0.00045156674,0.000001908272,0.00003870901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99970067,0.00007070694,0.000031232776,0.000053448497,0.00006827072,0.00007574528],"domain_scores_gemma":[0.99875987,0.00011698552,0.00083629903,0.000026958733,0.00009193786,0.00016795656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028308821,0.00015606507,0.00032080835,0.0002821718,0.00022331052,0.00035306747,0.0001529081,0.00016502877,0.0003396387],"category_scores_gemma":[0.0011787136,0.0000817853,0.00019820008,0.00044850627,0.00032200213,0.00028286455,0.00029408946,0.00025534435,0.000084889856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038861888,0.000046347046,0.9879681,0.000025854068,0.000069102956,0.0005335917,0.00011246658,0.00048336343,0.00086253573,0.00003507763,0.00021240838,0.009262465],"study_design_scores_gemma":[0.00004327077,0.0010500763,0.9917853,0.000020583675,0.00007892343,0.0045534205,0.00031402873,0.00049049116,0.00078786194,0.0000763279,0.00079297874,0.0000068112563],"about_ca_topic_score_codex":0.0024808366,"about_ca_topic_score_gemma":0.0038872822,"teacher_disagreement_score":0.0024808366,"about_ca_system_score_codex":0.0005944774,"about_ca_system_score_gemma":0.00041447018,"threshold_uncertainty_score":0.004932821},"labels":[],"label_agreement":null},{"id":"W3034002596","doi":"10.1200/po.19.00295","title":"Exploring Predictors of Response to Dacomitinib in <i>EGFR</i>-Amplified Recurrent Glioblastoma","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Brain Institute","funders":"National Cancer Institute","keywords":"Epidermal growth factor receptor; Medicine; Oncology; Context (archaeology); Internal medicine; Missense mutation; Tyrosine-kinase inhibitor; Clinical trial; Cancer research; Mutation; Gene; Biology; Cancer","score_opus":0.12207920875486032,"score_gpt":0.348671926389238,"score_spread":0.22659271763437766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034002596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993686,0.00015555976,0.00011767164,0.0000271245,0.0000027423632,0.000009551051,0.000108684624,0.0000045898,0.00020551206],"genre_scores_gemma":[0.99958605,0.000042919713,0.000107450585,0.0000223687,0.000005864066,0.0000074460827,0.00016788532,0.0000016412703,0.000058383222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998061,0.00004001041,0.000025262134,0.000054726046,0.00003106519,0.000042808926],"domain_scores_gemma":[0.99937314,0.00018935236,0.00022395089,0.000020964462,0.000058895734,0.0001337565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034242988,0.00027197925,0.00045732813,0.00041793386,0.00018203478,0.0004674131,0.00014451926,0.00025677425,0.0006885739],"category_scores_gemma":[0.0010905842,0.00008344119,0.00025268976,0.0003601352,0.00018198325,0.00020844955,0.00017566264,0.00036322893,0.00015007876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013949006,0.00008591693,0.98087674,0.000018181285,0.000050947707,0.00012564712,0.000038250542,0.00043339387,0.0065898453,0.000023606051,0.0001331558,0.010229409],"study_design_scores_gemma":[0.000027804714,0.0009919619,0.9921091,0.0000072100574,0.000076161916,0.0005235768,0.0001139316,0.003071094,0.0025749893,0.00007100284,0.00042492553,0.000008256823],"about_ca_topic_score_codex":0.0011486269,"about_ca_topic_score_gemma":0.0013606838,"teacher_disagreement_score":0.0011486269,"about_ca_system_score_codex":0.0002829827,"about_ca_system_score_gemma":0.00023409966,"threshold_uncertainty_score":0.0023035407},"labels":[],"label_agreement":null},{"id":"W3062793978","doi":"10.1200/po.19.00301","title":"Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Environmental Health Sciences; National Cancer Institute","keywords":"Breast cancer; Medicine; Cancer; Oncology; Germline mutation; Internal medicine; Mutation; PALB2; Mutation rate; Genetics; Biology; Population; Gene","score_opus":0.01344799936803707,"score_gpt":0.29623009112087556,"score_spread":0.28278209175283847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3062793978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989429,0.000277622,0.00006154965,0.000025197802,0.0000039438587,0.0000035571943,0.00047605994,0.00000599345,0.00020318931],"genre_scores_gemma":[0.9993512,0.00007479384,0.0000768436,0.000016398375,0.0000060240245,0.0000039092233,0.00039987382,0.0000023832101,0.00006844657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995084,0.000074913834,0.000054677927,0.00021667054,0.00008278788,0.00006257889],"domain_scores_gemma":[0.99865353,0.00034956663,0.0006098533,0.00011960137,0.000116916635,0.00015048572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043814955,0.00023536505,0.0003814244,0.0012020447,0.00036746552,0.00051061966,0.00030292518,0.0004891043,0.0021209891],"category_scores_gemma":[0.0024810326,0.0001793184,0.00029183767,0.0009254823,0.00023646138,0.0002987592,0.00039785317,0.00035606214,0.0002220246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013221544,0.000009966207,0.9977017,0.000006965242,0.000037749272,0.00013366746,0.000028877117,0.00003672846,0.0006816476,0.000012779984,0.00008036146,0.0011373471],"study_design_scores_gemma":[0.000013584684,0.0000650553,0.997054,0.0000053418416,0.000044213244,0.0019690334,0.00007636843,0.00016888582,0.0003594403,0.00005563233,0.00018453924,0.0000039065726],"about_ca_topic_score_codex":0.0028072097,"about_ca_topic_score_gemma":0.0025671122,"teacher_disagreement_score":0.0028072097,"about_ca_system_score_codex":0.0002381329,"about_ca_system_score_gemma":0.00016172983,"threshold_uncertainty_score":0.007095456},"labels":[],"label_agreement":null},{"id":"W3083461000","doi":"10.1200/po.20.00016","title":"Systematic Assessment of Tumor Purity and Its Clinical Implications","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Prostate cancer; Concordance; Cancer; Computational biology; Biology; Transcriptome; Bioinformatics; Oncology; Medicine; Genetics; Gene expression; Gene","score_opus":0.047370018260806356,"score_gpt":0.40446640975225373,"score_spread":0.3570963914914474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083461000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.735863,0.042305537,0.21411906,0.00123195,0.00028731595,0.00031860705,0.0015533052,0.0006340852,0.0036872053],"genre_scores_gemma":[0.9838336,0.0010922719,0.013722335,0.0001946384,0.00008141554,0.0000798479,0.0006520164,0.00012291128,0.00022096242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9664719,0.017260265,0.0031243123,0.005971872,0.0067518945,0.0004197019],"domain_scores_gemma":[0.8816175,0.071983226,0.01842924,0.014964598,0.0122715905,0.0007338765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03972657,0.0007085888,0.0009744217,0.0019232688,0.000736537,0.0020195923,0.0011109757,0.00085763016,0.00061079283],"category_scores_gemma":[0.103506215,0.00037653447,0.000779092,0.0012974592,0.0017763671,0.0010880796,0.0021295575,0.000848994,0.00026876046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011921847,0.00008342971,0.8116945,0.0010027385,0.0017505058,0.00022101204,0.00094847556,0.0067362003,0.016001593,0.0016142079,0.0014435786,0.1573116],"study_design_scores_gemma":[0.0000668724,0.0011958894,0.85273343,0.0010281204,0.0021742561,0.0033093952,0.0008982944,0.040315617,0.073973775,0.007901981,0.016203422,0.0001989775],"about_ca_topic_score_codex":0.0011762158,"about_ca_topic_score_gemma":0.0011324654,"teacher_disagreement_score":0.03972657,"about_ca_system_score_codex":0.0007974032,"about_ca_system_score_gemma":0.00082145754,"threshold_uncertainty_score":0.21009672},"labels":[],"label_agreement":null},{"id":"W3087896793","doi":"10.1200/po.20.00115","title":"Personalized Multimodal Demarcation of Peritumoral Tissue in Glioma","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Glioma; Exome sequencing; Magnetic resonance imaging; Medicine; Biopsy; Pathology; Brain tissue; Histology; Infiltration (HVAC); Neuroimaging; Biology; Radiology; Gene; Cancer research; Anatomy","score_opus":0.039032026238928014,"score_gpt":0.35805033617922705,"score_spread":0.319018309940299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087896793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97484845,0.003451526,0.019606922,0.0002501261,0.0000207932,0.000057406505,0.00051778764,0.0001463877,0.0011004797],"genre_scores_gemma":[0.9874472,0.00070750085,0.010839421,0.00010947265,0.000024917663,0.000047292637,0.00045639407,0.000030958294,0.00033683504],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999069,0.000023849005,0.0000062794015,0.000031048658,0.000018290411,0.000013629845],"domain_scores_gemma":[0.99988186,0.000026552048,0.000045610363,0.000010188205,0.000021381835,0.000014349611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027194765,0.0003215236,0.00032375794,0.0007658154,0.00013521628,0.00032917433,0.00020270942,0.00031823004,0.0006798999],"category_scores_gemma":[0.00059643254,0.00008433457,0.00020353096,0.00027547393,0.00017721529,0.00027127124,0.00030777388,0.00022878769,0.00020092196],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015363387,0.00015085052,0.21424179,0.0006836056,0.00021788411,0.0020077988,0.00052231405,0.005057459,0.52125597,0.0005339019,0.0018978337,0.25189438],"study_design_scores_gemma":[0.00007278292,0.0012827164,0.73063964,0.00020352779,0.0005497816,0.008530286,0.00097507593,0.040283415,0.20090908,0.0043729953,0.012094446,0.00008620194],"about_ca_topic_score_codex":0.00065068505,"about_ca_topic_score_gemma":0.0015922496,"teacher_disagreement_score":0.0007658154,"about_ca_system_score_codex":0.00020010369,"about_ca_system_score_gemma":0.0001590896,"threshold_uncertainty_score":0.0022745132},"labels":[],"label_agreement":null},{"id":"W3090984898","doi":"10.1200/po.20.00087","title":"Nearly Half of <i>TP53</i> Germline Variants Predicted To Be Pathogenic in Patients With Osteosarcoma Are De Novo: A Report From the Children’s Oncology Group","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute","keywords":"Sanger sequencing; Exome sequencing; Genetics; Germline; Exact test; Gene; Biology; Copy-number variation; Mutation; Medicine; Internal medicine; Genome","score_opus":0.020590188654738488,"score_gpt":0.28020910921499936,"score_spread":0.25961892056026087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090984898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982766,0.00084799854,0.00017471841,0.000050301867,0.0000059226154,0.0000051512843,0.00018006681,0.000009472818,0.00044982455],"genre_scores_gemma":[0.9993069,0.0003289842,0.000108208376,0.00003285216,0.000013412861,0.0000018341872,0.00016156373,0.0000033032156,0.000042760916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994412,0.000071622315,0.00007296337,0.00019734525,0.00014615801,0.000070686365],"domain_scores_gemma":[0.9985966,0.00049880944,0.0005463282,0.00009385813,0.00015506647,0.00010927617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051693904,0.00027843897,0.00023350024,0.0007870128,0.0002620926,0.00037484724,0.0002515729,0.0003713449,0.0007986778],"category_scores_gemma":[0.0021383222,0.00017038113,0.00016937085,0.00057245244,0.00043602294,0.00022365978,0.00019021533,0.0002734345,0.00017673706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006867929,0.000010195356,0.99073505,0.000017681248,0.00002454206,0.0019705673,0.00015233086,0.00005066944,0.0021237792,0.00003266019,0.00018357688,0.00463033],"study_design_scores_gemma":[0.000012657233,0.00016176773,0.9716007,0.000019385994,0.00006737837,0.024236226,0.0002921574,0.00019707672,0.0018140249,0.000045467175,0.0015447986,0.000008516495],"about_ca_topic_score_codex":0.0029066037,"about_ca_topic_score_gemma":0.0022927609,"teacher_disagreement_score":0.0029066037,"about_ca_system_score_codex":0.00021294216,"about_ca_system_score_gemma":0.00016308048,"threshold_uncertainty_score":0.0057793856},"labels":[],"label_agreement":null},{"id":"W3091309223","doi":"10.1200/po.20.00050","title":"Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ottawa Hospital","funders":"Rosetrees Trust; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Internal medicine; Hazard ratio; Cetuximab; Colorectal cancer; Oncology; Odds ratio; Cohort; Epidermal growth factor receptor; Univariate analysis; Progression-free survival; Multivariate analysis; Cancer; Overall survival; Confidence interval","score_opus":0.03191056901264257,"score_gpt":0.30157792678446776,"score_spread":0.2696673577718252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091309223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987956,0.00046444358,0.00011107759,0.0000531545,0.000009395668,0.000012999141,0.00026524885,0.0000037053273,0.00028434803],"genre_scores_gemma":[0.998689,0.00011790773,0.00010078952,0.000055065797,0.000019647821,0.000023321707,0.0007914584,0.0000032710318,0.00019956495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99958545,0.00014333932,0.000031991865,0.000118753385,0.00006827528,0.000052273197],"domain_scores_gemma":[0.9988444,0.00030429938,0.00048168493,0.0001028289,0.000091043505,0.00017576094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010458301,0.00021197407,0.0006137377,0.00017466155,0.0002024637,0.0005843262,0.00018691387,0.00028643679,0.00079016],"category_scores_gemma":[0.0010626733,0.00013502636,0.0003641727,0.00024314245,0.00024169347,0.00021769342,0.0002917061,0.00047108997,0.0001237436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06692692,0.0006648039,0.8412678,0.00020958479,0.001068652,0.00021767571,0.00014714467,0.0010237313,0.054922093,0.00011158917,0.001186136,0.032253847],"study_design_scores_gemma":[0.0010784864,0.0057216785,0.98241824,0.000015409149,0.00070594467,0.00046248263,0.000091345784,0.0018089296,0.0055508344,0.00015967326,0.0019661156,0.000020898104],"about_ca_topic_score_codex":0.000224554,"about_ca_topic_score_gemma":0.00061422924,"teacher_disagreement_score":0.0010458301,"about_ca_system_score_codex":0.00025882685,"about_ca_system_score_gemma":0.00021339665,"threshold_uncertainty_score":0.005530894},"labels":[],"label_agreement":null},{"id":"W3093179741","doi":"10.1200/po.20.00013","title":"Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Decipher Biosciences (Canada)","funders":"","keywords":"Nomogram; Prostate cancer; Prostatectomy; Medicine; Logistic regression; Oncology; Cohort; Internal medicine; Prostate; Cancer; Urology","score_opus":0.03633023327856901,"score_gpt":0.2947791237358805,"score_spread":0.2584488904573115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093179741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788504,0.000987262,0.016131273,0.00033613917,0.000032423937,0.00012468449,0.0024646705,0.00030344498,0.000769682],"genre_scores_gemma":[0.9819326,0.00022541764,0.013555837,0.000096249576,0.00001779243,0.000056450797,0.0038688127,0.00002077529,0.00022602965],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99946743,0.00013861466,0.000035852543,0.00015154516,0.00015866748,0.000047908063],"domain_scores_gemma":[0.9989396,0.00041315585,0.00023658686,0.00010053005,0.00022863921,0.000081493425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017989547,0.00056909746,0.0004255879,0.0013975126,0.0002393231,0.0009688986,0.0005922562,0.00038539196,0.0006159187],"category_scores_gemma":[0.0036547293,0.00018958487,0.0004778921,0.0007235707,0.0003034261,0.00028756054,0.0006650872,0.00048792086,0.00032834188],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064468867,0.00024042069,0.8855903,0.0001462756,0.0002943859,0.00014342518,0.00009231295,0.012892729,0.016078452,0.00024158067,0.0013218757,0.082313575],"study_design_scores_gemma":[0.0002487305,0.0018419266,0.70047367,0.00016384207,0.0006006477,0.0014802947,0.00036536963,0.25858396,0.028184678,0.001957701,0.0060406975,0.000058383375],"about_ca_topic_score_codex":0.0015566502,"about_ca_topic_score_gemma":0.0025862912,"teacher_disagreement_score":0.0017989547,"about_ca_system_score_codex":0.0003996988,"about_ca_system_score_gemma":0.0009136969,"threshold_uncertainty_score":0.009513915},"labels":[],"label_agreement":null},{"id":"W3118235744","doi":"10.1200/po.20.00218","title":"Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma","year":2021,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Vector Institute; Hospital for Sick Children; University of Toronto","funders":"Hyundai Hope On Wheels; Canadian Institutes of Health Research; University of Toronto; National Cancer Institute; National Institutes of Health; Consejo Nacional de Ciencia y Tecnología; Children’s Oncology Group; Hope Foundation; Huntsman Cancer Institute; Cancer Prevention and Research Institute of Texas","keywords":"Germline; Genetics; Biology; Exome; CHEK2; Exome sequencing; Germline mutation; Cancer; Fusion gene; Oncology; Gene; Medicine; Mutation","score_opus":0.015798789811242317,"score_gpt":0.3125947657448777,"score_spread":0.2967959759336354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118235744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989367,0.00022372566,0.00007556948,0.000019835375,0.0000034173188,0.0000048259344,0.00048260862,0.00000501436,0.00024832308],"genre_scores_gemma":[0.9991534,0.00014998566,0.00013888387,0.00002410121,0.0000058316086,0.000007093849,0.0004397939,0.000003256311,0.00007782615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99970776,0.000030127421,0.000028615153,0.00012263097,0.00006370189,0.00004711272],"domain_scores_gemma":[0.9994332,0.00015505997,0.00024601095,0.000031785898,0.000045361474,0.00008853658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031787073,0.0002973628,0.00026090856,0.00086761295,0.00043240015,0.00031851657,0.00022569892,0.00033798796,0.0015499574],"category_scores_gemma":[0.0011298755,0.00015424126,0.00028916693,0.00069290446,0.00035466554,0.0001888313,0.00039957155,0.00033534726,0.00017388967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010112525,0.0000103725615,0.9946931,0.000011230954,0.000029154808,0.00090864865,0.00012354231,0.00006401681,0.0019328663,0.000040630246,0.00013682482,0.0019484329],"study_design_scores_gemma":[0.0000103602215,0.00006085604,0.9943335,0.000010240351,0.000027662349,0.0042435485,0.00017214571,0.0000854764,0.000495204,0.000052972424,0.0005039509,0.000003972231],"about_ca_topic_score_codex":0.0029445945,"about_ca_topic_score_gemma":0.003369396,"teacher_disagreement_score":0.0029445945,"about_ca_system_score_codex":0.00023409208,"about_ca_system_score_gemma":0.00027902756,"threshold_uncertainty_score":0.0058549047},"labels":[],"label_agreement":null},{"id":"W3120676907","doi":"10.1200/po.20.00214","title":"Revisiting Risk and Benefit in Early Oncology Trials in the Era of Precision Medicine: A Systematic Review and Meta-Analysis of Phase I Trials of Targeted Single-Agent Anticancer Therapies","year":2021,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Allison University; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Medicine; Clinical trial; Internal medicine; Oncology; Adverse effect; Meta-analysis; Cancer","score_opus":0.7534315246724375,"score_gpt":0.6499043875348117,"score_spread":0.10352713713762574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120676907","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032241137,0.99263316,0.0018966064,0.00045554445,0.0002775229,0.0007113112,0.0005224245,0.000028637984,0.00025069693],"genre_scores_gemma":[0.36594146,0.60787505,0.012145777,0.0040740585,0.0010329947,0.0068017244,0.0015777837,0.00014506138,0.0004061245],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.8646914,0.078474104,0.04117992,0.0069971955,0.007655,0.0010024324],"domain_scores_gemma":[0.7125484,0.23447983,0.036400903,0.008110386,0.00759801,0.00086257857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1046678,0.0034344592,0.029539535,0.012661753,0.00077313324,0.0059847054,0.003417539,0.0031405676,0.0029140455],"category_scores_gemma":[0.21189313,0.002510784,0.036627058,0.011634562,0.0018672299,0.004567746,0.0025830374,0.002652411,0.0003161833],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013309694,0.000019374678,0.004448264,0.40374318,0.5779525,0.000116512674,0.00012956184,0.00044834169,0.00014581249,0.00032754536,0.0005025465,0.01083536],"study_design_scores_gemma":[0.0013508276,0.00024325773,0.00461728,0.06692952,0.92180854,0.00012826535,0.00009750518,0.00035817802,0.0001801319,0.0011741921,0.0030684413,0.00004379757],"about_ca_topic_score_codex":0.0033218786,"about_ca_topic_score_gemma":0.007412639,"teacher_disagreement_score":0.1046678,"about_ca_system_score_codex":0.004041698,"about_ca_system_score_gemma":0.0057194387,"threshold_uncertainty_score":0.55354285},"labels":[],"label_agreement":null},{"id":"W3130023215","doi":"10.1200/po.20.00419","title":"Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC","year":2021,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Defense","keywords":"Medicine; Cohort; Oncology; Osimertinib; Internal medicine; KRAS; T790M; Lung cancer; Digital polymerase chain reaction; Cancer; Biology; Polymerase chain reaction; Genetics","score_opus":0.011309667848475131,"score_gpt":0.31052400366877686,"score_spread":0.2992143358203017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130023215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920759,0.0025770366,0.0027112507,0.000094297175,0.000022064498,0.000072729395,0.0007418851,0.00011566231,0.0015891319],"genre_scores_gemma":[0.9981791,0.00019524783,0.000806057,0.00005902103,0.000016847674,0.0000342239,0.0003605269,0.000011334101,0.00033762466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907637,0.00023844463,0.00010057614,0.00021055731,0.00031513826,0.0000588988],"domain_scores_gemma":[0.9970176,0.0010248277,0.0013761832,0.00014201915,0.0002650695,0.00017425476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010411176,0.00028317,0.0004932323,0.0005562675,0.00016719296,0.0004929451,0.00024517984,0.0003924705,0.0008960684],"category_scores_gemma":[0.0032218208,0.00014765306,0.00019836532,0.00043905058,0.00020634593,0.00037239373,0.0002652857,0.0005888792,0.00021161058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049291546,0.0002729122,0.7745688,0.00022472258,0.00017280599,0.00025156338,0.00020653193,0.0017790444,0.14722855,0.000112302434,0.00058902084,0.06966459],"study_design_scores_gemma":[0.000037409638,0.002634106,0.95979357,0.000019585452,0.00007329756,0.0009610991,0.00007744793,0.0024468722,0.03236492,0.0001004167,0.0014757576,0.000015583404],"about_ca_topic_score_codex":0.0005375105,"about_ca_topic_score_gemma":0.0007715403,"teacher_disagreement_score":0.0010411176,"about_ca_system_score_codex":0.00041474114,"about_ca_system_score_gemma":0.00019470227,"threshold_uncertainty_score":0.005505979},"labels":[],"label_agreement":null},{"id":"W3134802082","doi":"10.1200/po.20.00370","title":"Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment","year":2021,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University Health Network; Toronto General Hospital; University of Toronto; McMaster University; Juravinski Hospital","funders":"Canadian Institutes of Health Research","keywords":"Myocarditis; Immune checkpoint; Medicine; Immune system; Immunology; Inflammation; Cancer research; Immunotherapy; Internal medicine","score_opus":0.02483418104461527,"score_gpt":0.30841904254623725,"score_spread":0.283584861501622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134802082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98423517,0.0069069494,0.0020720472,0.00086655107,0.00020368864,0.0000623702,0.00012205146,0.00011489952,0.005416262],"genre_scores_gemma":[0.997792,0.0007051937,0.000330037,0.00026167702,0.00030371282,0.000011125212,0.00016240412,0.000008384226,0.00042543773],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.999653,0.000066044035,0.000041316376,0.00006823297,0.00006882317,0.00010256275],"domain_scores_gemma":[0.9992269,0.00016447791,0.00034420018,0.0000846726,0.000042942036,0.00013670827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043176318,0.00046497097,0.00064128375,0.00035776393,0.00030257565,0.00049840426,0.00029095728,0.00076421554,0.0010874817],"category_scores_gemma":[0.0011343543,0.00014901684,0.0005419664,0.00028724188,0.00028139402,0.00033764238,0.00021478265,0.0009860712,0.00042436062],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014595014,0.0012744563,0.24970254,0.00063849764,0.0007038531,0.3335758,0.0005219587,0.00065443414,0.2710842,0.0010690728,0.0030405167,0.123139605],"study_design_scores_gemma":[0.00063525303,0.0067555746,0.56796336,0.0002018311,0.000852159,0.37802774,0.0003801185,0.0030005525,0.029528018,0.0010267742,0.011560832,0.00006784451],"about_ca_topic_score_codex":0.00014758043,"about_ca_topic_score_gemma":0.00018825673,"teacher_disagreement_score":0.0010874817,"about_ca_system_score_codex":0.00021848713,"about_ca_system_score_gemma":0.00016962104,"threshold_uncertainty_score":0.003638029},"labels":[],"label_agreement":null},{"id":"W3157171213","doi":"10.1200/po.20.00348","title":"Metastatic Large-Cell Neuroendocrine Lung Carcinoma With ALK Fusion Oncogene With Partial Response to Alectinib","year":2021,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Alectinib; Medicine; Cancer research; Internal medicine; Oncology; Lung cancer; Crizotinib","score_opus":0.02582143413691037,"score_gpt":0.35746795894768646,"score_spread":0.3316465248107761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157171213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9354002,0.010234997,0.003647685,0.01617716,0.0012985375,0.00046307975,0.0029345017,0.00041423045,0.029429577],"genre_scores_gemma":[0.9885035,0.0013063602,0.001148221,0.0024302576,0.000285745,0.000058930156,0.0016874471,0.000036216807,0.0045432923],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998424,0.000013308872,0.000017553793,0.0000365715,0.000032107844,0.00005806643],"domain_scores_gemma":[0.9996804,0.00006738832,0.000029814028,0.000033373894,0.000032436732,0.00015660828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022224509,0.00050823326,0.0007796405,0.00035237125,0.00048554904,0.0004784505,0.00042419278,0.0008855201,0.0022288233],"category_scores_gemma":[0.0006486585,0.00012530238,0.000838652,0.00036376048,0.0003561458,0.00035813573,0.00030537398,0.0012819335,0.0006457388],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073131295,0.00064989255,0.04601762,0.0007754243,0.0004008919,0.73657835,0.00032671855,0.0044127814,0.07704845,0.0013300536,0.01593175,0.109214865],"study_design_scores_gemma":[0.0016944989,0.0050674463,0.14084339,0.00011674949,0.0009463814,0.74856913,0.0005081989,0.009733571,0.034205265,0.0037988487,0.054417063,0.0000994665],"about_ca_topic_score_codex":0.0016513012,"about_ca_topic_score_gemma":0.005322849,"teacher_disagreement_score":0.0022288233,"about_ca_system_score_codex":0.0009885253,"about_ca_system_score_gemma":0.00052026357,"threshold_uncertainty_score":0.0074561834},"labels":[],"label_agreement":null},{"id":"W3194774701","doi":"10.1200/po.20.00489","title":"Ethical and Analytic Challenges With Genomic Sequencing of Relapsed Hematologic Malignancies Following Allogeneic Hematopoietic Stem-Cell Transplantation","year":2021,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Canadian Blood Services; Dalhousie University; SickKids Foundation; University of Toronto; University of Ottawa; Hospital for Sick Children","funders":"","keywords":"Transplantation; Hematopoietic stem cell transplantation; Germline; Oncology; Leukemia; DNA sequencing; Stem cell; Cancer; Haematopoiesis; Biology; Medicine; Immunology; Bioinformatics; Internal medicine; Genetics; Gene","score_opus":0.023030350924798763,"score_gpt":0.2738923576790774,"score_spread":0.2508620067542786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194774701","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16494878,0.022678684,0.29962313,0.45329362,0.006879221,0.0020626772,0.0010820387,0.0006824398,0.048749465],"genre_scores_gemma":[0.68682176,0.01155734,0.19233787,0.09438941,0.004471434,0.0022230507,0.0008021963,0.00039737922,0.00699954],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9077584,0.065014064,0.006669355,0.0035547544,0.015211081,0.0017922709],"domain_scores_gemma":[0.82127976,0.12297182,0.016754722,0.016754135,0.017841626,0.0043978738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.13421977,0.00033798412,0.00067875686,0.0012831765,0.002158948,0.0054908157,0.0021958034,0.003898852,0.0022058254],"category_scores_gemma":[0.124617614,0.00048341017,0.0005352765,0.00089880393,0.007437544,0.001827555,0.0038456495,0.00591374,0.0012153515],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017657162,0.00034021263,0.093716875,0.001975337,0.00030153702,0.016635695,0.022786366,0.008033396,0.020287221,0.1589258,0.11953624,0.5556956],"study_design_scores_gemma":[0.00015591452,0.00071237027,0.03362836,0.0055493983,0.00025116972,0.033042774,0.021485182,0.011471859,0.028712919,0.37991998,0.4848181,0.0002520018],"about_ca_topic_score_codex":0.0017669483,"about_ca_topic_score_gemma":0.003222887,"teacher_disagreement_score":0.13421977,"about_ca_system_score_codex":0.002137418,"about_ca_system_score_gemma":0.007857202,"threshold_uncertainty_score":0.70983046},"labels":[],"label_agreement":null},{"id":"W3197515132","doi":"10.1200/po.21.00153","title":"Upfront Adjuvant Immunotherapy of Replication Repair–Deficient Pediatric Glioblastoma With Chemoradiation-Sparing Approach","year":2021,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Adjuvant; Glioblastoma; Replication (statistics); Immunotherapy; Oncology; Internal medicine; Cancer research; Cancer; Virology","score_opus":0.018086391426018276,"score_gpt":0.29517537609717054,"score_spread":0.2770889846711523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197515132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95707595,0.021341948,0.011908025,0.0011558941,0.00038665853,0.00025285085,0.00066078384,0.00050557795,0.006712403],"genre_scores_gemma":[0.98597395,0.005594791,0.005290587,0.0003953309,0.00006395169,0.00015880451,0.0009604586,0.000041948144,0.0015201488],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99993145,0.000008288072,0.000004244638,0.000018219236,0.000011586873,0.00002622402],"domain_scores_gemma":[0.99994934,0.00000738018,0.000010326176,0.000010788456,0.00000810684,0.000013999218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014804654,0.00026635063,0.0005242382,0.00020693168,0.00018958938,0.0002812379,0.00028155342,0.00022400079,0.0011323214],"category_scores_gemma":[0.00017229289,0.00008639397,0.00034885426,0.00019760265,0.00015397588,0.0002796212,0.0002482739,0.00071211613,0.00023321167],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008128772,0.0018368625,0.014169004,0.0009781317,0.00044510444,0.002690623,0.00031035833,0.006990762,0.26885366,0.0054741343,0.011677005,0.67844546],"study_design_scores_gemma":[0.007032103,0.043650478,0.09192431,0.00079873076,0.003825199,0.03360995,0.00069137936,0.027489629,0.49726748,0.011793488,0.28174928,0.000167993],"about_ca_topic_score_codex":0.00072281953,"about_ca_topic_score_gemma":0.0017977238,"teacher_disagreement_score":0.0011323214,"about_ca_system_score_codex":0.00041803284,"about_ca_system_score_gemma":0.00051971065,"threshold_uncertainty_score":0.0037879348},"labels":[],"label_agreement":null},{"id":"W3198276706","doi":"10.1200/po.21.00112","title":"Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma","year":2021,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Cancer Care Ontario","funders":"National Cancer Institute; NRG Oncology; Ohio State University; Pennsylvania Department of Health","keywords":"Methylation; Temozolomide; Oncology; Hazard ratio; Internal medicine; Glioma; ATRX; Proportional hazards model; Medicine; Progression-free survival; Radiation therapy; Cancer research; Biology; Gene; Overall survival; Genetics; Confidence interval; Mutation","score_opus":0.022589782427132058,"score_gpt":0.3559463888212738,"score_spread":0.3333566063941417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198276706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971079,0.0013021876,0.00041841052,0.00014959669,0.000013971851,0.00008680927,0.0005144513,0.000027388709,0.00037918755],"genre_scores_gemma":[0.9954081,0.0007060072,0.00084844645,0.00023881784,0.000035430403,0.00010612709,0.0018158697,0.000019068157,0.00082214136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99944705,0.00025117467,0.000033027543,0.000094356015,0.00010721456,0.00006713226],"domain_scores_gemma":[0.9992174,0.00009666272,0.00023150309,0.00012298577,0.00007875489,0.00025259916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022089006,0.00045868484,0.0008423614,0.00022956888,0.00029132256,0.0005604217,0.00038707166,0.00030179514,0.00052701705],"category_scores_gemma":[0.0011693693,0.00023886329,0.00042231882,0.0002533563,0.00033948186,0.00028157947,0.00023465698,0.0005350905,0.00027174235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041003454,0.008277167,0.5425543,0.00039554428,0.0026293655,0.0011619653,0.00053368846,0.002877908,0.18852937,0.00013078742,0.004876731,0.20702955],"study_design_scores_gemma":[0.0066951206,0.10450163,0.83581585,0.000040318464,0.0023897402,0.0034320066,0.0002816272,0.0022333155,0.031438716,0.00018707685,0.012924889,0.00005962127],"about_ca_topic_score_codex":0.0013848322,"about_ca_topic_score_gemma":0.0030068106,"teacher_disagreement_score":0.0022089006,"about_ca_system_score_codex":0.000673591,"about_ca_system_score_gemma":0.0006593208,"threshold_uncertainty_score":0.011681914},"labels":[],"label_agreement":null},{"id":"W3217758388","doi":"10.1200/po.21.00543","title":"Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Oncology; PTEN; Prostate cancer; Prostate; Lung; Lung cancer; Internal medicine; Pathology; Cancer; Biology; Genetics","score_opus":0.026086967435030754,"score_gpt":0.377235857640557,"score_spread":0.35114889020552625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217758388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982786,0.00052196096,0.00043940716,0.000020637803,0.0000014319833,0.0000071355953,0.00030640684,0.000017995806,0.0004064104],"genre_scores_gemma":[0.99958116,0.00006565254,0.00012319304,0.000008173274,0.0000025000595,0.0000020363425,0.0001752418,0.0000024597769,0.00003952825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99988353,0.00001899903,0.00000918444,0.000039260503,0.000029656672,0.000019360714],"domain_scores_gemma":[0.9996309,0.00007626491,0.0001574292,0.000035827507,0.00004059192,0.00005887599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016466631,0.00016800304,0.00018148644,0.0007452566,0.00019353382,0.00031135083,0.00021197651,0.00016747827,0.001452239],"category_scores_gemma":[0.00067144673,0.000088346125,0.00013155662,0.00053707644,0.000243867,0.00015233892,0.0002702021,0.00017695138,0.00017127406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017750588,0.000017555845,0.9599572,0.000059091617,0.00005691876,0.0014623344,0.00010685273,0.00036051933,0.02670462,0.00009655144,0.00013884247,0.010862039],"study_design_scores_gemma":[0.000003889723,0.00011200191,0.9896596,0.0000049995115,0.00003802726,0.0066513093,0.00008633411,0.00040257696,0.0024958388,0.000112822556,0.00042797445,0.000004491177],"about_ca_topic_score_codex":0.0011629985,"about_ca_topic_score_gemma":0.0018892409,"teacher_disagreement_score":0.001452239,"about_ca_system_score_codex":0.00018650386,"about_ca_system_score_gemma":0.00016712843,"threshold_uncertainty_score":0.004858196},"labels":[],"label_agreement":null},{"id":"W4205496667","doi":"10.1200/po.21.00303","title":"Sustained Response to the Mitogen-Activated Extracellular Kinase Inhibitor Trametinib in a Spindle Cell Sarcoma Harboring a QKI-RAF1 Gene Fusion","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Trametinib; Fusion gene; Kinase; Extracellular; Fusion protein; Sarcoma; Cell culture; Gene","score_opus":0.014707803517898384,"score_gpt":0.26693388961498593,"score_spread":0.2522260860970875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205496667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998752,0.00020198616,0.00020540191,0.00013510302,0.000027237671,0.000011754931,0.0001505541,0.000021449057,0.0004944237],"genre_scores_gemma":[0.99902177,0.000078755016,0.00014341978,0.00003181569,0.000004518203,0.0000057404964,0.00020108306,0.000002420658,0.0005104637],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.99992776,0.000007114862,0.0000059434933,0.000012293636,0.000014028104,0.00003276059],"domain_scores_gemma":[0.99993265,0.000021185524,0.000011497451,0.0000063613757,0.000005660504,0.000022771057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008824139,0.00014712379,0.0002564371,0.0001245633,0.00015374714,0.00021168726,0.0001515892,0.00037143254,0.0007467093],"category_scores_gemma":[0.00016042539,0.00007889466,0.00023167979,0.00012224824,0.00013157066,0.00011732654,0.00008449855,0.0006247679,0.000177676],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019703768,0.00028787856,0.0010817191,0.000023629067,0.000017885843,0.0030244614,0.000040299143,0.0004060764,0.98882616,0.00008358988,0.00030482074,0.003933218],"study_design_scores_gemma":[0.00037544325,0.008398538,0.04547517,0.00000619661,0.00010604841,0.012792595,0.00018800121,0.010631027,0.91808605,0.00014882746,0.003763346,0.000028874858],"about_ca_topic_score_codex":0.0019282813,"about_ca_topic_score_gemma":0.002281598,"teacher_disagreement_score":0.0019282813,"about_ca_system_score_codex":0.0003047896,"about_ca_system_score_gemma":0.00019901853,"threshold_uncertainty_score":0.0038340688},"labels":[],"label_agreement":null},{"id":"W4214884454","doi":"10.1200/po.21.00286","title":"Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"St. Baldrick's Foundation; Hospital for Sick Children; Bristol-Myers Squibb","keywords":"Somatic hypermutation; Immune checkpoint; Immune system; Medicine; Oncology; Immunology; Immunotherapy; Antibody; B cell","score_opus":0.04808232243282154,"score_gpt":0.35595393747601456,"score_spread":0.30787161504319305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214884454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880233,0.0062289243,0.0009620263,0.0002593851,0.00012141816,0.00054195686,0.00036929426,0.0000549957,0.0034387726],"genre_scores_gemma":[0.98892874,0.0061224606,0.0015020076,0.00048845337,0.00011378959,0.0003255862,0.00064427656,0.00004852222,0.0018261162],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9995615,0.00012090241,0.000027967792,0.000109141045,0.00006129262,0.000119214754],"domain_scores_gemma":[0.99949133,0.00010645648,0.00007160535,0.00014052604,0.000035755198,0.00015433383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012412895,0.0006468481,0.001783667,0.00046066716,0.00036793243,0.0009309682,0.0006897837,0.0005155349,0.0027142575],"category_scores_gemma":[0.0006635383,0.00026175397,0.0013392569,0.0005875506,0.00073106465,0.00057846186,0.0003254442,0.0031216356,0.0005102494],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16949324,0.11725154,0.016159873,0.0021499067,0.003151008,0.00093200087,0.0007998715,0.0048977653,0.12747483,0.0023064362,0.0052362024,0.55014735],"study_design_scores_gemma":[0.07124248,0.82072437,0.026705686,0.00030833372,0.0044459654,0.0035438433,0.00046824664,0.0033090739,0.042480685,0.00080488564,0.025882378,0.00008399379],"about_ca_topic_score_codex":0.0012933126,"about_ca_topic_score_gemma":0.0022816241,"teacher_disagreement_score":0.0027142575,"about_ca_system_score_codex":0.0007839156,"about_ca_system_score_gemma":0.0010865409,"threshold_uncertainty_score":0.009080052},"labels":[],"label_agreement":null},{"id":"W4220893093","doi":"10.1200/po.21.00444","title":"Perspectives and Experiences of Parents and Adolescents Who Participate in a Pediatric Precision Oncology Program: \"When You Feel Helpless, This Kind of Thing Is Very Helpful\"","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Pediatric oncology; Psychology; Precision oncology; Medical education; Medicine; Precision medicine; Internal medicine; Pathology; Cancer","score_opus":0.04581433474278136,"score_gpt":0.38000507260566985,"score_spread":0.3341907378628885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220893093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407464,0.000778368,0.0005325885,0.0028487314,0.00010347904,0.000041830448,0.00006422017,0.000008494846,0.0015477673],"genre_scores_gemma":[0.99643517,0.0009710842,0.0004523556,0.0014287668,0.000028319906,0.000061800056,0.000040614243,0.000008305521,0.0005736538],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9964987,0.0026935912,0.00009942278,0.00014960898,0.00025643612,0.00030220693],"domain_scores_gemma":[0.9945492,0.002910684,0.000981681,0.00010577211,0.00047652886,0.000976098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048336056,0.00034103825,0.00038357105,0.0003686938,0.003298153,0.0024764119,0.00054842304,0.0012623774,0.0014087973],"category_scores_gemma":[0.010982172,0.00039885833,0.00035326948,0.00035631392,0.0027608,0.001860381,0.0026026107,0.0028477625,0.00020476113],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070955895,0.0000674407,0.043928795,0.00014131588,0.000022476255,0.0038029773,0.939101,0.00005467137,0.0008669469,0.00064136,0.002287889,0.009014147],"study_design_scores_gemma":[0.000004810235,0.00010839128,0.00887166,0.00012829625,0.000014662171,0.0017342109,0.9810472,0.000055954908,0.0002229817,0.00015641753,0.0076389303,0.000016415592],"about_ca_topic_score_codex":0.002818619,"about_ca_topic_score_gemma":0.0052198735,"teacher_disagreement_score":0.0048336056,"about_ca_system_score_codex":0.0010124375,"about_ca_system_score_gemma":0.0018192001,"threshold_uncertainty_score":0.025562882},"labels":[],"label_agreement":null},{"id":"W4224233487","doi":"10.1200/po.21.00450","title":"Common Variant in ALDH2 Modifies the Risk of Breast Cancer Among Carriers of the p.K3326* Variant in BRCA2","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Public Health Ontario; Women's College Hospital; University of Toronto","funders":"","keywords":"ALDH2; Breast cancer; Penetrance; Allele; Genotype; Odds ratio; Cancer; Aldehyde dehydrogenase; Oncology; Internal medicine; Genetics; Medicine; Cancer research; Biology; Gene; Phenotype","score_opus":0.0101542968579992,"score_gpt":0.2856685276857461,"score_spread":0.2755142308277469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224233487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992894,0.0001941195,0.00014747033,0.000020681133,0.000005940792,0.0000048199463,0.00013817585,0.000006329045,0.00019301707],"genre_scores_gemma":[0.9996184,0.00006167485,0.00007059939,0.000013831266,0.0000063344446,0.0000030492608,0.00008568088,0.000003464418,0.00013702594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99970335,0.00006409643,0.000027318218,0.00012469896,0.000043050935,0.00003757133],"domain_scores_gemma":[0.9995654,0.00010685935,0.00019140792,0.00004667538,0.00003215318,0.00005751966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028826518,0.0005198982,0.00043288912,0.0005392039,0.0003220715,0.0004272739,0.00024321431,0.0003919861,0.0023011838],"category_scores_gemma":[0.0013496085,0.00031831834,0.0005509678,0.00078843156,0.00026043688,0.00018817202,0.00027632303,0.00038493503,0.0002274403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011057501,0.00005186692,0.9873921,0.000026838545,0.0004498779,0.0008011337,0.00012701041,0.00011263976,0.006755738,0.00006244513,0.00013902325,0.0029756275],"study_design_scores_gemma":[0.000035550172,0.0002058818,0.9961067,0.000008759382,0.00026199195,0.0016897667,0.00009615075,0.0004217907,0.00078290456,0.000110670626,0.00027353916,0.0000061877704],"about_ca_topic_score_codex":0.0034437322,"about_ca_topic_score_gemma":0.0021054829,"teacher_disagreement_score":0.0034437322,"about_ca_system_score_codex":0.00012537182,"about_ca_system_score_gemma":0.00013015562,"threshold_uncertainty_score":0.007698238},"labels":[],"label_agreement":null},{"id":"W4282915006","doi":"10.1200/po.22.00111","title":"Primary Clonal Loss of Mismatch Repair Protein on Immunohistochemistry: A Pattern of Abnormality That Warrants Genetic Workup","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Citation; Cancer; Library science; Medicine; History; Internal medicine; Computer science","score_opus":0.024669997840590898,"score_gpt":0.3091589239311139,"score_spread":0.284488926090523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282915006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5618158,0.042369995,0.034436174,0.03843187,0.0039173937,0.0011129819,0.0028179814,0.0035131823,0.31158456],"genre_scores_gemma":[0.9567714,0.014880748,0.0075221327,0.0040565147,0.0022263373,0.00006522951,0.00081857585,0.00028122865,0.013377873],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99937457,0.000060860253,0.000073908974,0.0000827637,0.0002690163,0.00013901402],"domain_scores_gemma":[0.99773115,0.00062038173,0.00065441756,0.00031847775,0.0003266851,0.00034892463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007653069,0.0012074386,0.0008415543,0.0028855256,0.00073496567,0.0013325568,0.0010668951,0.002388938,0.013990149],"category_scores_gemma":[0.0029958994,0.0005848904,0.0006390361,0.0018015304,0.0010182434,0.0021489535,0.0010299113,0.0014876944,0.0070322333],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015917847,0.00005690333,0.028015187,0.00036582135,0.00006839426,0.89585406,0.00015439866,0.00028230602,0.010539855,0.0015383129,0.025044188,0.03792145],"study_design_scores_gemma":[0.000021454756,0.00004932263,0.015768684,0.00027879156,0.00006793215,0.9693535,0.00028668146,0.0008246932,0.0030934727,0.0014623941,0.008771089,0.000022071974],"about_ca_topic_score_codex":0.0013149438,"about_ca_topic_score_gemma":0.0025122794,"teacher_disagreement_score":0.013990149,"about_ca_system_score_codex":0.0009596331,"about_ca_system_score_gemma":0.00060930237,"threshold_uncertainty_score":0.046801686},"labels":[],"label_agreement":null},{"id":"W4283016030","doi":"10.1200/po.21.00561","title":"Locoregionally Advanced, BRAF V600L–Positive, Mucosal Melanoma of the Hypopharynx Treated With a Combination of <i>BRAF</i> and <i>MEK</i> Inhibitors","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Université de Montréal; Hôpital Maisonneuve-Rosemont; Université de Sherbrooke","funders":"","keywords":"Mucosal melanoma; Medicine; Melanoma; Cancer research; MEK inhibitor; Trametinib; Dermatology; Oncology; Internal medicine; Biology; Genetics; MAPK/ERK pathway","score_opus":0.005415797021471048,"score_gpt":0.21854370826433173,"score_spread":0.21312791124286068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283016030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9400515,0.03556762,0.000705174,0.0020435606,0.000567767,0.00032298197,0.000514921,0.000206592,0.020019794],"genre_scores_gemma":[0.9820877,0.008984372,0.0008417196,0.0010822467,0.0002821083,0.00007363244,0.0008009929,0.000019454652,0.0058278334],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99994826,0.000006703056,0.00000371133,0.000008325302,0.00001820037,0.000014785357],"domain_scores_gemma":[0.9999372,0.00000864487,0.000010096772,0.0000052320197,0.0000067228725,0.000032085238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015744483,0.0003273489,0.000692548,0.00026748766,0.00033440418,0.00028944275,0.00022301178,0.0003169423,0.0023688055],"category_scores_gemma":[0.00016174001,0.00016045707,0.0005990894,0.0002456717,0.00017894963,0.0003158236,0.0001658769,0.00064511044,0.00042544777],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0683504,0.006626637,0.065109074,0.0017744254,0.0016690285,0.05653277,0.00056400266,0.0030991999,0.21537499,0.00053605397,0.039026868,0.54133654],"study_design_scores_gemma":[0.015037679,0.11608991,0.7020094,0.0010281035,0.0030931563,0.059942793,0.00063871354,0.0064682798,0.024701543,0.00060734455,0.07025685,0.00012631949],"about_ca_topic_score_codex":0.0033736003,"about_ca_topic_score_gemma":0.014008494,"teacher_disagreement_score":0.0033736003,"about_ca_system_score_codex":0.0005138541,"about_ca_system_score_gemma":0.00037827442,"threshold_uncertainty_score":0.0079244375},"labels":[],"label_agreement":null},{"id":"W4289531577","doi":"10.1200/po.22.00105","title":"Response to Alpelisib in an Adolescent With <i>PIK3CA</i>-Mutated Metastatic Gastrointestinal Stromal Tumor","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Sick child; Citation; Medicine; Associate editor; University hospital; Stromal tumor; Family medicine; Editorial board; Pediatrics; Internal medicine; Oncology; Library science; Stromal cell","score_opus":0.04098127799607804,"score_gpt":0.3651710420074702,"score_spread":0.32418976401139216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289531577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93954384,0.013372999,0.0024666872,0.021881642,0.00070389145,0.00025392658,0.00063122896,0.00025274372,0.020893015],"genre_scores_gemma":[0.99279904,0.00221619,0.00048831286,0.002567925,0.0002329086,0.000022804232,0.0001838874,0.000020809857,0.001468023],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9997317,0.000042295786,0.000027827013,0.00004601316,0.0000625282,0.00008961544],"domain_scores_gemma":[0.9993056,0.00021254305,0.00013637968,0.000021572781,0.000049651597,0.00027416594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024158724,0.000376973,0.0005615459,0.00065936596,0.00086555287,0.00049005187,0.00047077393,0.0016268324,0.0029333364],"category_scores_gemma":[0.0012446275,0.00023708308,0.0007336701,0.0006361336,0.00043311573,0.0006715693,0.0003513547,0.0021766224,0.00062723766],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023222892,0.00010392587,0.053490706,0.00011292984,0.000042829415,0.92867,0.00023805391,0.0003749872,0.0017709739,0.0003604455,0.004460177,0.010142718],"study_design_scores_gemma":[0.00009185395,0.00042095236,0.052318837,0.00017486712,0.00006546157,0.93988657,0.0005776014,0.0013881609,0.0008268043,0.00047334406,0.0037507212,0.000024708437],"about_ca_topic_score_codex":0.0031054532,"about_ca_topic_score_gemma":0.0055419644,"teacher_disagreement_score":0.0031054532,"about_ca_system_score_codex":0.0010405267,"about_ca_system_score_gemma":0.0005667752,"threshold_uncertainty_score":0.009812951},"labels":[],"label_agreement":null},{"id":"W4290719500","doi":"10.1200/po.22.00165","title":"Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Afatinib; Medicine; Internal medicine; Oncology; Cancer; Breast cancer; Targeted therapy; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Gefitinib; Estrogen receptor; Epidermal growth factor receptor; Phases of clinical research; Clinical trial; Chemotherapy","score_opus":0.06288459229454123,"score_gpt":0.4389085319902534,"score_spread":0.3760239396957122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290719500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98597753,0.0032347057,0.00088640273,0.001146385,0.000220718,0.003767578,0.002281329,0.00009142973,0.0023939314],"genre_scores_gemma":[0.98748267,0.0016420322,0.0014691902,0.0010420296,0.00018379411,0.0028031268,0.0030579711,0.000038702317,0.0022804819],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993917,0.00031848982,0.000030429936,0.00009354452,0.000051169714,0.00011467383],"domain_scores_gemma":[0.9990195,0.0001485851,0.00017745089,0.000065551656,0.00006224871,0.00052656344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023174302,0.0020433452,0.0024566476,0.00032579468,0.00046990864,0.0012204058,0.0008100044,0.0014536406,0.0038432577],"category_scores_gemma":[0.00138909,0.00061389536,0.0013526265,0.00037932326,0.0008775473,0.0011341576,0.00040864764,0.002924185,0.0010304654],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.820624,0.04670722,0.013286014,0.0012200125,0.0021852248,0.00058436976,0.00061758695,0.004354981,0.02858993,0.00065502565,0.012231727,0.06894393],"study_design_scores_gemma":[0.80590487,0.17302494,0.013258384,0.000039489503,0.00033207907,0.00052230316,0.00007550152,0.0014054711,0.0019910624,0.00038381017,0.0030258514,0.000036233283],"about_ca_topic_score_codex":0.0008853555,"about_ca_topic_score_gemma":0.002241847,"teacher_disagreement_score":0.0038432577,"about_ca_system_score_codex":0.0013055525,"about_ca_system_score_gemma":0.0015486203,"threshold_uncertainty_score":0.01285696},"labels":[],"label_agreement":null},{"id":"W4290994299","doi":"10.1200/po.22.00010","title":"Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Oxaliplatin; Internal medicine; Hazard ratio; Oncology; Fluorouracil; Colorectal cancer; Proportional hazards model; Stage (stratigraphy); Chemotherapy; Cancer; Confidence interval","score_opus":0.018935429631523355,"score_gpt":0.3079839319114025,"score_spread":0.28904850227987916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290994299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99920803,0.00025862714,0.00011276301,0.000077747325,0.000014277728,0.000052727868,0.000051865813,0.0000046834184,0.00021931344],"genre_scores_gemma":[0.9990459,0.00009733319,0.00029338308,0.00007007672,0.00003067352,0.000059957005,0.00022505126,0.0000021736982,0.00017544805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932694,0.0004347929,0.000036792426,0.000064756496,0.0000721456,0.000064583626],"domain_scores_gemma":[0.9987864,0.0002882335,0.00038582933,0.000062346706,0.00005901809,0.0004180488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021357385,0.0003647731,0.00057661755,0.0001783065,0.00021457775,0.00057507824,0.0002597195,0.00030015784,0.00084636005],"category_scores_gemma":[0.0017400251,0.00015736184,0.0006277206,0.00017915126,0.0003125014,0.00036344485,0.00026438702,0.000639853,0.00013382724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4553719,0.0031193683,0.47797856,0.00014304982,0.0011387906,0.00011304997,0.00010552158,0.0018074346,0.012195433,0.00013478435,0.0013081419,0.046583913],"study_design_scores_gemma":[0.07544355,0.15123995,0.739616,0.00007250116,0.001944089,0.00066796073,0.0001306758,0.018905878,0.0076995282,0.00072641484,0.0034967898,0.000056739795],"about_ca_topic_score_codex":0.00027827892,"about_ca_topic_score_gemma":0.0009977991,"teacher_disagreement_score":0.0021357385,"about_ca_system_score_codex":0.000340003,"about_ca_system_score_gemma":0.00043048855,"threshold_uncertainty_score":0.011295021},"labels":[],"label_agreement":null},{"id":"W4292265616","doi":"10.1200/po.22.00107","title":"Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors","year":2022,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University Health Centre; University of Toronto; University Health Network; McGill University; Jewish General Hospital","funders":"National Cancer Institute; Fonds de Recherche du Québec - Santé; Association Neurofibromatoses et Recklinghause; American Society of Clinical Oncology; Conquer Cancer Foundation","keywords":"Medicine; MAPK/ERK pathway; Lung cancer; Melanoma; Targeted therapy; Oncology; Cancer; Cancer research; Internal medicine; Protein kinase A; Mutant; Kinase; Biology; Gene; Genetics","score_opus":0.038454183383332424,"score_gpt":0.34254752105524694,"score_spread":0.3040933376719145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292265616","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017345876,0.9812383,0.00021037707,0.00018084912,0.00007344797,0.00007135889,0.00042413402,0.00001061155,0.0004450443],"genre_scores_gemma":[0.58906543,0.407667,0.00095314893,0.000802501,0.00027456105,0.00022977384,0.0007689681,0.000016709071,0.00022192732],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949067,0.0024101185,0.0015309253,0.0005382863,0.00050447666,0.00010935939],"domain_scores_gemma":[0.98214424,0.013426923,0.003260035,0.00033934854,0.0006905892,0.00013894228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007046282,0.00089337205,0.0051647364,0.0027144833,0.00023881752,0.0015249476,0.0008078834,0.0009525148,0.0012838605],"category_scores_gemma":[0.017255316,0.00056215696,0.015271558,0.0029848646,0.00033630116,0.00089929,0.00047998282,0.00090452173,0.00012217832],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061406204,0.000056603287,0.034942128,0.28044608,0.6286482,0.0001459472,0.0001271283,0.0012441276,0.00086020876,0.00018177737,0.0011693204,0.04603783],"study_design_scores_gemma":[0.0013669955,0.0010683788,0.04507586,0.031479724,0.91433513,0.000360484,0.00011647775,0.00050824124,0.00069225003,0.00036969487,0.0045862882,0.00004049988],"about_ca_topic_score_codex":0.0019074396,"about_ca_topic_score_gemma":0.0047941273,"teacher_disagreement_score":0.007046282,"about_ca_system_score_codex":0.0010676775,"about_ca_system_score_gemma":0.0008893209,"threshold_uncertainty_score":0.037264764},"labels":[],"label_agreement":null},{"id":"W4292995296","doi":"10.1200/po.22.00129","title":"Refining Prognosis in Localized Gastrointestinal Stromal Tumor: Clinical Significance of Phosphatase and Tensin Homolog Low Expression and Gene Loss","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"Agence Nationale de la Recherche","keywords":"Tensin; Stromal cell; Cancer research; Clinical significance; Phosphatase; Gene; Refining (metallurgy); Gene expression; PTEN; Biology; Pathology; Medicine; Cell biology; Chemistry; Genetics; Enzyme; Biochemistry; Signal transduction","score_opus":0.04381538820703224,"score_gpt":0.36730579661290774,"score_spread":0.3234904084058755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292995296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992995,0.00030134787,0.00013755642,0.000034721117,0.0000026931696,0.0000032092355,0.00005960707,0.0000039847246,0.00015725054],"genre_scores_gemma":[0.99969995,0.00006291045,0.0000817715,0.000011488979,0.000008434456,0.0000021460337,0.00008540926,9.743974e-7,0.000046965484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99981457,0.00005622782,0.000017573975,0.00004012753,0.00003897239,0.000032638512],"domain_scores_gemma":[0.99934524,0.00022251191,0.0002143569,0.00003402105,0.00005633697,0.00012749252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005764977,0.00026833263,0.00040885943,0.0007125685,0.0001682403,0.00036814963,0.00020334378,0.0002559459,0.0005914665],"category_scores_gemma":[0.0015165876,0.0000848184,0.00023500112,0.0004774295,0.00034718143,0.00028223798,0.0003156923,0.00022508431,0.00020978066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032412264,0.000011900363,0.9941995,0.0000075759185,0.000019353001,0.00011449866,0.000019274756,0.00012594013,0.0014299637,0.00000781665,0.00004850176,0.0036915971],"study_design_scores_gemma":[0.000018394328,0.00031365498,0.9963284,0.000004586795,0.000062436506,0.0008612164,0.00008096554,0.0012928002,0.0007894318,0.000060050163,0.00018292488,0.0000050730446],"about_ca_topic_score_codex":0.00084084563,"about_ca_topic_score_gemma":0.0014218139,"teacher_disagreement_score":0.00084084563,"about_ca_system_score_codex":0.00019388419,"about_ca_system_score_gemma":0.00018648786,"threshold_uncertainty_score":0.0030488372},"labels":[],"label_agreement":null},{"id":"W4295957335","doi":"10.1200/po.22.00072","title":"Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Spectrum Pharmaceuticals; Merck KGaA; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Stage (stratigraphy); Adjuvant; Lung; Chemotherapy","score_opus":0.008945787073170643,"score_gpt":0.2801589057826575,"score_spread":0.2712131187094869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295957335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99930704,0.00021246876,0.00013691458,0.000017689315,0.0000025154047,0.0000030231122,0.0001430285,0.0000031731836,0.0001741252],"genre_scores_gemma":[0.9993881,0.00008815111,0.00012498414,0.000014474189,0.000004605021,0.00000504653,0.00025396634,9.267001e-7,0.000119658995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999194,0.000015131749,0.000007078297,0.000024252013,0.000015300455,0.000018922392],"domain_scores_gemma":[0.99985754,0.000045283723,0.000050025366,0.0000076104716,0.000015723324,0.000023801478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010345282,0.000121368976,0.00026009194,0.00042295497,0.0001518331,0.0002849273,0.00007694546,0.00017747283,0.0007618164],"category_scores_gemma":[0.00039643628,0.00007359296,0.00013130797,0.00033363226,0.00014591808,0.00013978314,0.00013969213,0.0001603821,0.000119068645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061563065,0.00003820968,0.958933,0.000023018249,0.00003373099,0.00021034335,0.000066175984,0.00011662218,0.033478912,0.00004924211,0.000114086855,0.0063209855],"study_design_scores_gemma":[0.0000076205692,0.00014065682,0.99573565,0.000003079834,0.000024809748,0.00058306666,0.00013213485,0.0006470386,0.0024226515,0.00006810865,0.00023273162,0.0000024543995],"about_ca_topic_score_codex":0.00045144424,"about_ca_topic_score_gemma":0.0008603001,"teacher_disagreement_score":0.0007618164,"about_ca_system_score_codex":0.00013952029,"about_ca_system_score_gemma":0.00008651532,"threshold_uncertainty_score":0.0025485158},"labels":[],"label_agreement":null},{"id":"W4306250689","doi":"10.1200/po.22.00355","title":"State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Defense","keywords":"Ovarian cancer; Medicine; Oncology; Biomarker; Cancer; Internal medicine; Medical physics; Biology","score_opus":0.30856198912367905,"score_gpt":0.5672117160136698,"score_spread":0.25864972688999077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306250689","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0102454275,0.2745516,0.020608675,0.6388449,0.008288202,0.015076001,0.004314745,0.00044074573,0.027629724],"genre_scores_gemma":[0.20688142,0.24405842,0.271868,0.20107715,0.013988699,0.043218046,0.009679707,0.0003952678,0.00883329],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.876136,0.096913904,0.008226051,0.0025674056,0.013480078,0.002676542],"domain_scores_gemma":[0.8184505,0.08386614,0.022774158,0.0078118495,0.04749305,0.019604284],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.27264622,0.0010441954,0.0028746692,0.0030874338,0.0018821923,0.010005013,0.0035684858,0.0058534006,0.0044285213],"category_scores_gemma":[0.14448935,0.0009286551,0.0024993597,0.005354832,0.0020638737,0.005168214,0.00548808,0.008188328,0.0013464444],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052534943,0.00076134584,0.010766874,0.013166468,0.0015962039,0.0002863093,0.0006045033,0.0046001174,0.002394442,0.022782883,0.28298634,0.6548011],"study_design_scores_gemma":[0.005733391,0.0060429005,0.020434095,0.045632638,0.0028268106,0.0005392624,0.000769404,0.007964657,0.003295062,0.04599319,0.8604288,0.00033978646],"about_ca_topic_score_codex":0.0034715384,"about_ca_topic_score_gemma":0.006539073,"teacher_disagreement_score":0.27264622,"about_ca_system_score_codex":0.009633643,"about_ca_system_score_gemma":0.07314626,"threshold_uncertainty_score":0.8969567},"labels":[],"label_agreement":null},{"id":"W4306957266","doi":"10.1200/po.22.00033","title":"Germline Testing and Somatic Tumor Testing for<i>BRCA1/2</i>Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Germline; Olaparib; PARP inhibitor; Ovarian cancer; Medicine; Genetic testing; Oncology; BRCA mutation; Germline mutation; Population; Internal medicine; Cancer; Biology; Genetics; Mutation; Polymerase; Poly ADP ribose polymerase","score_opus":0.09293274554144984,"score_gpt":0.3785759257374067,"score_spread":0.2856431801959569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306957266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80751157,0.03216256,0.08590213,0.043424662,0.00050309254,0.0017876871,0.003509654,0.0002541443,0.024944488],"genre_scores_gemma":[0.9816543,0.0042913626,0.0111089535,0.0015234861,0.00009555218,0.00029211154,0.00032637344,0.00001660524,0.00069126935],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99585164,0.0031678816,0.000111740446,0.00026568148,0.00032006804,0.00028304392],"domain_scores_gemma":[0.98426104,0.012833559,0.0016940176,0.00020858353,0.00037452753,0.00062820216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005688865,0.0005820964,0.0012710637,0.00077209336,0.00029404377,0.001492143,0.00096952193,0.0012711866,0.004420642],"category_scores_gemma":[0.029930882,0.00047237668,0.0019425036,0.00074918615,0.0008839074,0.0016819183,0.00071591267,0.0014752868,0.00021880711],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034975961,0.00058149185,0.041075394,0.0010399424,0.0007567011,0.0003220301,0.000098315584,0.8308008,0.00052587996,0.023351822,0.0044494923,0.09350043],"study_design_scores_gemma":[0.0018349023,0.0027671552,0.020457609,0.0019326424,0.0014262119,0.0007129696,0.0002845829,0.8797878,0.0009970446,0.08480187,0.004881583,0.00011555275],"about_ca_topic_score_codex":0.016035285,"about_ca_topic_score_gemma":0.01634475,"teacher_disagreement_score":0.016035285,"about_ca_system_score_codex":0.0046723797,"about_ca_system_score_gemma":0.006231052,"threshold_uncertainty_score":0.03390062},"labels":[],"label_agreement":null},{"id":"W4310887545","doi":"10.1200/po.22.00245","title":"Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care","year":2022,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Medical Research Council; Deutschen Konsortium für Translationale Krebsforschung; Knut och Alice Wallenbergs Stiftelse; University of Twente; Karolinska Institutet; Radiumhemmets Forskningsfonder; Cancerfonden; ZonMw; National Institute for Health and Care Research; Vetenskapsrådet; Cancer Research UK","keywords":"Reimbursement; Health care; Test (biology); Medicine; Diagnostic test; Computer science; Biology","score_opus":0.0822959380479917,"score_gpt":0.4622204442496928,"score_spread":0.37992450620170104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310887545","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005310583,0.9958086,0.00042573953,0.0021020353,0.0004872807,0.000010556738,0.0000238758,0.000014060134,0.0010747154],"genre_scores_gemma":[0.0006613688,0.9964553,0.0006968971,0.0014861616,0.0003228379,0.000016923224,0.00004295348,0.0000041982944,0.00031339232],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998524,0.0005638699,0.00014640442,0.00021711543,0.00043222558,0.00011644093],"domain_scores_gemma":[0.9950675,0.0032065157,0.0003328476,0.00013180538,0.0010490149,0.00021237598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050734594,0.0009904226,0.0013526343,0.0022175973,0.00028144126,0.0016863799,0.0016004888,0.0026469433,0.0037713998],"category_scores_gemma":[0.007579325,0.0003826974,0.0012789706,0.0019163651,0.000889818,0.002165624,0.0015208189,0.0038701338,0.0020099902],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054549437,0.00003068836,0.00021357213,0.015006965,0.00016252809,0.000089521964,0.000053037627,0.00048692772,0.00040805354,0.008936838,0.034914535,0.9396427],"study_design_scores_gemma":[0.000029391966,0.000098916375,0.0008265447,0.015485008,0.00015831595,0.00046739788,0.000065880005,0.00016618353,0.0003241383,0.004908007,0.9774441,0.0000260664],"about_ca_topic_score_codex":0.0032989744,"about_ca_topic_score_gemma":0.0040474413,"teacher_disagreement_score":0.0050734594,"about_ca_system_score_codex":0.0020145099,"about_ca_system_score_gemma":0.0044517196,"threshold_uncertainty_score":0.026831329},"labels":[],"label_agreement":null},{"id":"W4315750714","doi":"10.1200/po.22.00342","title":"Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer","year":2023,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Institutes for BioMedical Research; Genentech; Foundation Medicine; Sierra Oncology; Daiichi Sankyo Europe; Servier; Eisai; Natera; Silverback Therapeutics; Moderna; Pfizer; Incyte; Agios Pharmaceuticals; Mirati Therapeutics; Abbott Laboratories; Clovis Oncology; Pacira Pharmaceuticals; Stryker; Ipsen; Array BioPharma; GlaxoSmithKline; Pacira BioSciences; Jounce Therapeutics; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; Invitae; AstraZeneca; Edwards Lifesciences; Amgen; Dana-Farber Cancer Institute; Revolution Medicines; Exelixis; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Puma Biotechnology; Advanced Accelerator Applications","keywords":"Medicine; Precision medicine; Clinical trial; Pancreatic cancer; Internal medicine; Gastrointestinal cancer; Oncology; Colorectal cancer; Cancer; Personalized medicine; Precision oncology; Targeted therapy; Bioinformatics; Pathology","score_opus":0.039852672956354564,"score_gpt":0.3876875231769671,"score_spread":0.3478348502206125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315750714","genre_codex":"methods","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38542807,0.011014327,0.39533272,0.11912615,0.0009577822,0.0053087035,0.01312611,0.013260341,0.056445695],"genre_scores_gemma":[0.74638176,0.0018755293,0.23776773,0.006306562,0.0005608683,0.00087348983,0.0043275845,0.00037852404,0.001527927],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9814274,0.011966937,0.002350215,0.0020065813,0.0017111637,0.00053775415],"domain_scores_gemma":[0.91660184,0.06011384,0.011261315,0.0038891796,0.004459647,0.0036742424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01814085,0.0008094215,0.0007237976,0.0028451912,0.0013299634,0.003876041,0.0017675776,0.0009643505,0.008559427],"category_scores_gemma":[0.08763133,0.0004679345,0.0009762434,0.0020104311,0.00070832414,0.0029339471,0.0034457867,0.0019259481,0.0016190582],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018109272,0.0008893881,0.23556376,0.0013331944,0.00044898785,0.001957828,0.0024377939,0.035948053,0.0019121058,0.009712266,0.06810954,0.63987607],"study_design_scores_gemma":[0.0021784748,0.0019110361,0.06524657,0.0038825665,0.0010074227,0.0045723147,0.0056807864,0.43990675,0.017387362,0.1174377,0.34030983,0.00047926448],"about_ca_topic_score_codex":0.0027749992,"about_ca_topic_score_gemma":0.004961725,"teacher_disagreement_score":0.01814085,"about_ca_system_score_codex":0.002064294,"about_ca_system_score_gemma":0.0072979745,"threshold_uncertainty_score":0.09593916},"labels":[],"label_agreement":null},{"id":"W4362703880","doi":"10.1200/po.22.00509","title":"Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials","year":2023,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Internal medicine; Immunotherapy; Hazard ratio; Medicine; Biomarker; Progression-free survival; Gastroenterology; Clinical trial; Tumor progression; Circulating tumor DNA; Oncology; Cancer; Overall survival; Confidence interval; Biology; Genetics","score_opus":0.07638013486350287,"score_gpt":0.44089207221425536,"score_spread":0.3645119373507525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362703880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800079,0.011793303,0.0043067406,0.0003750603,0.00008335592,0.00028841905,0.0006942734,0.00012969255,0.0023212272],"genre_scores_gemma":[0.9935968,0.0007686458,0.003834143,0.00034498042,0.00011330057,0.00020495668,0.00063917035,0.000015746398,0.00048216592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670094,0.0018990629,0.00028189685,0.0004125686,0.00057581865,0.00012964565],"domain_scores_gemma":[0.9884071,0.0055473293,0.0043473733,0.00035387705,0.0006476894,0.000696593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062957914,0.00051449053,0.0011888694,0.0008574933,0.00019050158,0.001280382,0.0004529952,0.0007057314,0.00093609194],"category_scores_gemma":[0.009366901,0.00023925625,0.00032879642,0.00069898204,0.00036862024,0.0010006326,0.0002882869,0.00073917455,0.00024798527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01748519,0.0004979068,0.8538321,0.0005845983,0.00042791953,0.00015727815,0.00018120065,0.0016516872,0.018128105,0.00024245131,0.00097061525,0.105840914],"study_design_scores_gemma":[0.0013791079,0.016785517,0.9462435,0.00019788869,0.0006578022,0.001386157,0.00016338272,0.009316216,0.015705487,0.00067651056,0.0074335905,0.000054912365],"about_ca_topic_score_codex":0.0001805537,"about_ca_topic_score_gemma":0.00043099833,"teacher_disagreement_score":0.0062957914,"about_ca_system_score_codex":0.00048266313,"about_ca_system_score_gemma":0.00043632629,"threshold_uncertainty_score":0.03329569},"labels":[],"label_agreement":null},{"id":"W4367042670","doi":"10.1200/po.22.00317","title":"Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis","year":2023,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Breast cancer; Cohort; Triple-negative breast cancer; Metastatic breast cancer; Tumor-infiltrating lymphocytes; Progression-free survival; Cancer; Immunotherapy; Chemotherapy","score_opus":0.034109530947823555,"score_gpt":0.37195274827056923,"score_spread":0.3378432173227457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367042670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985024,0.00024026766,0.00009741058,0.000024328758,0.0000042890056,0.000039931194,0.00084261724,0.0000045790175,0.00024427322],"genre_scores_gemma":[0.9980812,0.0000558023,0.00016840152,0.00003263025,0.000016537406,0.00006640732,0.001415395,0.0000027405652,0.00016096055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994373,0.00017913255,0.00004951329,0.00016992276,0.000098692515,0.000065498185],"domain_scores_gemma":[0.9989157,0.0002473514,0.0004406539,0.00011750405,0.000082261846,0.00019660933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001209577,0.0004894368,0.00068439444,0.00041450612,0.00023213461,0.00059926446,0.0004995196,0.00048968766,0.0014098509],"category_scores_gemma":[0.0015004898,0.00026787713,0.0007346824,0.00045100466,0.00019260746,0.00053975557,0.000499095,0.0007041637,0.00025357163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028224614,0.00079728226,0.95472586,0.00012064537,0.0012792179,0.00020351965,0.00007003572,0.0006666264,0.0054436694,0.00007696468,0.0006567202,0.0077349413],"study_design_scores_gemma":[0.0011655901,0.00544603,0.98897797,0.000015926093,0.0004867687,0.00037028868,0.000084537394,0.0017792257,0.00079717045,0.000088450404,0.0007708012,0.000017259274],"about_ca_topic_score_codex":0.00042156005,"about_ca_topic_score_gemma":0.0006705534,"teacher_disagreement_score":0.0014098509,"about_ca_system_score_codex":0.00035596642,"about_ca_system_score_gemma":0.0004225802,"threshold_uncertainty_score":0.0063968897},"labels":[],"label_agreement":null},{"id":"W4381487668","doi":"10.1200/po.23.00132","title":"Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface","year":2023,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Carcinogenesis; Haematopoiesis; Immune system; Cancer; Oncology; Population; Interface (matter); Biology; Epigenetics; Solid tumor; Immunology; Bioinformatics; Internal medicine; Cancer research; Computational biology; Medicine; Genetics; Stem cell; Gene; Environmental health","score_opus":0.10010566176435874,"score_gpt":0.46656861484103807,"score_spread":0.3664629530766793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381487668","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004510683,0.99862444,0.00005410198,0.0007177752,0.00028568326,0.0000014476659,0.00000767666,0.000004029152,0.00025979476],"genre_scores_gemma":[0.00055620784,0.9978404,0.00011773139,0.0006198009,0.0006719305,0.000002854233,0.000015235334,0.0000012884017,0.0001745415],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995555,0.000110205976,0.00007570742,0.00006878293,0.0001490845,0.000040740688],"domain_scores_gemma":[0.9973929,0.0017784466,0.00021121328,0.000054355187,0.00044725707,0.00011580091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016405736,0.0007280431,0.0016591643,0.0024512608,0.0003145276,0.0016687448,0.0010157687,0.0017299232,0.002724822],"category_scores_gemma":[0.003177606,0.00031896084,0.0007203292,0.0021413348,0.0011684574,0.0023057943,0.0010450114,0.0028330765,0.00097183173],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009183622,0.00003941954,0.0004053102,0.017081589,0.0001391955,0.00019632929,0.00010614043,0.00039119698,0.0005519206,0.009921353,0.05112314,0.9199525],"study_design_scores_gemma":[0.000019139366,0.000081825514,0.0009908304,0.0076872795,0.00014856232,0.0013057158,0.000117184376,0.0001296884,0.0001879638,0.0062198597,0.9830851,0.000026811838],"about_ca_topic_score_codex":0.0013873641,"about_ca_topic_score_gemma":0.0024236953,"teacher_disagreement_score":0.002724822,"about_ca_system_score_codex":0.0010780097,"about_ca_system_score_gemma":0.001955344,"threshold_uncertainty_score":0.009115458},"labels":[],"label_agreement":null},{"id":"W4382051182","doi":"10.1200/po.23.00076","title":"Genomics of <i>ERBB2</i>-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab","year":2023,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Breast cancer; Oncology; Copy number analysis; Exome sequencing; Internal medicine; Cancer; Biology; Copy-number variation; Chemotherapy; Medicine; Mutation; Cancer research; Gene; Genetics; Genome","score_opus":0.004726130540452299,"score_gpt":0.2662725685712719,"score_spread":0.2615464380308196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382051182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992046,0.0001370646,0.000056704874,0.000026367325,0.000002593546,0.000004070225,0.00035702458,0.0000032124979,0.00020843348],"genre_scores_gemma":[0.9987618,0.00012441482,0.00012309299,0.00007151202,0.000006257566,0.000010283682,0.0006465562,0.0000052085597,0.00025090814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99991465,0.000014161651,0.0000052851196,0.000030364465,0.000012239267,0.000023297458],"domain_scores_gemma":[0.9998461,0.00003730405,0.0000565556,0.000007450272,0.000017769078,0.00003489095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008704784,0.00010883421,0.00022572798,0.0002946929,0.00018720173,0.00024883862,0.00007953963,0.00021911088,0.0007246759],"category_scores_gemma":[0.0004949355,0.0000732334,0.00017578043,0.00036812472,0.00009038548,0.00008044715,0.0001488206,0.00012657109,0.00015936379],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008794518,0.00004860944,0.9554681,0.000038263042,0.000065457825,0.0020167872,0.00042716705,0.00015319191,0.030742241,0.000053838434,0.00055186945,0.00955498],"study_design_scores_gemma":[0.0000064144137,0.00011555776,0.99688417,0.0000038131898,0.000023350802,0.0013868777,0.00015533027,0.00011827253,0.0007025419,0.000028647843,0.00057227997,0.0000027234287],"about_ca_topic_score_codex":0.0032578337,"about_ca_topic_score_gemma":0.002930735,"teacher_disagreement_score":0.0032578337,"about_ca_system_score_codex":0.00018732493,"about_ca_system_score_gemma":0.00012508595,"threshold_uncertainty_score":0.006477773},"labels":[],"label_agreement":null},{"id":"W4382517901","doi":"10.1200/po.22.00633","title":"Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in <i>BRD4-NUTM1</i> NUT Carcinoma Harboring a <i>BRD4</i> Splice Site Mutation","year":2023,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute; Daiichi Sankyo Europe; AstraZeneca","keywords":"Bromodomain; Citation; BRD4; Cancer; Library science; Medicine; Cancer research; Internal medicine; Biology; Genetics; Computer science; Gene; Histone","score_opus":0.013570923099663098,"score_gpt":0.2839932525883621,"score_spread":0.270422329488699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382517901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93069655,0.011924229,0.012526033,0.008736091,0.001058983,0.00034927268,0.00090546504,0.0009227634,0.032880545],"genre_scores_gemma":[0.99009293,0.0017680485,0.001790489,0.0023727592,0.00025257864,0.000046579848,0.00065800594,0.00008588877,0.0029326333],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.999688,0.0000388017,0.000041292336,0.000055783614,0.000079862606,0.00009637899],"domain_scores_gemma":[0.999328,0.00015883791,0.00007899885,0.00009345635,0.000040230665,0.00030049722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003755782,0.0004806075,0.0008284947,0.0006292174,0.00056246994,0.0004557812,0.00045503562,0.0012857738,0.0014263985],"category_scores_gemma":[0.00088415213,0.00018749415,0.0009545971,0.0003941254,0.0003802909,0.0006006783,0.0004632688,0.0018431917,0.0008718806],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028211924,0.00058160827,0.03033731,0.00043639535,0.00026949056,0.76695067,0.0002843993,0.0023670003,0.03959636,0.0014977682,0.008197561,0.14666031],"study_design_scores_gemma":[0.0005075825,0.003104465,0.06937176,0.00013593209,0.0003007195,0.8789101,0.00022637735,0.006357577,0.022556098,0.0023418707,0.016098773,0.00008872347],"about_ca_topic_score_codex":0.00081567327,"about_ca_topic_score_gemma":0.002145826,"teacher_disagreement_score":0.0014263985,"about_ca_system_score_codex":0.0008534441,"about_ca_system_score_gemma":0.0003089787,"threshold_uncertainty_score":0.0061922073},"labels":[],"label_agreement":null},{"id":"W4387382626","doi":"10.1200/po.23.00235","title":"Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer","year":2023,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carboplatin; Bromodomain; Medicine; Tolerability; ARID1A; Endometrial cancer; Ovarian cancer; Combination therapy; Internal medicine; Oncology; Phases of clinical research; Cancer; BET inhibitor; Clinical trial; Cancer research; Chemotherapy; Epigenetics; Mutation; Adverse effect; Cisplatin; Biology; Genetics","score_opus":0.023522442884728295,"score_gpt":0.35376435630881475,"score_spread":0.3302419134240865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387382626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98602784,0.0026382913,0.0008589642,0.00043095878,0.000082384744,0.0066877613,0.0008738287,0.00009315654,0.0023067968],"genre_scores_gemma":[0.9888841,0.00138007,0.0019243511,0.00068908307,0.00011853011,0.0034443873,0.0015459833,0.000024517218,0.0019889767],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993457,0.00034302694,0.00004212884,0.00009911544,0.00004893808,0.000120996134],"domain_scores_gemma":[0.99929297,0.0001042801,0.00015077852,0.0000688658,0.000043573138,0.00033948116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022174001,0.0013383981,0.0018151583,0.0005569769,0.0004814138,0.0007322388,0.0007571508,0.0015949643,0.0024468247],"category_scores_gemma":[0.00070949056,0.0007201648,0.0009861746,0.00047752308,0.0011225925,0.00057130505,0.00034103516,0.0023224675,0.0005993462],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53568,0.09324849,0.022768378,0.0013054834,0.001450315,0.0011893257,0.00056915905,0.004770974,0.21745591,0.000890014,0.0053642886,0.115307756],"study_design_scores_gemma":[0.3589225,0.6080378,0.015728364,0.00004870731,0.00033931414,0.0005941579,0.00009144474,0.0012155275,0.01133601,0.00025564895,0.0034004804,0.00002995589],"about_ca_topic_score_codex":0.00069038454,"about_ca_topic_score_gemma":0.0017332697,"teacher_disagreement_score":0.0024468247,"about_ca_system_score_codex":0.00078588905,"about_ca_system_score_gemma":0.0014371406,"threshold_uncertainty_score":0.011726856},"labels":[],"label_agreement":null},{"id":"W4387786011","doi":"10.1200/po.23.00033","title":"Adoption of Universal Testing in Endometrial Cancers for Microsatellite Instability Using Next-Generation Sequencing","year":2023,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute","keywords":"Microsatellite instability; Endometrial cancer; Exact test; Oncology; Cohort; Internal medicine; Microsatellite; Medicine; Lynch syndrome; Genetic testing; Retrospective cohort study; Cancer; DNA mismatch repair; Biology; Genetics; Gene","score_opus":0.27233504926788493,"score_gpt":0.3875973513722165,"score_spread":0.11526230210433158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387786011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97479147,0.0050449637,0.012765566,0.0018517554,0.00014767036,0.0002299902,0.0004511008,0.00023295793,0.0044844374],"genre_scores_gemma":[0.98909223,0.00049519824,0.009492853,0.0005009829,0.000018635637,0.00004643728,0.0001545906,0.000010094454,0.00018905518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99118304,0.004873356,0.00076964166,0.0009716205,0.0017362098,0.00046613417],"domain_scores_gemma":[0.9806275,0.0073899506,0.003783768,0.0017946203,0.005489554,0.0009145949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017141102,0.00029591535,0.0003339645,0.0006625765,0.00028133823,0.00080334116,0.00060802896,0.00058643497,0.00059405743],"category_scores_gemma":[0.027906315,0.00019170328,0.00023694344,0.000583311,0.00073290244,0.00063368806,0.0008471027,0.00066345325,0.000110339075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063710904,0.000112049194,0.84342855,0.0002901494,0.000100310914,0.00009154603,0.00049877947,0.000893187,0.009796205,0.0005762578,0.00078769715,0.14278814],"study_design_scores_gemma":[0.00009594167,0.003715064,0.9421837,0.00057717744,0.0002690143,0.0016095096,0.0009880041,0.008962518,0.026924457,0.00086213887,0.013769866,0.000042589047],"about_ca_topic_score_codex":0.003987092,"about_ca_topic_score_gemma":0.006827921,"teacher_disagreement_score":0.017141102,"about_ca_system_score_codex":0.0009435735,"about_ca_system_score_gemma":0.0018315704,"threshold_uncertainty_score":0.09065193},"labels":[],"label_agreement":null},{"id":"W4390603547","doi":"10.1200/po.23.00441","title":"Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Clinical trial; Clinical study design; Limiting; Medicine; Research design; Toxicity; Medical physics; Computer science; Internal medicine; Statistics; Mathematics; Engineering","score_opus":0.7710930725259459,"score_gpt":0.7075061255547076,"score_spread":0.06358694697123835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390603547","genre_codex":"review","genre_gemma":"methods","domain_codex":"methods","domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018706562,0.65271014,0.25019628,0.056719545,0.0035808424,0.011026532,0.0008111956,0.0005094077,0.005739394],"genre_scores_gemma":[0.24571797,0.23326741,0.4588187,0.028068047,0.0060591823,0.025448497,0.00088404777,0.0004309263,0.0013052096],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.2535526,0.6086579,0.09021293,0.013775034,0.032217883,0.0015837817],"domain_scores_gemma":[0.056177855,0.7549975,0.09099751,0.05301998,0.043471985,0.0013353103],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.69141847,0.0022260384,0.009340982,0.006538382,0.002042106,0.012910412,0.007986125,0.006863821,0.003488987],"category_scores_gemma":[0.82980984,0.0018514821,0.009397667,0.00957677,0.008985534,0.018060738,0.0057177497,0.0070648286,0.0009902999],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004829311,0.00040219814,0.016140997,0.12640373,0.0075346814,0.00022750652,0.0059584714,0.0034004203,0.0011211738,0.021849293,0.008080913,0.80405134],"study_design_scores_gemma":[0.010709145,0.012812079,0.037234835,0.52883744,0.021579629,0.0022677565,0.005306374,0.016623963,0.007673082,0.17669772,0.1790681,0.0011898301],"about_ca_topic_score_codex":0.0023005141,"about_ca_topic_score_gemma":0.0038017281,"teacher_disagreement_score":0.69141847,"about_ca_system_score_codex":0.0070067444,"about_ca_system_score_gemma":0.029380627,"threshold_uncertainty_score":0.38053602},"labels":[],"label_agreement":null},{"id":"W4392123065","doi":"10.1200/po.23.00411","title":"Association of RNF43 Genetic Alterations With BRAF<sup>V600E</sup> and MSI<sup>high</sup> in Colorectal Cancer","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Microsatellite instability; Oncology; Medicine; Colorectal cancer; Internal medicine; Retrospective cohort study; Cancer; Cohort; Mutation; Microsatellite; Genetics; Biology; Allele","score_opus":0.012431789788760805,"score_gpt":0.3153826187600332,"score_spread":0.3029508289712724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392123065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99807584,0.0010575941,0.00011162161,0.000057424742,0.0000047170015,0.0000046953323,0.00029708195,0.0000040542823,0.00038692987],"genre_scores_gemma":[0.9996424,0.00012769485,0.000056053457,0.000015518259,0.000005318325,0.0000016882988,0.000116269024,0.0000010535201,0.000033955628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992192,0.00021478471,0.00011213413,0.00018884118,0.00017270521,0.000092359696],"domain_scores_gemma":[0.9961694,0.00061836536,0.0025266253,0.00025229473,0.00021140129,0.00022197596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010735258,0.00014111366,0.00026008848,0.0010140114,0.0002807466,0.00043763072,0.00024868397,0.00032495218,0.001155384],"category_scores_gemma":[0.0035691017,0.00016479276,0.00022215037,0.0010997998,0.0003329415,0.0002987159,0.00035021867,0.0002986108,0.00010695414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115172516,0.0000069751914,0.9976216,0.00001281738,0.000049969225,0.00012458047,0.000014521695,0.000056745692,0.0003776448,0.000025776368,0.000046111665,0.0015481088],"study_design_scores_gemma":[0.0000033333001,0.00006212414,0.9979449,0.0000080856835,0.00003351404,0.0010904791,0.000058765592,0.00020610855,0.00025848945,0.000046328965,0.00028509708,0.0000028337954],"about_ca_topic_score_codex":0.0022600568,"about_ca_topic_score_gemma":0.0033815631,"teacher_disagreement_score":0.0022600568,"about_ca_system_score_codex":0.00024626782,"about_ca_system_score_gemma":0.00023752586,"threshold_uncertainty_score":0.005677402},"labels":[],"label_agreement":null},{"id":"W4392795393","doi":"10.1200/po.23.00489","title":"Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data Set","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; Genentech; Swiss Re; Seagen; Mirati Therapeutics; Gilead Sciences; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; American Association for Cancer Research; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer; Amgen; Doris Duke Charitable Foundation","keywords":"Medicine; Biomarker; Prostate cancer; Oncology; Hazard ratio; Internal medicine; Cohort; Cancer; Disease; Biomarker discovery; Breast cancer; Confidence interval; Biology","score_opus":0.30554007219725215,"score_gpt":0.45541324603401606,"score_spread":0.1498731738367639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392795393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714281,0.0014791036,0.021733725,0.00079660007,0.000088155786,0.0000709271,0.0037275804,0.00013438075,0.0005415457],"genre_scores_gemma":[0.9917366,0.00011786802,0.0050667995,0.00015330284,0.000029545174,0.000044638142,0.0027261493,0.00002491574,0.00010012319],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9650887,0.022406623,0.0022705204,0.007324893,0.0019083594,0.0010008987],"domain_scores_gemma":[0.8247676,0.124504186,0.028500313,0.017537342,0.0022089514,0.0024816496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06933361,0.00065232086,0.0011323952,0.0016303221,0.0007800496,0.0025654656,0.0018949828,0.0012115125,0.00093844504],"category_scores_gemma":[0.11058413,0.0007903923,0.0019957724,0.0027984148,0.0009440963,0.0016528112,0.0017323154,0.0023241595,0.0002193429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093156064,0.000063630505,0.9848513,0.00004994249,0.0011234982,0.00015608077,0.00012260446,0.0064987475,0.0003710931,0.00030215294,0.00034533546,0.00518413],"study_design_scores_gemma":[0.00017988968,0.0006510443,0.8822776,0.00012233951,0.0018230829,0.0010546179,0.00032947917,0.10615651,0.002159269,0.0029861096,0.0021621531,0.00009781562],"about_ca_topic_score_codex":0.0066498825,"about_ca_topic_score_gemma":0.0061121727,"teacher_disagreement_score":0.06933361,"about_ca_system_score_codex":0.0012161818,"about_ca_system_score_gemma":0.001442945,"threshold_uncertainty_score":0.36667556},"labels":[],"label_agreement":null},{"id":"W4393282846","doi":"10.1200/po.23.00487","title":"Human Epidermal Growth Factor Receptor 2–Low Breast Cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Health Sciences Centre; Statistics Canada; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Immunohistochemistry; Oncology; Internal medicine; Progesterone receptor; Human Epidermal Growth Factor Receptor 2; Cancer; Estrogen receptor; Fluorescence in situ hybridization; Population; Cohort; Gynecology; Biology","score_opus":0.03903125623679429,"score_gpt":0.35698912556096823,"score_spread":0.3179578693241739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393282846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969001,0.00086277706,0.00028056026,0.00051024946,0.000009712843,0.000017896267,0.00011527772,0.000004794593,0.0012986108],"genre_scores_gemma":[0.9988476,0.0004143137,0.00017289555,0.00018664931,0.000048537848,0.000010782759,0.00011743354,0.00000247124,0.00019927752],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9998902,0.000027763823,0.000008930972,0.000020104348,0.000023163984,0.000029803625],"domain_scores_gemma":[0.99982953,0.00003294246,0.00005990826,0.000007702418,0.0000173238,0.000052603256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018930217,0.00012602734,0.0002595561,0.00029335075,0.000306475,0.00042904913,0.0001240575,0.00017856222,0.001741007],"category_scores_gemma":[0.0005040115,0.0000788757,0.000115314964,0.00025839783,0.0001897308,0.00038828183,0.00028441678,0.0002458725,0.00024700174],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004075239,0.00008588132,0.9688709,0.00003574703,0.000023258728,0.0027576652,0.000094788105,0.0001292819,0.004000655,0.00021071779,0.0010591267,0.02232443],"study_design_scores_gemma":[0.000054924254,0.0006048618,0.9691608,0.000039487557,0.000052711446,0.023023596,0.0011296778,0.0011450218,0.0009923353,0.0006132572,0.003171278,0.000012039396],"about_ca_topic_score_codex":0.00084805896,"about_ca_topic_score_gemma":0.0023938834,"teacher_disagreement_score":0.001741007,"about_ca_system_score_codex":0.00018689089,"about_ca_system_score_gemma":0.0002565342,"threshold_uncertainty_score":0.0058243275},"labels":[],"label_agreement":null},{"id":"W4393282851","doi":"10.1200/po.23.00654","title":"Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Prostate Cancer Foundation","keywords":"Context (archaeology); Personalized medicine; Precision medicine; Overdiagnosis; Cancer; Germline; Genetic testing; Prostate cancer; Medicine; Genotyping; Bioinformatics; Computational biology; Biology; Genetics; Gene; Internal medicine; Genotype","score_opus":0.0799215156848305,"score_gpt":0.49077883953531504,"score_spread":0.41085732385048457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393282851","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08470159,0.034104776,0.51940733,0.2958363,0.003012089,0.0023717969,0.0007828561,0.0014653293,0.058317997],"genre_scores_gemma":[0.40525517,0.010054883,0.5440494,0.03443387,0.0025370154,0.0010594262,0.0004120652,0.00021435015,0.0019837483],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9226207,0.06056383,0.004894646,0.0016453946,0.009172216,0.0011032338],"domain_scores_gemma":[0.901754,0.072417,0.0069494927,0.0051414897,0.01185972,0.0018782875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08707377,0.00072016683,0.0010986866,0.0027727438,0.0013370438,0.0070146183,0.0021478187,0.0041016373,0.00138385],"category_scores_gemma":[0.15823333,0.000663201,0.00088172755,0.0012646888,0.0037439691,0.0029752136,0.0037065076,0.007436242,0.0012431435],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009577317,0.00043449664,0.08052618,0.0009919744,0.0002385775,0.004024963,0.0059039686,0.007871043,0.0055472124,0.05281811,0.05131677,0.7893689],"study_design_scores_gemma":[0.00040411277,0.0012731329,0.07185542,0.009647664,0.0006530439,0.012384971,0.008968092,0.046926033,0.03687811,0.47569084,0.33464292,0.0006757139],"about_ca_topic_score_codex":0.0027205583,"about_ca_topic_score_gemma":0.004379843,"teacher_disagreement_score":0.08707377,"about_ca_system_score_codex":0.0023185892,"about_ca_system_score_gemma":0.008495045,"threshold_uncertainty_score":0.46049565},"labels":[],"label_agreement":null},{"id":"W4394908620","doi":"10.1200/po.23.00687","title":"Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Queen's University","funders":"","keywords":"Radiomics; Multidisciplinary approach; Precision oncology; Drug development; Medicine; Medical physics; Clinical trial; Oncology; Precision medicine; Patient care; Internal medicine; Drug; Pathology; Pharmacology; Radiology","score_opus":0.030831788705128912,"score_gpt":0.4029483198222747,"score_spread":0.37211653111714577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394908620","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003045872,0.41329086,0.013680903,0.55518836,0.010109293,0.00011583195,0.00015543473,0.00011197595,0.004301476],"genre_scores_gemma":[0.08932941,0.5912372,0.059145156,0.22199027,0.031329274,0.00042185522,0.00042255138,0.00022608272,0.0058982437],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9856306,0.008580501,0.0011320905,0.0009851911,0.0031200245,0.00055170845],"domain_scores_gemma":[0.9320924,0.048759293,0.0035156403,0.0015020656,0.011092583,0.0030379998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07399859,0.00080621074,0.0012541615,0.0028256194,0.001284557,0.007772685,0.0015509592,0.005019247,0.0017042268],"category_scores_gemma":[0.05976628,0.00073140685,0.0010407721,0.0019190785,0.005663997,0.008174314,0.005438179,0.009621531,0.000671194],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030628286,0.00007902823,0.003365414,0.0016956927,0.00012611861,0.00027466295,0.0011546023,0.0011110979,0.0021055443,0.023325551,0.2244252,0.7420308],"study_design_scores_gemma":[0.00008824902,0.0005090787,0.005407231,0.0041425778,0.00022496893,0.0011768838,0.0016869798,0.0025008149,0.0043804166,0.061831098,0.9178033,0.00024846874],"about_ca_topic_score_codex":0.0040928037,"about_ca_topic_score_gemma":0.007969362,"teacher_disagreement_score":0.07399859,"about_ca_system_score_codex":0.0054194178,"about_ca_system_score_gemma":0.010141497,"threshold_uncertainty_score":0.39134663},"labels":[],"label_agreement":null},{"id":"W4399879771","doi":"10.1200/po.24.00174","title":"MEK Inhibition in a Pilocytic Astrocytoma With a Rare <i>KRAS Q61R</i> Mutation in a Young Adult Patient: A Case Report","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Pilocytic astrocytoma; Medicine; Astrocytoma; KRAS; Cancer research; Internal medicine; Glioma; Cancer; Colorectal cancer","score_opus":0.01248254578821615,"score_gpt":0.3017933109536509,"score_spread":0.28931076516543475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399879771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973457,0.003186126,0.0040861615,0.0046829446,0.0003189499,0.00010804284,0.00031670692,0.000341549,0.01350251],"genre_scores_gemma":[0.9951174,0.0009174346,0.0014527702,0.0007794565,0.00015221555,0.000010202456,0.00007133743,0.000036027006,0.0014631964],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.999863,0.000010309364,0.000015118722,0.00003082496,0.000022184628,0.000058508107],"domain_scores_gemma":[0.99973327,0.00004480589,0.000050818082,0.000014661255,0.000016673821,0.00013985246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009054024,0.0007711058,0.00055163255,0.00079922745,0.0012326655,0.0009383359,0.00044016194,0.0023565746,0.0012565486],"category_scores_gemma":[0.00062961935,0.00044206125,0.0007224177,0.00045187006,0.0006591483,0.0008574966,0.0005925764,0.0016457841,0.0007427988],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040489092,0.00002406151,0.0039887135,0.000018277156,0.0000075190574,0.9907488,0.00007282791,0.000095471456,0.0020726847,0.00017372302,0.0003633339,0.0023939493],"study_design_scores_gemma":[0.000005263292,0.00005149571,0.0019951179,0.000006022752,0.0000118006155,0.99591136,0.000056806166,0.0002954445,0.0009227259,0.00017730093,0.0005594838,0.000007260656],"about_ca_topic_score_codex":0.0017790715,"about_ca_topic_score_gemma":0.004414602,"teacher_disagreement_score":0.0023565746,"about_ca_system_score_codex":0.00083954225,"about_ca_system_score_gemma":0.0006737255,"threshold_uncertainty_score":0.0060913563},"labels":[],"label_agreement":null},{"id":"W4400073956","doi":"10.1200/po.24.00092","title":"Clinical Utility of Tumor Next-Generation Sequencing Panel Testing to Inform Treatment Decisions for Patients With Advanced Solid Tumors in a Tertiary Care Center","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre; University of Toronto","funders":"Seagen; Gilead Sciences; Sanofi; Genentech; Government of Ontario; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline; Princess Margaret Cancer Foundation; Amgen","keywords":"Tertiary care; Solid tumor; Center (category theory); Medical physics; Medicine; Patient care; Oncology; Internal medicine; Nursing; Cancer; Chemistry","score_opus":0.08487258725041298,"score_gpt":0.3691614437258927,"score_spread":0.28428885647547975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400073956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346477,0.0010101964,0.00060053443,0.0019701445,0.000020231135,0.00006965474,0.00070938695,0.000043403612,0.0021116405],"genre_scores_gemma":[0.9981489,0.00024140933,0.00086600165,0.00038447927,0.000041568415,0.000018743984,0.00020541476,0.0000033204421,0.00009023441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699926,0.0015555732,0.0003349635,0.0003964741,0.0004837133,0.00023011168],"domain_scores_gemma":[0.9810846,0.008266521,0.0073281047,0.0004713743,0.0011118023,0.0017375449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025378172,0.00017459095,0.0003009292,0.0008869569,0.00053461234,0.00087484065,0.00043002222,0.00038817376,0.0017619921],"category_scores_gemma":[0.016809257,0.00016218601,0.00025099528,0.00094796304,0.00033167872,0.0005096185,0.0007622597,0.0004622018,0.00020565024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012276878,0.00007684939,0.9855583,0.000036997397,0.000027405596,0.00006681185,0.00013701139,0.00038830168,0.00016506566,0.000028740818,0.0008585617,0.0125331385],"study_design_scores_gemma":[0.000043710726,0.0004053551,0.9905144,0.00009923503,0.00005890504,0.00031723126,0.0006511901,0.006206403,0.00048455814,0.00012866755,0.001074063,0.000016270882],"about_ca_topic_score_codex":0.011997376,"about_ca_topic_score_gemma":0.02662031,"teacher_disagreement_score":0.011997376,"about_ca_system_score_codex":0.0017125461,"about_ca_system_score_gemma":0.0016659454,"threshold_uncertainty_score":0.02385509},"labels":[],"label_agreement":null},{"id":"W4401208972","doi":"10.1200/po.24.00094","title":"Germline Susceptibility to Renal Cell Carcinoma and Implications for Genetic Screening","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University of Ottawa; McGill University","funders":"","keywords":"Germline; Renal cell carcinoma; Medicine; Genetic predisposition; Oncology; Internal medicine; CHEK2; Odds ratio; Genetic testing; BAP1; Cancer; Kidney cancer; Germline mutation; Clear cell renal cell carcinoma; Biology; Genetics; Gene; Mutation","score_opus":0.05107389019641016,"score_gpt":0.3599442137011169,"score_spread":0.3088703235047067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401208972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97193855,0.008078557,0.0012564132,0.011013343,0.00011976819,0.000040264116,0.00057738926,0.000059330843,0.006916372],"genre_scores_gemma":[0.99646795,0.0015802929,0.0009316733,0.0006225792,0.00010763387,0.0000053080694,0.000122029014,0.00000723319,0.00015533206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980951,0.00046811742,0.00010973621,0.00031301304,0.00071260496,0.00030149514],"domain_scores_gemma":[0.9937884,0.0030836342,0.001134331,0.00024625173,0.0011168566,0.0006305037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00276865,0.00037961898,0.00040281474,0.0011342539,0.00096165994,0.00088114257,0.0011040401,0.0008204248,0.0015291957],"category_scores_gemma":[0.0152384145,0.00012268593,0.00030265294,0.0014044377,0.0018902052,0.00039886215,0.0006007485,0.00077745266,0.000096546064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010867352,0.0000229056,0.9762862,0.00006136992,0.00004921848,0.00069434807,0.00021197039,0.0003725641,0.00088074553,0.0004928516,0.00079410826,0.020025212],"study_design_scores_gemma":[0.00001747579,0.00011057508,0.98929626,0.00019841295,0.00015859643,0.0029915622,0.00092899037,0.001823753,0.00044066773,0.0012622736,0.0027522633,0.000019262035],"about_ca_topic_score_codex":0.31751862,"about_ca_topic_score_gemma":0.27539128,"teacher_disagreement_score":0.31751862,"about_ca_system_score_codex":0.0023707028,"about_ca_system_score_gemma":0.004901848,"threshold_uncertainty_score":0.6313409},"labels":[],"label_agreement":null},{"id":"W4401326937","doi":"10.1200/po.24.00167","title":"Improving Access to Hereditary Testing in Pancreatic Ductal Carcinoma","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Pancreas Centre (Canada); University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Canada Research Chairs; AstraZeneca Canada; AstraZeneca; Pfizer","keywords":"Pancreatic carcinoma; Pancreatic ductal adenocarcinoma; Medicine; Carcinoma; Oncology; Internal medicine; Pancreatic cancer; Cancer","score_opus":0.08624623307428479,"score_gpt":0.4163307433603118,"score_spread":0.330084510286027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401326937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98871964,0.0017778877,0.00034687284,0.00291103,0.000031294207,0.000050957176,0.00063483405,0.000071410104,0.0054561207],"genre_scores_gemma":[0.99771947,0.0007589401,0.00039709796,0.00034872562,0.000046317964,0.00001683391,0.00036322363,0.000007109251,0.0003423306],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985154,0.00044750219,0.000102294136,0.00021375241,0.00030828352,0.00041282727],"domain_scores_gemma":[0.9929141,0.0015903508,0.0028488103,0.00024944812,0.0005214726,0.0018757822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010854929,0.00013278757,0.00018420142,0.00068992644,0.00060391595,0.0011028044,0.0006550246,0.00034941896,0.0038519753],"category_scores_gemma":[0.008045999,0.00012845903,0.00029233837,0.001129096,0.0004424428,0.0006051467,0.0014178178,0.0005937659,0.0003013935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010277122,0.00018616032,0.95553553,0.000071941555,0.00001868092,0.00034096275,0.00028300373,0.00046741645,0.00032243386,0.0001412773,0.0019039287,0.04062591],"study_design_scores_gemma":[0.00005499555,0.000352827,0.99079376,0.00017090407,0.000032368844,0.0014048864,0.0011295235,0.0012965559,0.00043619226,0.0003190397,0.0039954623,0.000013473075],"about_ca_topic_score_codex":0.081968755,"about_ca_topic_score_gemma":0.09443624,"teacher_disagreement_score":0.081968755,"about_ca_system_score_codex":0.0028465604,"about_ca_system_score_gemma":0.004941041,"threshold_uncertainty_score":0.1629833},"labels":[],"label_agreement":null},{"id":"W4401412002","doi":"10.1200/po.24.00184","title":"“I Just Assumed This Was Already Being Done”: Canadian Patient Preferences for Enhanced Data Sharing for Precision Oncology","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Provincial Health Services Authority; Queen's University; University of Toronto; Canada's Michael Smith Genome Sciences Centre; University of British Columbia; St. Michael's Hospital; Simon Fraser University","funders":"National Cancer Institute; National Institutes of Health; University of Toronto; Government of Ontario","keywords":"Focus group; Thematic analysis; Data sharing; Transparency (behavior); Qualitative property; Autonomy; Population; Psychology; Medicine; Qualitative research; Internet privacy; Medical education; Business; Computer science; Political science; Alternative medicine; Environmental health; Computer security","score_opus":0.6041546404413033,"score_gpt":0.6094429951412814,"score_spread":0.005288354699978126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401412002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reproducibility","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"reproducibility","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7129204,0.0028145942,0.00196615,0.23748584,0.00045360875,0.00035879642,0.0009908463,0.00009277091,0.04291701],"genre_scores_gemma":[0.9694231,0.0009476334,0.0019450891,0.024488276,0.000042031268,0.00010100939,0.000129784,0.00003574439,0.0028873817],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9868482,0.005433276,0.00058403244,0.0007903089,0.003240396,0.0031037524],"domain_scores_gemma":[0.96884745,0.00983928,0.0033199196,0.00086305075,0.0074372534,0.009692992],"candidate_categories":["metaresearch","open_science"],"consensus_categories":[],"category_scores_codex":[0.0122208465,0.00023068105,0.0004057151,0.00068860216,0.021539098,0.0044190497,0.0016352113,0.0023829103,0.008310134],"category_scores_gemma":[0.0310437,0.00045500696,0.00050375506,0.0021477297,0.0065560485,0.0024507141,0.003869194,0.005305492,0.00039191454],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005492739,0.00017381825,0.10210105,0.0010123043,0.00009488913,0.0069576786,0.6986073,0.00040308505,0.0027869833,0.015971746,0.10431044,0.06703138],"study_design_scores_gemma":[0.00009600969,0.00024313385,0.047788333,0.0010318244,0.00007410327,0.0046515046,0.7631659,0.0006618922,0.0005009149,0.0038603763,0.17758851,0.0003374372],"about_ca_topic_score_codex":0.87757,"about_ca_topic_score_gemma":0.92565566,"teacher_disagreement_score":0.9983648,"about_ca_system_score_codex":0.05644541,"about_ca_system_score_gemma":0.11855127,"threshold_uncertainty_score":0.40954196},"labels":[],"label_agreement":null},{"id":"W4401803980","doi":"10.1200/po.24.00100","title":"Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"Genentech; Merck Canada; CRIS Cancer Foundation; Sociedad Española de Oncología Médica; Natera; Gilead Sciences; Eli Lilly and Company","keywords":"Pembrolizumab; Internal medicine; Oncology; Medicine; Biomarker; Immunotherapy; Progression-free survival; Cancer research; Cancer; Biology; Overall survival","score_opus":0.033039067890378006,"score_gpt":0.37552085143387254,"score_spread":0.3424817835434945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401803980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99880326,0.00038579942,0.00024415026,0.00004319947,0.0000041984617,0.0000113788465,0.00030759256,0.000010042324,0.00019041078],"genre_scores_gemma":[0.99896336,0.00007616558,0.00023570315,0.00004246808,0.000006775512,0.000017069671,0.0005464182,0.0000023669,0.000109707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996555,0.00011135796,0.000036204285,0.00010069338,0.00005881004,0.00003731003],"domain_scores_gemma":[0.9991893,0.00017304296,0.00038004358,0.00006816139,0.00009505486,0.00009429517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007996948,0.00019488558,0.00036172362,0.00027953056,0.00013988142,0.00043015488,0.00014919983,0.00022917085,0.00073270267],"category_scores_gemma":[0.0012961321,0.0001235705,0.00022101121,0.00027714146,0.00013704093,0.00023991709,0.00022848467,0.00035573356,0.00013555295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055177384,0.00020975283,0.9476681,0.00006502433,0.00028200148,0.000041395295,0.00006306498,0.00072444446,0.022431139,0.000028136867,0.00048375028,0.022485588],"study_design_scores_gemma":[0.000095493706,0.0007895305,0.9930392,0.000011023963,0.00014845467,0.00017823567,0.000050211343,0.0024253358,0.002651938,0.00004940989,0.0005550222,0.0000062140507],"about_ca_topic_score_codex":0.00045629544,"about_ca_topic_score_gemma":0.00074868015,"teacher_disagreement_score":0.0007996948,"about_ca_system_score_codex":0.00028325155,"about_ca_system_score_gemma":0.00017951513,"threshold_uncertainty_score":0.0042292476},"labels":[],"label_agreement":null},{"id":"W4401805383","doi":"10.1200/po.24.00031","title":"Kinetic Profiling of <i>RAS</i> Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of <i>RAS</i> Mutations in Neo-<i>RAS</i>-Wildtype Metastatic Colorectal Cancer Is Transient","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Ottawa; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Neuroblastoma RAS viral oncogene homolog; KRAS; Cetuximab; Medicine; Internal medicine; Hazard ratio; Colorectal cancer; Panitumumab; Oncology; HRAS; Mutation; Cancer; Cancer research; Biology; Genetics; Gene; Confidence interval","score_opus":0.030536048013300253,"score_gpt":0.34769754583515433,"score_spread":0.3171614978218541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401805383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99221814,0.0019906256,0.00033670015,0.00042139553,0.000026605636,0.00014661597,0.0005340359,0.00003351047,0.004292331],"genre_scores_gemma":[0.9980944,0.0002243905,0.00027610036,0.00020524161,0.00001660938,0.000027532113,0.00037233435,0.0000075086427,0.0007759367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99923766,0.00020296531,0.000028163615,0.0001510723,0.00025235245,0.00012782258],"domain_scores_gemma":[0.99872535,0.00025689372,0.0004358994,0.00009592398,0.00017124206,0.00031472364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015928531,0.0002712469,0.0004996922,0.00018346136,0.0003232543,0.00056075247,0.00030474257,0.00025963728,0.0018424707],"category_scores_gemma":[0.0013664855,0.00013815735,0.0002776146,0.00024345024,0.0004328722,0.0002607238,0.00012076785,0.0008253668,0.00020759588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13222927,0.0031959591,0.5785557,0.0005926799,0.0010303383,0.00017135465,0.00032122532,0.0018235017,0.110922836,0.0006318532,0.008122635,0.1624026],"study_design_scores_gemma":[0.007858716,0.05095411,0.8965231,0.00005751267,0.0012027657,0.0006504184,0.00013148595,0.004199927,0.029218895,0.00024714612,0.00890285,0.00005306487],"about_ca_topic_score_codex":0.02171679,"about_ca_topic_score_gemma":0.07403364,"teacher_disagreement_score":0.9782832,"about_ca_system_score_codex":0.00162412,"about_ca_system_score_gemma":0.0014236091,"threshold_uncertainty_score":0.043180823},"labels":[],"label_agreement":null},{"id":"W4401988220","doi":"10.1200/po.24.00269","title":"A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"EMD Serono; Regeneron Pharmaceuticals; Genentech; AstraZeneca; Pfizer; DOD Prostate Cancer Research Program; Sanofi; Foundation Medicine; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Overdiagnosis; Prostate cancer; Medicine; Oncology; Blood test; Disease; Internal medicine; Cancer research; Pathology; Cancer","score_opus":0.02480000990877935,"score_gpt":0.3183627302285673,"score_spread":0.293562720319788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401988220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675935,0.015083881,0.0059123375,0.0008403338,0.000091354785,0.00024277967,0.0044189333,0.00017103707,0.0056456877],"genre_scores_gemma":[0.9931132,0.001224185,0.0031915822,0.0004747036,0.000076457654,0.00008287923,0.0010873983,0.000011667692,0.0007378174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983607,0.0005115582,0.00010964531,0.00050377136,0.00040220656,0.000112220216],"domain_scores_gemma":[0.9970139,0.0010618583,0.0012073438,0.0001569654,0.0003854713,0.00017452106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002057823,0.00039589265,0.0005036576,0.0010592479,0.00024824857,0.0006546969,0.00048581482,0.0004680846,0.0014465717],"category_scores_gemma":[0.0038347743,0.00019553631,0.00036844876,0.00084543065,0.00038644488,0.00041102522,0.00039278978,0.00039520845,0.0002615816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016280612,0.00022157378,0.90861243,0.00047756778,0.00049355894,0.00007786662,0.00008510522,0.00059628807,0.015121602,0.0002934684,0.0019080454,0.07048439],"study_design_scores_gemma":[0.00026953494,0.0027943437,0.950149,0.00020860389,0.00089131517,0.0017928899,0.000091650174,0.0031327296,0.030327167,0.00051744614,0.0097854035,0.0000399224],"about_ca_topic_score_codex":0.0026093158,"about_ca_topic_score_gemma":0.009540118,"teacher_disagreement_score":0.0026093158,"about_ca_system_score_codex":0.00050497113,"about_ca_system_score_gemma":0.000453014,"threshold_uncertainty_score":0.010882914},"labels":[],"label_agreement":null},{"id":"W4403709384","doi":"10.1200/po.24.00145","title":"Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology","year":2024,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; NRG Oncology","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Histopathology; Cancer; Clinical trial; Randomized controlled trial; Pathology","score_opus":0.10550044020706685,"score_gpt":0.4751473990672055,"score_spread":0.36964695886013865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403709384","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96394855,0.0137840565,0.012897555,0.002034058,0.000255734,0.0035041787,0.00083798426,0.00026849756,0.0024694675],"genre_scores_gemma":[0.9867541,0.0011154936,0.009108488,0.0004914012,0.00008371373,0.001380565,0.00062035257,0.000013507169,0.00043225082],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9970214,0.0023756826,0.00011733202,0.00020537653,0.00020329436,0.000076964956],"domain_scores_gemma":[0.99847716,0.00062254036,0.00055479485,0.000120311655,0.00009025651,0.00013496257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007261592,0.0007453525,0.00085092196,0.00047297162,0.00012672303,0.00063720974,0.0004940437,0.0004320553,0.0011421416],"category_scores_gemma":[0.0070285816,0.00021352201,0.001515484,0.00040993758,0.00035792598,0.0006302993,0.00049046776,0.00096499117,0.00015705707],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3121428,0.0051239417,0.12934402,0.0027395387,0.009678187,0.000096679796,0.00016098836,0.060524013,0.0050432086,0.0013940722,0.006173137,0.46757945],"study_design_scores_gemma":[0.298718,0.20906143,0.17812115,0.0015476393,0.016433166,0.00042285596,0.00021249094,0.25794914,0.009317284,0.011275139,0.016707934,0.00023377604],"about_ca_topic_score_codex":0.00075712375,"about_ca_topic_score_gemma":0.0018835121,"teacher_disagreement_score":0.007261592,"about_ca_system_score_codex":0.0008444758,"about_ca_system_score_gemma":0.0010110119,"threshold_uncertainty_score":0.03840339},"labels":[],"label_agreement":null},{"id":"W4404125687","doi":"10.1200/po-24-00375","title":"DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; National Institute of General Medical Sciences; Pfizer; University of Texas MD Anderson Cancer Center; University of North Carolina at Chapel Hill; National Institutes of Health; Melanoma Institute Australia; Medical Research Council; National Health and Medical Research Council; Huntsman Cancer Foundation; Char and Chuck Fowler Family Foundation; National Cancer Institute; Melanoma Research Alliance; National Institute of Environmental Health Sciences; Memorial Sloan-Kettering Cancer Center","keywords":"Stage (stratigraphy); DNA methylation; Methylation; Primary (astronomy); Clinical significance; Biology; DNA; Cancer research; Oncology; Medicine; Genetics; Internal medicine; Gene; Gene expression; Paleontology","score_opus":0.03563761992787889,"score_gpt":0.3467736763202066,"score_spread":0.3111360563923277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404125687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99886143,0.00027650865,0.00016866245,0.000016115728,0.000002208713,0.000008080893,0.00039138485,0.000005556126,0.00027003197],"genre_scores_gemma":[0.9993787,0.000043092237,0.00011167367,0.000008430933,0.000003552886,0.0000059748813,0.00033759835,0.0000017663266,0.00010924249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997408,0.000044088985,0.00002987999,0.000091538066,0.0000449918,0.00004856703],"domain_scores_gemma":[0.99937564,0.000091627764,0.0003194953,0.00004886404,0.000065746724,0.00009865141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002693022,0.00022278482,0.00024663744,0.0007880019,0.0002804673,0.00038040368,0.00019658318,0.0002458493,0.0012517787],"category_scores_gemma":[0.0010423393,0.00013487478,0.00019504993,0.00043916758,0.00022135265,0.00016586726,0.00027111737,0.00025791884,0.0002090094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013630737,0.000009255916,0.99587196,0.0000071030736,0.000024072282,0.00003796923,0.000039874718,0.000024786299,0.0018806471,0.0000130742865,0.000052452986,0.0019024444],"study_design_scores_gemma":[0.0000036244735,0.00004712448,0.99867344,0.0000031285704,0.000013864933,0.00039092236,0.00007113691,0.00016690516,0.0004378173,0.000035605055,0.00015454763,0.0000019157644],"about_ca_topic_score_codex":0.002441795,"about_ca_topic_score_gemma":0.0031342336,"teacher_disagreement_score":0.002441795,"about_ca_system_score_codex":0.00023823419,"about_ca_system_score_gemma":0.00013122811,"threshold_uncertainty_score":0.0048552155},"labels":[],"label_agreement":null},{"id":"W4404125770","doi":"10.1200/po.24.00328","title":"Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Pazopanib; Histone deacetylase; Histone deacetylase inhibitor; Medicine; Internal medicine; Oncology; Cancer research; Pharmacology; Biology; Cancer; Histone; Genetics; Sunitinib","score_opus":0.01511728436312147,"score_gpt":0.3375026105248496,"score_spread":0.3223853261617281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404125770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98941433,0.0021185891,0.00080575043,0.00034498924,0.000060282662,0.00023942304,0.0039398186,0.00006153679,0.0030151508],"genre_scores_gemma":[0.9895007,0.00041310344,0.00072572957,0.00045188912,0.00004877969,0.00025894557,0.0076860944,0.000011967927,0.0009027226],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99954176,0.00014875212,0.000046332785,0.00010802571,0.00007730815,0.00007780964],"domain_scores_gemma":[0.99908686,0.00014449135,0.00031872746,0.00007065329,0.00008410931,0.00029523356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013706359,0.00031458517,0.0009737928,0.00020727824,0.00036275724,0.0007021985,0.00022236738,0.00033966426,0.0012920838],"category_scores_gemma":[0.0009610101,0.0001247416,0.00070549065,0.00029071298,0.0001448393,0.0004487626,0.00029431554,0.00094859465,0.00029082914],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16167665,0.0021240206,0.5796208,0.0005331119,0.0028249628,0.00040532,0.00022520882,0.0048547597,0.0287333,0.00044676437,0.008748331,0.20980678],"study_design_scores_gemma":[0.011866615,0.05608499,0.8995101,0.00010564939,0.0029956484,0.0010200606,0.000121528545,0.0041072783,0.008512544,0.00069650845,0.014930927,0.00004820698],"about_ca_topic_score_codex":0.0005219914,"about_ca_topic_score_gemma":0.001396671,"teacher_disagreement_score":0.0013706359,"about_ca_system_score_codex":0.0005229847,"about_ca_system_score_gemma":0.00046155349,"threshold_uncertainty_score":0.0072486997},"labels":[],"label_agreement":null},{"id":"W4404625463","doi":"10.1200/po.24.00331","title":"Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Osimertinib; T790M; Medicine; Lung cancer; Internal medicine; Meta-analysis; Epidermal growth factor receptor; Oncology; Cochrane Library; Adverse effect; Gastroenterology; Cancer; Gefitinib; Erlotinib","score_opus":0.05529877687620812,"score_gpt":0.39678806373164016,"score_spread":0.34148928685543206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404625463","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009087226,0.9885083,0.0005973076,0.0001801941,0.000115763105,0.0003520252,0.0007659286,0.00002911282,0.00036419687],"genre_scores_gemma":[0.28848386,0.70538586,0.0020954784,0.0010013824,0.0002456558,0.0011298998,0.0011837138,0.00003645243,0.00043775034],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99405587,0.002493938,0.0019466889,0.0006721433,0.000634812,0.00019654767],"domain_scores_gemma":[0.99066305,0.0059911422,0.0019301254,0.00031213628,0.0009491806,0.00015430528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01075148,0.0022888333,0.018160833,0.0049248934,0.0004595102,0.002515918,0.0016936694,0.0016152598,0.002713896],"category_scores_gemma":[0.016802387,0.0012091616,0.03425971,0.005869647,0.0006071621,0.0013929271,0.0011144388,0.0012527292,0.00029000707],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020825607,0.000025854672,0.0033339772,0.33215386,0.65216225,0.000106832,0.0000619567,0.00058004056,0.0003438356,0.00009804596,0.00046060467,0.0085901385],"study_design_scores_gemma":[0.00053289824,0.00020093894,0.0027920234,0.013559152,0.9813244,0.00007384619,0.000027774051,0.00016895989,0.000106946805,0.00011380759,0.001081925,0.000017250679],"about_ca_topic_score_codex":0.005483707,"about_ca_topic_score_gemma":0.012734722,"teacher_disagreement_score":0.018160833,"about_ca_system_score_codex":0.0022113537,"about_ca_system_score_gemma":0.0024548278,"threshold_uncertainty_score":0.05685997},"labels":[],"label_agreement":null},{"id":"W4405301403","doi":"10.1200/po-24-00407","title":"Clinical Utility of Genomic Sequencing for Hereditary Cancer Syndromes: An Observational Cohort Study","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Hospital for Sick Children; University of British Columbia; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; University Health Network; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Cancer; Observational study; Breast cancer; Family history; Internal medicine; Clinical trial; Cohort; Genetic testing; Genetic counseling; Oncology; Genetics; Biology","score_opus":0.14439222216664757,"score_gpt":0.4435259865020033,"score_spread":0.29913376433535577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405301403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99834085,0.00025399364,0.0001768814,0.000058594458,0.0000062193226,0.0000399437,0.0008669161,0.0000033227977,0.0002532803],"genre_scores_gemma":[0.9988588,0.00012632935,0.00017774988,0.000059010494,0.000011626162,0.00003869711,0.00066282676,0.000002747051,0.00006221408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977126,0.00079381524,0.00030725787,0.0006113292,0.00034901715,0.00022606026],"domain_scores_gemma":[0.9926596,0.0018162313,0.0035670418,0.00087661226,0.00045640953,0.00062403426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032382896,0.00033452947,0.00052022364,0.00078604335,0.00061702775,0.0007993277,0.00057515333,0.00055653165,0.0016982784],"category_scores_gemma":[0.009087287,0.0003393628,0.0008116249,0.0013539786,0.0005144429,0.00061132223,0.00083887577,0.0008525528,0.00026446392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000222534,0.000047911075,0.9985642,0.000021824322,0.00013297328,0.000093077724,0.000114175826,0.00002747793,0.00009300098,0.000030410802,0.00015732975,0.00049509946],"study_design_scores_gemma":[0.00007188445,0.0004749397,0.9967463,0.000045729506,0.00023052527,0.0010144849,0.00040171493,0.00040433256,0.00006180756,0.000089187015,0.00044456057,0.000014615638],"about_ca_topic_score_codex":0.006187686,"about_ca_topic_score_gemma":0.006550864,"teacher_disagreement_score":0.006187686,"about_ca_system_score_codex":0.00059772347,"about_ca_system_score_gemma":0.00075081433,"threshold_uncertainty_score":0.017125905},"labels":[],"label_agreement":null},{"id":"W4405302030","doi":"10.1200/po-24-00514","title":"Phase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; ECOG-ACRIN Cancer Research Group; Margaret A. Cargill Foundation; National Institutes of Health; American College of Radiology Imaging Network","keywords":"Sunitinib; Medicine; Internal medicine; Renal cell carcinoma; Oncology; Gastroenterology; Clinical endpoint; Progressive disease; Clinical trial; Disease","score_opus":0.07533586281381977,"score_gpt":0.4325817661142351,"score_spread":0.35724590330041534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405302030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97580284,0.0031420733,0.0009149651,0.00069888204,0.00020552847,0.009013935,0.0048058475,0.00017443673,0.0052415105],"genre_scores_gemma":[0.97195125,0.0016741805,0.0024193614,0.001465768,0.00026688603,0.008058095,0.007972781,0.000058186037,0.0061336155],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99953425,0.00022741947,0.000028823662,0.000067942936,0.000050979343,0.00009063383],"domain_scores_gemma":[0.9994753,0.00007472071,0.00013120184,0.000044283563,0.000033011787,0.0002415179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018666231,0.0012886102,0.0014363062,0.0003248537,0.00045598325,0.0008713615,0.0006137602,0.0011713989,0.0038593744],"category_scores_gemma":[0.0007800221,0.00037155027,0.0010127038,0.00028563448,0.0005637863,0.0006355122,0.00036301877,0.0015027798,0.0008378533],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7926474,0.036323175,0.013078662,0.0013921281,0.001308092,0.00042520778,0.00025365825,0.0028520366,0.04906343,0.00062554155,0.01842325,0.08360739],"study_design_scores_gemma":[0.68979263,0.27196217,0.023117559,0.000051706495,0.00038691398,0.00045410183,0.00005088938,0.0013156091,0.0062088137,0.00036405938,0.006259924,0.000035677393],"about_ca_topic_score_codex":0.0010712928,"about_ca_topic_score_gemma":0.0028703464,"teacher_disagreement_score":0.0038593744,"about_ca_system_score_codex":0.0011753915,"about_ca_system_score_gemma":0.0016492655,"threshold_uncertainty_score":0.0129109025},"labels":[],"label_agreement":null},{"id":"W4406854679","doi":"10.1200/po.24.00199","title":"Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers","year":2025,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"National Cancer Institute; Conquer Cancer Foundation","keywords":"MAPK/ERK pathway; Mutant; Cancer; Mutation; Cancer research; Medicine; Kinase; Protein kinase A; Internal medicine; Oncology; Biology; Gene; Genetics","score_opus":0.033493044826011814,"score_gpt":0.3678672657524481,"score_spread":0.3343742209264363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406854679","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010820363,0.98759764,0.00014491027,0.00019448069,0.000056894103,0.000056881516,0.00076959404,0.000006915525,0.00035231863],"genre_scores_gemma":[0.44190666,0.5539083,0.0008711693,0.0010643062,0.00037530073,0.00026900755,0.0014168335,0.000017405175,0.0001709457],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.99450535,0.0021633166,0.0018401656,0.0007583816,0.00060496735,0.00012781321],"domain_scores_gemma":[0.9850603,0.009870066,0.0036816169,0.00031346612,0.0009206228,0.0001538973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075624357,0.0007675491,0.006149663,0.003189997,0.00022386435,0.0013997016,0.00079207326,0.00087660295,0.001243326],"category_scores_gemma":[0.016986344,0.00058134063,0.011358516,0.0047100713,0.00037045332,0.0007572326,0.00055397436,0.0008681539,0.00013159036],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073605045,0.00007144244,0.05019973,0.37103644,0.4994627,0.00018085222,0.0001449034,0.001047304,0.0011075246,0.00024477707,0.0021391278,0.06700462],"study_design_scores_gemma":[0.0020284972,0.0010072956,0.0820253,0.043606523,0.86039186,0.0005567376,0.00014655519,0.0005129235,0.0007567166,0.00052188605,0.008388813,0.000056899447],"about_ca_topic_score_codex":0.002840255,"about_ca_topic_score_gemma":0.006238373,"teacher_disagreement_score":0.0075624357,"about_ca_system_score_codex":0.0011382023,"about_ca_system_score_gemma":0.0010319022,"threshold_uncertainty_score":0.03999442},"labels":[],"label_agreement":null},{"id":"W4407011452","doi":"10.1200/po-24-00653","title":"Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Histopathology; Hazard ratio; Proportional hazards model; Medicine; Prostate cancer; Internal medicine; Oncology; Urology; Clinical trial; Confidence interval; Cancer; Pathology","score_opus":0.038948330216087804,"score_gpt":0.4126592573118778,"score_spread":0.37371092709579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407011452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973219,0.0010643787,0.0005559739,0.00014665847,0.000037846483,0.0003549641,0.00011891475,0.000026036523,0.00037333032],"genre_scores_gemma":[0.99778795,0.00030897424,0.0010170735,0.000106663836,0.00004105376,0.0003119046,0.00020680223,0.0000026708321,0.00021697131],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992674,0.0005306478,0.000028475582,0.000070782065,0.00006803624,0.00003464809],"domain_scores_gemma":[0.999361,0.00024280473,0.00021682544,0.000040198473,0.000032257343,0.000106898246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019419158,0.00064526784,0.00083258783,0.00025639188,0.000108029366,0.00050564064,0.00035673723,0.00030748764,0.00080921286],"category_scores_gemma":[0.002005113,0.00015831813,0.00087774714,0.00022329688,0.0004395887,0.00031218873,0.00025031154,0.00076916575,0.00007850105],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73491657,0.010898091,0.06679429,0.0006387787,0.0041829534,0.00006808089,0.000107442946,0.015953725,0.0046778037,0.0003726338,0.0010095657,0.16038005],"study_design_scores_gemma":[0.47095144,0.347107,0.12180913,0.00009883645,0.003629226,0.00020355394,0.000088684,0.048405048,0.0041404213,0.0016281932,0.001869586,0.000068904665],"about_ca_topic_score_codex":0.0005298377,"about_ca_topic_score_gemma":0.00089992903,"teacher_disagreement_score":0.0019419158,"about_ca_system_score_codex":0.0004454294,"about_ca_system_score_gemma":0.0005409466,"threshold_uncertainty_score":0.0102699995},"labels":[],"label_agreement":null},{"id":"W4407395562","doi":"10.1200/po-24-00675","title":"Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Tissue microarray; Medicine; Immunohistochemistry; Internal medicine; Oncology; Pathology; Cancer; Histology","score_opus":0.038866336250880235,"score_gpt":0.3938108376245462,"score_spread":0.35494450137366595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407395562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99880314,0.00018931241,0.00006643006,0.000010786783,0.0000011683326,0.0000046004866,0.00071413565,0.0000030926706,0.0002072815],"genre_scores_gemma":[0.9989121,0.00006634474,0.000047344914,0.000006608095,0.0000030525275,0.0000061233554,0.0008693873,0.0000015869505,0.00008749376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995363,0.000090350004,0.000065005705,0.00013328501,0.000105737905,0.00006935056],"domain_scores_gemma":[0.99924845,0.00013471975,0.00029897835,0.00006254125,0.00012505573,0.00013024677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057531486,0.00017199725,0.0001835247,0.0010485876,0.0002160526,0.0003719002,0.00020738618,0.0003141578,0.00094173854],"category_scores_gemma":[0.0012163961,0.00010081345,0.0002802107,0.00068617926,0.00017326637,0.00020687545,0.00074344815,0.00014249243,0.00025668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018704437,0.0000113786145,0.9965888,0.000011118221,0.00003484158,0.00011214996,0.000044093646,0.000048157282,0.0010689022,0.000008766956,0.00013113834,0.0017535402],"study_design_scores_gemma":[0.0000032084806,0.000033146076,0.9990264,0.000002398963,0.000011977166,0.00038205445,0.00007571354,0.00007099455,0.0001849657,0.0000070456276,0.0002006505,0.0000013815727],"about_ca_topic_score_codex":0.0014265534,"about_ca_topic_score_gemma":0.0012738724,"teacher_disagreement_score":0.0014265534,"about_ca_system_score_codex":0.00019178099,"about_ca_system_score_gemma":0.00012583174,"threshold_uncertainty_score":0.003150463},"labels":[],"label_agreement":null},{"id":"W4407828113","doi":"10.1200/po-24-00631","title":"Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Health; Canada's Michael Smith Genome Sciences Centre; Queen's University; University of British Columbia; Simon Fraser University","funders":"","keywords":"Medicine; Hazard ratio; Proportional hazards model; Oncology; Internal medicine; Population; Censoring (clinical trials); Survival analysis; Confidence interval; Pathology","score_opus":0.09579530884220487,"score_gpt":0.43047834553754183,"score_spread":0.33468303669533694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407828113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97551936,0.0006948234,0.011273027,0.0009238853,0.000094229734,0.005802426,0.0036204758,0.00007231525,0.001999506],"genre_scores_gemma":[0.9865984,0.00012462043,0.0066204546,0.00039041726,0.00005065681,0.0044413395,0.0012966548,0.000015596768,0.00046180593],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9557475,0.039192326,0.0010060408,0.0022356953,0.0010407057,0.0007778478],"domain_scores_gemma":[0.9505063,0.033455774,0.00811891,0.0050822594,0.0017974905,0.001039147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.051560663,0.0011170055,0.001361354,0.0006617416,0.00060882635,0.0015762916,0.0016589408,0.0016949672,0.0033986645],"category_scores_gemma":[0.07048758,0.0007320825,0.002828714,0.00085581996,0.0016668815,0.0014060999,0.0013420844,0.0018457727,0.00043408602],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3352753,0.028299725,0.22979869,0.002669636,0.025156809,0.0007906303,0.0012584181,0.25105378,0.0042765676,0.014194264,0.011842521,0.095383674],"study_design_scores_gemma":[0.12912866,0.17277949,0.19742791,0.00077126804,0.016795216,0.001074779,0.0009918192,0.43473732,0.009382333,0.022430308,0.013938105,0.0005427257],"about_ca_topic_score_codex":0.006973282,"about_ca_topic_score_gemma":0.0050318358,"teacher_disagreement_score":0.051560663,"about_ca_system_score_codex":0.0046884664,"about_ca_system_score_gemma":0.0030035747,"threshold_uncertainty_score":0.27268207},"labels":[],"label_agreement":null},{"id":"W4408245897","doi":"10.1200/po-24-00641","title":"Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Hazard ratio; Oncology; Internal medicine; Metastatic breast cancer; Subgroup analysis; Population; Cancer; Cohort; Brain metastasis; Gynecology; Metastasis; Meta-analysis; Confidence interval","score_opus":0.01767704248195932,"score_gpt":0.36299924804994055,"score_spread":0.3453222055679812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408245897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987991,0.00020479174,0.000054067907,0.000018163062,0.000005819786,0.0000128400125,0.00069260824,0.0000023020038,0.00021023567],"genre_scores_gemma":[0.99905926,0.00011190232,0.000058750138,0.000023523655,0.000008262133,0.000015024516,0.0006329106,0.0000021106675,0.00008821829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99949217,0.000080182865,0.00006307915,0.00018969196,0.00008653091,0.00008836272],"domain_scores_gemma":[0.99872845,0.00016004503,0.0005414016,0.0001890978,0.00014881448,0.00023222057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000642944,0.00027719905,0.00053950766,0.000703198,0.0005604919,0.0006612398,0.00044878208,0.00040694012,0.0011304191],"category_scores_gemma":[0.0015729241,0.00043609884,0.00055487297,0.0011977957,0.00024878167,0.0005194638,0.0004173104,0.00066809845,0.00021506014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012655556,0.00002121503,0.99924755,0.000004963169,0.00006510734,0.00005077828,0.000032262727,0.000017728458,0.00011952971,0.0000071309914,0.000056515815,0.00025075406],"study_design_scores_gemma":[0.000018484,0.0001451095,0.9989718,0.00000556035,0.00005985236,0.000301214,0.00013077022,0.00013635831,0.000040699466,0.000015313357,0.00017030588,0.0000045210973],"about_ca_topic_score_codex":0.011850547,"about_ca_topic_score_gemma":0.011507265,"teacher_disagreement_score":0.011850547,"about_ca_system_score_codex":0.0003939872,"about_ca_system_score_gemma":0.00046667145,"threshold_uncertainty_score":0.023563087},"labels":[],"label_agreement":null},{"id":"W4409127671","doi":"10.1200/po-24-00546","title":"Multiplex Spatial Proteomic Analysis of HER2–Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Translational Breast Cancer Research Consortium; Breakthrough Cancer Research; American Society of Clinical Oncology; Genentech; Breast Cancer Research Foundation","keywords":"Breast cancer; Trastuzumab; Pertuzumab; Immunohistochemistry; Immune system; Medicine; Oncology; Estrogen receptor; Stromal cell; Antibody; Internal medicine; Pathology; Cancer; Cancer research; Biology; Immunology","score_opus":0.015748799155744012,"score_gpt":0.36758629728602243,"score_spread":0.3518374981302784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409127671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99863654,0.00028160727,0.0004897023,0.000018163535,0.0000026932107,0.000007572468,0.0002479156,0.000017682438,0.00029808257],"genre_scores_gemma":[0.9985215,0.000117663425,0.0007463435,0.000021659982,0.000004674923,0.00001169977,0.00026041912,0.0000026419361,0.00031335946],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99985135,0.00002081748,0.000012706784,0.000038578844,0.000050463444,0.000026046035],"domain_scores_gemma":[0.9998629,0.00002573361,0.000059669233,0.000010511434,0.000021126627,0.000020055237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019170347,0.0001743798,0.000188549,0.00044852015,0.00010617687,0.0003325491,0.000087038796,0.00015189232,0.0007304863],"category_scores_gemma":[0.00035384603,0.000085329986,0.000111679066,0.00040058015,0.000103503146,0.00016452867,0.0001263627,0.00014569187,0.00015387298],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010387843,0.00009898234,0.12556563,0.00005547468,0.000064910986,0.00012733023,0.000053802014,0.00041961294,0.8610126,0.000057478446,0.00016576343,0.011339619],"study_design_scores_gemma":[0.000025776722,0.00054002565,0.7758692,0.0000061043706,0.00007306919,0.0012684452,0.00017907955,0.0059400476,0.21489891,0.00013696437,0.0010498995,0.00001253868],"about_ca_topic_score_codex":0.0002671726,"about_ca_topic_score_gemma":0.00042997077,"teacher_disagreement_score":0.0007304863,"about_ca_system_score_codex":0.00015734711,"about_ca_system_score_gemma":0.00006919847,"threshold_uncertainty_score":0.0024437308},"labels":[],"label_agreement":null},{"id":"W4409318045","doi":"10.1200/po-24-00742","title":"<i>BRCA1/2</i> and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2– Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Palbociclib; Oncology; Breast cancer; Medicine; Internal medicine; Hazard ratio; Cancer; Hormone receptor; Placebo; Metastatic breast cancer; Confidence interval; Pathology","score_opus":0.015640053231237825,"score_gpt":0.3257295918809627,"score_spread":0.3100895386497248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409318045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99367356,0.0021689306,0.00035446993,0.00010729795,0.000040264906,0.00051306625,0.0014646455,0.000013124252,0.0016646627],"genre_scores_gemma":[0.9969727,0.00041129728,0.00022928693,0.00013975026,0.00008832181,0.00019910176,0.0012745156,0.000004634671,0.00068044633],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9993568,0.00030246272,0.00004506868,0.00017573612,0.00005518103,0.000064780485],"domain_scores_gemma":[0.9992279,0.00020725913,0.00020148758,0.000110974426,0.000059852457,0.00019250922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014367356,0.00044905767,0.0008341523,0.00022648381,0.00022005849,0.00070546335,0.00038125136,0.00031929032,0.0041259937],"category_scores_gemma":[0.0011051638,0.00016812388,0.001209906,0.00024146245,0.00027291387,0.00028615972,0.00027901639,0.00071992225,0.00025107616],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6479583,0.007811293,0.22250327,0.0021373436,0.010789358,0.0007804028,0.00015907187,0.0016607293,0.018813597,0.0006160027,0.0048358375,0.08193485],"study_design_scores_gemma":[0.17613624,0.186966,0.58379376,0.00038799652,0.017160004,0.0030292103,0.00021830134,0.0047050407,0.012487017,0.0011790635,0.01386252,0.000074789066],"about_ca_topic_score_codex":0.00052471465,"about_ca_topic_score_gemma":0.0009014949,"teacher_disagreement_score":0.0041259937,"about_ca_system_score_codex":0.00037402753,"about_ca_system_score_gemma":0.00062126905,"threshold_uncertainty_score":0.013802767},"labels":[],"label_agreement":null},{"id":"W4409721270","doi":"10.1200/po-24-00500","title":"Larotrectinib Compared With Real-World Non–Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thermo Fisher Scientific (Canada); Bayer (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Trk receptor; Oncology; Cancer; Hazard ratio; Progression-free survival; Lung cancer; Receptor; Confidence interval; Neurotrophin; Chemotherapy","score_opus":0.011398444702965325,"score_gpt":0.34334784540911234,"score_spread":0.33194940070614704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409721270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9641721,0.02724902,0.0012828376,0.00077886804,0.0004184878,0.0010914019,0.0011317903,0.00005448751,0.0038210605],"genre_scores_gemma":[0.9961921,0.0018881203,0.00043073983,0.00031829928,0.00011476382,0.00038578216,0.00036505237,0.000003994035,0.00030112357],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99668306,0.0022906691,0.000286746,0.00032680287,0.00022299113,0.00018977135],"domain_scores_gemma":[0.99819773,0.00062751427,0.00078145624,0.00011939206,0.000091119684,0.0001827717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004311569,0.00051800197,0.0011847893,0.00043342856,0.00017891415,0.00094277,0.00047216035,0.00049835414,0.0029867766],"category_scores_gemma":[0.0059712096,0.00015786168,0.0025274674,0.0004140074,0.00045919212,0.0010260845,0.0004786471,0.0008784546,0.0002919774],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8262151,0.004032622,0.02010694,0.0028407683,0.01087667,0.00011857442,0.0001302526,0.004133798,0.002438178,0.00088438834,0.0019172746,0.12630548],"study_design_scores_gemma":[0.45043376,0.4223203,0.07925243,0.0007374156,0.015981605,0.0006473814,0.000372497,0.0112670325,0.0031397364,0.002572522,0.01317275,0.00010259113],"about_ca_topic_score_codex":0.00037831138,"about_ca_topic_score_gemma":0.0009971415,"teacher_disagreement_score":0.004311569,"about_ca_system_score_codex":0.00092470006,"about_ca_system_score_gemma":0.00057278597,"threshold_uncertainty_score":0.022802055},"labels":[],"label_agreement":null},{"id":"W4410390708","doi":"10.1200/po-24-00821","title":"Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) Survey","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Confidence interval; Genetic testing; Medicine; Descriptive statistics; Health care; Low Confidence; Genomic information; Family medicine; Psychology; Internal medicine; Genome; Statistics; Genetics; Biology","score_opus":0.09539806212524465,"score_gpt":0.42067178318017606,"score_spread":0.3252737210549314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410390708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960496,0.00024321,0.00032967722,0.0006822148,0.00001867898,0.00016967415,0.0003778746,0.0000071803215,0.0021219607],"genre_scores_gemma":[0.99752015,0.00032872622,0.00088013406,0.00030512264,0.000021977397,0.000220171,0.000394884,0.0000057023167,0.000323072],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99134445,0.005145531,0.0008066342,0.00033111274,0.0015953807,0.00077680225],"domain_scores_gemma":[0.9429166,0.03647841,0.008894211,0.0012704153,0.0059854756,0.004455007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009431531,0.0002459032,0.00037409095,0.0011752594,0.00062160107,0.0014444663,0.0005034824,0.0007242123,0.0017169751],"category_scores_gemma":[0.03622698,0.00024741492,0.0009289772,0.0012862171,0.000777363,0.0009367244,0.0018694771,0.0012240794,0.00019866307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010829172,0.00048826062,0.9703081,0.00018102844,0.00008963224,0.00008941274,0.0074902656,0.00023169463,0.00008260783,0.00014452169,0.0015629734,0.01922315],"study_design_scores_gemma":[0.000025683388,0.00046630893,0.9785271,0.00018542881,0.00006325392,0.00018477831,0.015152976,0.00067888875,0.00016173157,0.00019674838,0.0043149134,0.000042128162],"about_ca_topic_score_codex":0.0052034925,"about_ca_topic_score_gemma":0.0065856306,"teacher_disagreement_score":0.009431531,"about_ca_system_score_codex":0.0012384723,"about_ca_system_score_gemma":0.0026263213,"threshold_uncertainty_score":0.049879253},"labels":[],"label_agreement":null},{"id":"W4411085240","doi":"10.1200/po-24-00705","title":"Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 Men","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Prostate cancer; Correlation; Medicine; Logistic regression; Oncology; Internal medicine; Prostate; Cancer; Mathematics","score_opus":0.03672518077381527,"score_gpt":0.38038659173792916,"score_spread":0.3436614109641139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411085240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994955,0.00006766439,0.0002299906,0.000006449421,0.0000022839195,0.0000044656026,0.00012261744,0.0000051965776,0.00006590303],"genre_scores_gemma":[0.99944276,0.000016298918,0.00012208741,0.000009482057,0.0000039371603,0.0000058974224,0.0003351155,0.0000028065285,0.000061718434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987507,0.0004188583,0.00006447274,0.00051966484,0.00016718985,0.00007913918],"domain_scores_gemma":[0.99772483,0.0009977832,0.0004237348,0.0004579495,0.00021963354,0.0001759634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020342593,0.00022793133,0.00046836826,0.0005678729,0.00030546245,0.0004821208,0.00027491193,0.00039363882,0.00076153333],"category_scores_gemma":[0.0036445078,0.00020841896,0.0004528972,0.00047830955,0.00036476023,0.00028797015,0.0005260234,0.00034981422,0.00021794345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005043557,0.00005026582,0.9927003,0.000014458936,0.00034594917,0.00006526673,0.00012349522,0.0005531527,0.0019815804,0.000033120763,0.00011017044,0.003517869],"study_design_scores_gemma":[0.000014715554,0.00034585348,0.9961152,0.0000021632825,0.000119652075,0.0002667395,0.00010487962,0.0021288667,0.0006129576,0.00005766006,0.00022285772,0.0000084391],"about_ca_topic_score_codex":0.0013618525,"about_ca_topic_score_gemma":0.001760546,"teacher_disagreement_score":0.0020342593,"about_ca_system_score_codex":0.0002839567,"about_ca_system_score_gemma":0.00014744063,"threshold_uncertainty_score":0.01075834},"labels":[],"label_agreement":null},{"id":"W4412125701","doi":"10.1200/po-25-00200","title":"Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"DNA; Genome; Cell-free fetal DNA; DNA sequencing; Computational biology; Whole genome sequencing; Biology; Genetics; Gene","score_opus":0.012237026845153052,"score_gpt":0.30584458902256906,"score_spread":0.293607562177416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412125701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94842803,0.0037130665,0.044489868,0.00019147026,0.000017438311,0.000076738004,0.0015813321,0.00031948384,0.0011826253],"genre_scores_gemma":[0.9837421,0.000551669,0.013950612,0.00011967247,0.000021721517,0.000036880192,0.0010601024,0.00003094227,0.00048637026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994809,0.00017749576,0.00002978773,0.0001601812,0.000107691536,0.000043926284],"domain_scores_gemma":[0.99918896,0.00026762,0.00029955275,0.00011290644,0.00008047365,0.000050393184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008449415,0.0004943511,0.0003069455,0.0012949451,0.00016486112,0.0008292814,0.0003398178,0.0003826974,0.00068053487],"category_scores_gemma":[0.0021158203,0.00017758708,0.00023006671,0.0005756631,0.00025409026,0.0003042035,0.0007120014,0.00036451433,0.00022073367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077847,0.000068512054,0.7053476,0.00022624995,0.00029275724,0.00043642003,0.00026575007,0.00443598,0.18021719,0.00053697784,0.00080171815,0.10659231],"study_design_scores_gemma":[0.000051780942,0.0007362114,0.83248895,0.000117520496,0.00050740177,0.0044060107,0.000396111,0.039887305,0.109325476,0.0033528605,0.008672813,0.00005765975],"about_ca_topic_score_codex":0.0011047592,"about_ca_topic_score_gemma":0.0022234102,"teacher_disagreement_score":0.0012949451,"about_ca_system_score_codex":0.0003166859,"about_ca_system_score_gemma":0.00021308717,"threshold_uncertainty_score":0.0044685006},"labels":[],"label_agreement":null},{"id":"W4412166395","doi":"10.1200/po-25-00130","title":"Prostate-Related Germline Variant Frequencies Detected in a Cohort of Men With Metastatic Prostate Cancer in Northern India","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University Health Network; Health Sciences North; University of Toronto; NOSM University; Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Germline; Medicine; Oncology; Prostate; Cohort; Internal medicine; Cancer; Gynecology; Biology; Gene; Genetics","score_opus":0.010442309869281729,"score_gpt":0.3061228084469846,"score_spread":0.29568049857770284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412166395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99931204,0.00004687993,0.00004714175,0.000019229376,0.0000019074282,0.000006007404,0.00018564796,0.000006725003,0.00037440777],"genre_scores_gemma":[0.99964714,0.000045295656,0.000038117167,0.000017411496,0.000003149315,0.000004078977,0.0001408195,0.000002214396,0.00010180983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997843,0.00002903456,0.000015395834,0.0000902577,0.00003800025,0.00004300686],"domain_scores_gemma":[0.99967754,0.00004947478,0.00010113647,0.000048469705,0.000042708783,0.00008070288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015361614,0.00018609104,0.00023159145,0.00077648833,0.00082658086,0.00067576586,0.00037768256,0.00020603079,0.0015262752],"category_scores_gemma":[0.0006349573,0.00025404713,0.000218539,0.0009085464,0.0005116506,0.00016680811,0.00048094298,0.00036680524,0.0002642633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006138234,0.000014718,0.99608886,0.000014384039,0.00002790515,0.00053276145,0.00058638374,0.000058870144,0.001105664,0.000037689973,0.00012958728,0.0013419379],"study_design_scores_gemma":[0.0000027108158,0.00005045258,0.9972747,0.0000042433808,0.000023867482,0.0015318523,0.0007230267,0.000063213076,0.0001135729,0.000024001994,0.00018393222,0.0000044084895],"about_ca_topic_score_codex":0.020051312,"about_ca_topic_score_gemma":0.019024843,"teacher_disagreement_score":0.020051312,"about_ca_system_score_codex":0.00032368297,"about_ca_system_score_gemma":0.00039643605,"threshold_uncertainty_score":0.03986919},"labels":[],"label_agreement":null},{"id":"W4412831622","doi":"10.1200/po-25-00404","title":"Mucin 16–Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Children's Hospital; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Epithelioid sarcoma; Immunohistochemistry; Sarcoma; Alveolar soft part sarcoma; Pleural effusion; Retrospective cohort study; Oncology; Internal medicine; Cancer; Soft tissue sarcoma; Pathology","score_opus":0.03543992563335825,"score_gpt":0.3678757549915658,"score_spread":0.33243582935820754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412831622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781567,0.013527376,0.001765312,0.00060737756,0.00003210555,0.00006304826,0.0001537379,0.00003779673,0.005656568],"genre_scores_gemma":[0.99522495,0.0033091041,0.00092083676,0.00017214516,0.000034947872,0.000010430258,0.00007100371,0.000007850754,0.00024864692],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9997801,0.000059960683,0.000033939454,0.000042106654,0.000049491468,0.00003441801],"domain_scores_gemma":[0.99927276,0.00025230905,0.00024017571,0.0000651196,0.000054116663,0.00011559662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042735637,0.00021725403,0.00030628484,0.0002705217,0.0002871269,0.0003425417,0.0001793013,0.00048759257,0.00068749004],"category_scores_gemma":[0.0013253884,0.00012759933,0.0002720485,0.00027464735,0.00043683962,0.00031447812,0.00020000449,0.0004851563,0.00023019352],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016034443,0.00033867144,0.33538827,0.0010267637,0.00020397805,0.4328072,0.0012951082,0.0021337825,0.06203066,0.002685398,0.0026082029,0.15787844],"study_design_scores_gemma":[0.000093369825,0.0023137317,0.09806309,0.00021879151,0.00016122032,0.8514501,0.00044005126,0.0013725052,0.023815012,0.00037156872,0.021683542,0.00001709131],"about_ca_topic_score_codex":0.00079879427,"about_ca_topic_score_gemma":0.0017778677,"teacher_disagreement_score":0.00079879427,"about_ca_system_score_codex":0.00052024,"about_ca_system_score_gemma":0.00036732366,"threshold_uncertainty_score":0.003774643},"labels":[],"label_agreement":null},{"id":"W4413273638","doi":"10.1200/po-24-00810","title":"Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palbociclib; Genotyping; Biomarker; Breast cancer; Medicine; Oncology; Cancer; Gene; Internal medicine; Cancer research; Biology; Metastatic breast cancer; Genotype; Genetics","score_opus":0.013986420986430633,"score_gpt":0.31583188916411026,"score_spread":0.3018454681776796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413273638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99226177,0.00088854146,0.0002833951,0.00011856499,0.000016469605,0.00006428659,0.004460766,0.000023909375,0.0018823254],"genre_scores_gemma":[0.99212366,0.00040623677,0.0003543804,0.00012394201,0.000033059856,0.00005310439,0.006117395,0.000010270024,0.00077786227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995245,0.000106149375,0.000028250015,0.00015852104,0.00013165842,0.000050936324],"domain_scores_gemma":[0.9990138,0.00015398627,0.0003322581,0.00006410623,0.00028578646,0.00015005226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006355837,0.00040924898,0.000489564,0.00071636174,0.00026895758,0.00064919377,0.00035585312,0.00028036034,0.0013653777],"category_scores_gemma":[0.0012878567,0.0002547918,0.00018648643,0.0009916518,0.00028952802,0.00022784767,0.0004300868,0.0003483018,0.0004101236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024919144,0.000044695204,0.9865367,0.000037219903,0.00006811852,0.00013174352,0.00007748119,0.00014495713,0.0030312254,0.000027512107,0.0008704203,0.00653805],"study_design_scores_gemma":[0.0003663705,0.00063012895,0.99316084,0.000016925847,0.000083500694,0.0006336757,0.00018635762,0.00040834205,0.0015107966,0.000039934752,0.0029550665,0.000008007971],"about_ca_topic_score_codex":0.011324774,"about_ca_topic_score_gemma":0.014120416,"teacher_disagreement_score":0.011324774,"about_ca_system_score_codex":0.0009614227,"about_ca_system_score_gemma":0.0007137334,"threshold_uncertainty_score":0.022517681},"labels":[],"label_agreement":null},{"id":"W4413774700","doi":"10.1200/po-24-00505","title":"Therapeutic Outcomes and Biomarker Potential of <i>CDKL3</i> of Neoadjuvant Chemotherapy in Patients With Stage IIIC Versus Stage IV Epithelial Ovarian Cancer","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Stage (stratigraphy); Oncology; Medicine; Chemotherapy; Epithelial ovarian cancer; Internal medicine; Ovarian cancer; Biomarker; Neoadjuvant therapy; Cancer research; Cancer; Breast cancer; Biology","score_opus":0.017229505671301132,"score_gpt":0.3313117407260863,"score_spread":0.31408223505478516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413774700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988525,0.0003414288,0.00010603998,0.00003835832,0.000004161817,0.000004808181,0.00015484977,0.0000020530701,0.00049581635],"genre_scores_gemma":[0.99978155,0.000026865442,0.00002360919,0.000009483074,0.0000030617502,0.0000019254846,0.000118475415,5.7176834e-7,0.000034409855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997211,0.000106406944,0.000028049779,0.000056001874,0.00003944709,0.000049027807],"domain_scores_gemma":[0.99916625,0.00026103473,0.00038472694,0.00004964344,0.000045516255,0.00009282076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059394643,0.00011434503,0.00024957853,0.0003038212,0.00017950896,0.00048163524,0.00015680627,0.00019262233,0.0006440314],"category_scores_gemma":[0.0020854997,0.000056190594,0.0003278511,0.00032033035,0.00030568623,0.00026763562,0.00025971208,0.00025390572,0.00010442601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010742404,0.000017172362,0.99511176,0.0000071544036,0.000039153038,0.00005277282,0.00002171844,0.0001728937,0.00051895744,0.000028953156,0.000044149765,0.002911214],"study_design_scores_gemma":[0.000026133097,0.0003957799,0.9967906,0.000007729322,0.00007531973,0.00038518358,0.00012940493,0.0011469207,0.0005397143,0.0001226445,0.00037548528,0.0000050709173],"about_ca_topic_score_codex":0.0014760765,"about_ca_topic_score_gemma":0.0024542767,"teacher_disagreement_score":0.0014760765,"about_ca_system_score_codex":0.00046158495,"about_ca_system_score_gemma":0.00024412898,"threshold_uncertainty_score":0.0033490062},"labels":[],"label_agreement":null},{"id":"W4413920704","doi":"10.1200/po-25-00588","title":"Reply to: Germline and Somatic <i>BRCA1/2</i> Mutations in Breast Cancer Treatment Strategies","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Germline; Somatic cell; Germline mutation; Breast cancer; Oncology; Genetics; Medicine; Biology; Mutation; Cancer; Gene","score_opus":0.018202773317583652,"score_gpt":0.38088604077919874,"score_spread":0.3626832674616151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413920704","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017000236,0.002349999,0.000063221836,0.94127005,0.055333164,0.000008809816,0.000102199796,0.000013580428,0.00068893644],"genre_scores_gemma":[0.001787427,0.0028681578,0.00016435352,0.9294978,0.06357534,0.000028318567,0.00007602337,0.000019527339,0.0019830954],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970282,0.00065946643,0.00059889146,0.00040362906,0.00079690496,0.0005128637],"domain_scores_gemma":[0.9799558,0.010932883,0.0013192794,0.000377199,0.0050989664,0.0023159278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044991593,0.00090184074,0.0016690951,0.0014871852,0.0032534946,0.0034998516,0.0017822421,0.02700528,0.009560036],"category_scores_gemma":[0.041547086,0.0009353457,0.0010813944,0.0014732449,0.0029475102,0.0038450125,0.0027440588,0.033698615,0.005995818],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050827763,0.000011168104,0.00051136216,0.000102807084,0.000014417938,0.00016369393,0.00005455681,0.00004970463,0.00006292051,0.0006846361,0.99296206,0.0053317766],"study_design_scores_gemma":[0.00012226697,0.00005553348,0.0016079852,0.0005603083,0.00008899845,0.001112675,0.00049796514,0.00024017923,0.00022679915,0.0037811704,0.99160635,0.00009968933],"about_ca_topic_score_codex":0.0055654235,"about_ca_topic_score_gemma":0.009432582,"teacher_disagreement_score":0.02700528,"about_ca_system_score_codex":0.003367115,"about_ca_system_score_gemma":0.0072649233,"threshold_uncertainty_score":0.031981528},"labels":[],"label_agreement":null},{"id":"W4415068958","doi":"10.1200/po-25-00696","title":"Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pancreatic cancer; Risk stratification; Risk assessment; Family history; Pancreatic ductal adenocarcinoma; Clinical Practice","score_opus":0.04217056952120794,"score_gpt":0.41723676095551926,"score_spread":0.3750661914343113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415068958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99696416,0.00022569625,0.00014689106,0.0009806537,0.0000060473217,0.00007304141,0.00059028855,0.0000070243946,0.0010061564],"genre_scores_gemma":[0.99800664,0.00031875804,0.0003375969,0.00039995747,0.000016094615,0.00009482363,0.0006594014,0.0000045210822,0.00016227648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99388534,0.0023677144,0.0008716732,0.000699476,0.0014771475,0.00069864996],"domain_scores_gemma":[0.97220343,0.0068395743,0.012683936,0.0013125195,0.003175316,0.003785137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076457323,0.00016125063,0.00032640528,0.0013829824,0.0008233268,0.001335294,0.0007251153,0.00064416917,0.0010354114],"category_scores_gemma":[0.020854117,0.00027533816,0.00034559486,0.0024463919,0.0008948965,0.0012553756,0.002792545,0.0009587809,0.000139306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025767431,0.000041912714,0.99217963,0.000030365307,0.000018048642,0.00008792502,0.0019336379,0.000063979336,0.000068830675,0.0000493433,0.00084418897,0.004656551],"study_design_scores_gemma":[0.000005634528,0.00008922518,0.98960716,0.000050757004,0.000007717433,0.00021790016,0.00830068,0.00021031093,0.00006160868,0.000036163587,0.001401317,0.000011535825],"about_ca_topic_score_codex":0.025785742,"about_ca_topic_score_gemma":0.027618371,"teacher_disagreement_score":0.025785742,"about_ca_system_score_codex":0.0017607933,"about_ca_system_score_gemma":0.0030003153,"threshold_uncertainty_score":0.05127132},"labels":[],"label_agreement":null},{"id":"W4415711782","doi":"10.1200/po-25-00557","title":"Virtual CNS Tumor Board Rounds Within the Canadian Adolescent and Young Adult Neuro-Oncology Network","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; London Health Sciences Centre; Sunnybrook Health Science Centre; Western University; St. Michael's Hospital; University Health Network; SickKids Foundation; University of Toronto; Hospital for Sick Children","funders":"","keywords":"Young adult; Radiation therapy; MEDLINE; Cancer; Work (physics); Primary care","score_opus":0.014684526868310671,"score_gpt":0.29760949252447805,"score_spread":0.28292496565616737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415711782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85337335,0.0060990215,0.0049202438,0.012207162,0.0008143297,0.002503079,0.012256646,0.001043758,0.1067823],"genre_scores_gemma":[0.9595196,0.0038389526,0.009492402,0.0034922957,0.00036764253,0.0006842844,0.005706954,0.00012636387,0.0167715],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982278,0.0003483781,0.0000740025,0.0002411647,0.00048652047,0.0006221911],"domain_scores_gemma":[0.9898609,0.0005266527,0.0014388467,0.00021526644,0.0017831117,0.0061751977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012272268,0.00033888008,0.00022598426,0.0012426126,0.0025143488,0.0010934096,0.0011086114,0.00031961408,0.008124708],"category_scores_gemma":[0.0041719596,0.00024097832,0.00026245092,0.0015297229,0.000702321,0.0005160022,0.002185987,0.0006118305,0.00080651464],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051739253,0.0002560286,0.67187804,0.0003449096,0.00009989816,0.0017457962,0.002276132,0.0016250547,0.0015434215,0.0016362141,0.13379435,0.1842829],"study_design_scores_gemma":[0.0001181787,0.00030585856,0.8258124,0.00032236747,0.00007754045,0.0017245079,0.004082663,0.0024555235,0.0008244363,0.00061392714,0.1635912,0.000071317416],"about_ca_topic_score_codex":0.7977744,"about_ca_topic_score_gemma":0.9214786,"teacher_disagreement_score":0.98413265,"about_ca_system_score_codex":0.015867356,"about_ca_system_score_gemma":0.043764036,"threshold_uncertainty_score":0.4068331},"labels":[],"label_agreement":null},{"id":"W4415973611","doi":"10.1200/po-25-00245","title":"Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Nurses in Oncology","funders":"National Cancer Institute; National Institutes of Health","keywords":"Foundation (evidence); Quality (philosophy); Control (management); Circulating tumor DNA; Quality control; Disease control","score_opus":0.06694180683768487,"score_gpt":0.40673108948978015,"score_spread":0.3397892826520953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415973611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79021645,0.0011228245,0.18998541,0.0020693769,0.0001687202,0.006386381,0.0037964676,0.0018834346,0.0043709343],"genre_scores_gemma":[0.77915394,0.0003208976,0.20511137,0.0014748062,0.00007814763,0.0027024825,0.007642542,0.00033908576,0.003176727],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9899457,0.0029259024,0.00054232357,0.0014352059,0.004651939,0.0004987552],"domain_scores_gemma":[0.9924154,0.0014201606,0.0007575132,0.0009941104,0.003987576,0.00042516537],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013473325,0.00085440703,0.00035914316,0.00080587587,0.0007281715,0.0011217224,0.0014444188,0.001017998,0.0019621705],"category_scores_gemma":[0.010656527,0.00028468075,0.0004358954,0.00055255555,0.0012040731,0.00049015303,0.0007280761,0.0007187606,0.0006465135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014993077,0.0012895126,0.024057858,0.00036262043,0.000088179906,0.00029141206,0.00057846477,0.004661619,0.9112893,0.0010915588,0.00444205,0.050348204],"study_design_scores_gemma":[0.00026226987,0.0043774094,0.025215263,0.000073627794,0.000109669534,0.0007385269,0.00022286572,0.015378308,0.93095404,0.0002345123,0.02237777,0.00005581354],"about_ca_topic_score_codex":0.005989853,"about_ca_topic_score_gemma":0.0046320767,"teacher_disagreement_score":0.98652667,"about_ca_system_score_codex":0.0018388947,"about_ca_system_score_gemma":0.002372492,"threshold_uncertainty_score":0.07125467},"labels":[],"label_agreement":null},{"id":"W4417062080","doi":"10.1200/po-25-00279","title":"Clinical Utility of Multicancer Detection in Symptomatic Patients: A Decision-Making Perspective","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Perspective (graphical); Referral; Retraining; MEDLINE; Clinical judgment","score_opus":0.014525397196960348,"score_gpt":0.4011360747315419,"score_spread":0.38661067753458156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417062080","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3580387,0.045152903,0.3624743,0.17870863,0.0010792587,0.001483855,0.0020956744,0.00028303667,0.050683618],"genre_scores_gemma":[0.9559958,0.0022993148,0.037619427,0.0029046843,0.0004965999,0.00016685888,0.00030528088,0.000020204976,0.00019176421],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9068363,0.07787465,0.0038946911,0.0033260682,0.006742814,0.0013255664],"domain_scores_gemma":[0.78175455,0.18960653,0.014394165,0.0033198206,0.007441725,0.0034832358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06448906,0.0011976268,0.0017539114,0.004161062,0.0008306614,0.0067326603,0.0026209573,0.0026824295,0.0026670953],"category_scores_gemma":[0.19043753,0.00056639285,0.0020605125,0.0024168335,0.00452754,0.003424959,0.002806848,0.004845823,0.00038108023],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034965507,0.0012040619,0.24429156,0.0038553984,0.0035948367,0.0015648433,0.004954652,0.14817719,0.001343931,0.1491852,0.019564247,0.41876748],"study_design_scores_gemma":[0.00068850646,0.0023652196,0.051015083,0.006593857,0.0018681863,0.00287291,0.0035563202,0.3133115,0.0032741195,0.59290725,0.021108875,0.00043820898],"about_ca_topic_score_codex":0.0032185041,"about_ca_topic_score_gemma":0.0027071713,"teacher_disagreement_score":0.06448906,"about_ca_system_score_codex":0.0050783935,"about_ca_system_score_gemma":0.0054983147,"threshold_uncertainty_score":0.3410548},"labels":[],"label_agreement":null},{"id":"W4417208883","doi":"10.1200/po-25-00709","title":"Development and Validation of an Intratumor Heterogeneity–Based Prognostic Model for Clear Cell Renal Cell Carcinoma","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Clear cell renal cell carcinoma; Kidney cancer; Renal cell carcinoma; Immune system; Clear cell; Set (abstract data type); Prognostic model; Cell","score_opus":0.041305229038433956,"score_gpt":0.3198779747995676,"score_spread":0.2785727457611336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417208883","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9120287,0.0017317224,0.08210919,0.0005729369,0.000048167523,0.00013865257,0.0022982215,0.00038141262,0.0006910318],"genre_scores_gemma":[0.98911405,0.00014817648,0.008498533,0.00007207962,0.000027320766,0.00006535349,0.001833969,0.000015396581,0.00022512974],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9994142,0.00019765369,0.000052760428,0.00016315663,0.00011269274,0.00005954255],"domain_scores_gemma":[0.9988073,0.00063976314,0.00022845376,0.00007931057,0.00017057691,0.000074502044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003369817,0.00081515627,0.0010097692,0.0017196792,0.00030988082,0.0010430838,0.00065479084,0.00053093117,0.0004902565],"category_scores_gemma":[0.0030835983,0.00022057186,0.001435174,0.0006585085,0.00027286157,0.00040808748,0.0006578514,0.0006950457,0.00021645756],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010734455,0.00030995734,0.6178992,0.00016947647,0.0017303473,0.0001964331,0.00006593623,0.2766568,0.0057835556,0.00042315773,0.0018511136,0.093840614],"study_design_scores_gemma":[0.000048624825,0.00034916462,0.05111607,0.00003132576,0.00033424966,0.00011407753,0.000032844306,0.94498336,0.0014230891,0.0008766783,0.00066506735,0.000025394758],"about_ca_topic_score_codex":0.004714206,"about_ca_topic_score_gemma":0.004105357,"teacher_disagreement_score":0.004714206,"about_ca_system_score_codex":0.0007803522,"about_ca_system_score_gemma":0.0012338748,"threshold_uncertainty_score":0.01782155},"labels":[],"label_agreement":null},{"id":"W7116663774","doi":"10.1200/po-25-00221","title":"CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 ( <i>NRG1</i> ) Fusions","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"National Cancer Institute","keywords":"Monoclonal antibody; Solid tumor; Phase (matter); Cancer; Antibody; Tumor cells","score_opus":0.026661932388642968,"score_gpt":0.42918210070895435,"score_spread":0.4025201683203114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116663774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99375737,0.0011770446,0.000551423,0.00016408398,0.000054002543,0.0018527755,0.0007132028,0.000058779646,0.0016713197],"genre_scores_gemma":[0.9925034,0.0010605678,0.0012867547,0.00042453693,0.00007181599,0.0012499713,0.0015205195,0.000014000802,0.0018684686],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99938715,0.00027607486,0.000037577505,0.00009483723,0.00011545779,0.000088989524],"domain_scores_gemma":[0.99918085,0.0001394333,0.0001745664,0.00007112732,0.000070829476,0.0003630554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020529893,0.0012669723,0.0012452684,0.0003911734,0.0003576705,0.0008678499,0.000757211,0.00091871474,0.0020343987],"category_scores_gemma":[0.0010108385,0.00040466178,0.0011562229,0.00026947018,0.0009614203,0.0005346279,0.000424705,0.0017340818,0.00045261774],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6949934,0.055436943,0.020204684,0.002033502,0.0022903262,0.00065140275,0.0006287477,0.005681086,0.11403399,0.00087868574,0.004549049,0.09861832],"study_design_scores_gemma":[0.4598805,0.4861862,0.03326177,0.000071192495,0.0014282455,0.0006844116,0.000095439136,0.002887442,0.010389828,0.00022400699,0.004811038,0.00007992846],"about_ca_topic_score_codex":0.0010693321,"about_ca_topic_score_gemma":0.003459915,"teacher_disagreement_score":0.0020529893,"about_ca_system_score_codex":0.0006516665,"about_ca_system_score_gemma":0.0015380394,"threshold_uncertainty_score":0.010857403},"labels":[],"label_agreement":null},{"id":"W7116688526","doi":"10.1200/po-25-00507","title":"Master Protocol Design With Hybrid Control for Efficient Early-Phase Trial Consolidation","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Tellabs (Canada)","funders":"","keywords":"Protocol (science); Consolidation (business); Control (management); Hybrid system; Bayesian probability; Control system","score_opus":0.5109775295074659,"score_gpt":0.6108634696134609,"score_spread":0.09988594010599505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116688526","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016864281,0.0008453138,0.95390946,0.0006885178,0.00061641046,0.020941112,0.00039130944,0.0020748947,0.003668792],"genre_scores_gemma":[0.2655971,0.0003272198,0.6621623,0.0010366745,0.00046134985,0.066140555,0.00050995813,0.00034105233,0.003423805],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9129585,0.06925257,0.004895988,0.006975072,0.0048437957,0.0010740476],"domain_scores_gemma":[0.8740991,0.08218434,0.01165008,0.021490162,0.00794202,0.002634405],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.10527697,0.001867078,0.0025636225,0.0018097182,0.0007908892,0.0026811503,0.0034313514,0.0021180434,0.01903009],"category_scores_gemma":[0.16358465,0.0013573729,0.0023167457,0.0011919275,0.0030347072,0.0040895045,0.0049422467,0.0043084812,0.0023780547],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043825105,0.002081644,0.0073165116,0.0032325864,0.0029700159,0.0003586741,0.0013747823,0.08795893,0.014692405,0.19405723,0.012591061,0.6295411],"study_design_scores_gemma":[0.037484765,0.024114551,0.0058306023,0.0011518913,0.00270388,0.00047643523,0.00028553623,0.5506126,0.026949994,0.2720399,0.07797285,0.00037688695],"about_ca_topic_score_codex":0.00039134762,"about_ca_topic_score_gemma":0.00044731374,"teacher_disagreement_score":0.89472306,"about_ca_system_score_codex":0.0018724201,"about_ca_system_score_gemma":0.005953628,"threshold_uncertainty_score":0.5567645},"labels":[],"label_agreement":null}]}